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Ubiquitination is an essential cellular mechanism in which the small polypeptide ubiquitin is 
attached to proteins, so regulating protein function or targeting them for degradation via the 
proteasome. The transfer of ubiquitin to specific target proteins is regulated by the highly 
diverse group of E3 ubiquitin ligases. These require two key domains: a substrate recognition 
site, and a ubiquitin carrier E2 protein binding site, which allow close proximity of the two, 
so ubiquitin transfer can occur. One family of E3 ubiquitin ligases are the UBR proteins, which 
confer substrate specificity through the N-end Rule pathway – in which  they, canonically, 
bind either Type I (basic, e.g. Arginine) or Type II (bulky hydrophobic, e.g. Phenylalanine) 
amino acids on the N-terminus of the substrate. There are seven known UBR proteins, and 
UBR2 is one of four in this family that are thought to have overlapping roles in the N-end Rule 
pathway. Published murine phenotypes in a Ubr2-/- mouse include male infertility and female-
specific embryonic lethality. The tissue-specificity of the Ubr2-/- phenotype has been 
attributed to tissue-specific expression of UBR proteins allowing critical functions of the N-
end rule pathway to become detectable in specific cell types. These phenotypes also appear 
to overlap that of a Tex19.1-/- mouse, which has undetectable expression of the UBR2-
interacting protein TEX19.1. This is specifically expressed in hypomethylated tissues: the 
testes, ovaries, placenta, and in a mouse embryonic stem cell model. 
In addition to the male infertility observed in both mouse models, Tex19.1-/- phenotypes include 
placental defects associated with intrauterine growth restriction, and cohesin misregulation 
during female meiosis, in the oocyte. There is some evidence that UBR2’s interaction with 
TEX19.1 regulates its Type II N-end Rule activity, and so I hypothesized that UBR2 also has 
roles in the other phenotypes of the Tex19.1-/- mouse, and that these act through the N-end Rule, 
which has thus far not been directly shown in any of the phenotypes present. 
Firstly, I aimed to study a potential role for UBR2 during female meiosis. In oocytes, cohesin 
molecules hold homologous chromosomes in a tightly aligned conformation. This must be 
8 
 
maintained for long periods of time, between meiotic prophase in the embryonic ovary and 
resumption of meiosis prior to ovulation during adulthood. This maintains chromosome 
stability and prevents missegregation during the first meiotic division, leading to aneuploidy 
and reduced fertility. A longer arrest period, i.e. in oocytes isolated from older females, is 
associated with loss of cohesin and increased chance of aneuploidy. In absence of UBR2 in 
oocytes from young females, less cohesin is present on the chromosome arms at the first 
meiotic metaphase and homologs are less tightly held together, so implying a role for 
protection of chromosome cohesion over time. 
Next, in accordance with previous observations in absence of UBR2, I identified an embryonic 
lethality present in our Ubr2-/- mice, which is associated with intrauterine growth restriction 
and placental defects.  Although this is superficially similar to the Tex19.1-/- placental 
phenotype, there also appear to be TEX19.1-independent functions of UBR2 in this tissue. 
Finally, I aimed to ascertain the mechanism by which UBR2 plays a role in any of these 
phenotypes. As UBR2 is thought to confer particular specificity towards Type II N-end Rule 
substrates, and TEX19.1 is thought to regulate this role of UBR2, I used CRISPR-Cas9 
technology to generate an Ubr2T2/T2 mouse model, which has undetectable Type II substrate 
binding. There are no gross phenotypes in any of the tissues identified using the Ubr2-/- null 
mouse; both placental growth and meiotic cohesin appear to be normally regulated, and so 
these functions of UBR2 do not appear to be acting through the N-end Rule pathway. 
Additionally, the well-established role for UBR2 during spermatogenesis does not appear to 
act through Type II N-end Rule substrate binding, as has been assumed. Instead, I conclude 
that, although UBR2 is an important part of the N-end Rule pathway in other contexts, it has 
key non-canonical functions in both male and female fertility, and in placental development, 




Proteins are the functional products of genes, and they act in cells to carry out the processes 
required for cells to survive. In order to keep cells or tissues functioning optimally, individual 
protein levels need to be tightly controlled, and so an efficient recycling process exists in order 
to “tag” proteins that need to be turned over – this is called ubiquitination. A small molecule, 
called ubiquitin, is transferred to a target protein by an ubiquitin ligase enzyme and this “tags” 
the protein, directing it towards a recycling centre called the proteasome. There are over 
10,000 proteins in any given cell, and so target specificity is very important in order to recycle 
the correct proteins and ensure cell survival. One ubiquitin ligase, called UBR2, uses a process 
called the N-end Rule to specifically bind its target proteins. There are four UBR enzymes 
that are all thought to have overlapping roles in the N-end Rule pathway, but in a Ubr2 mutant 
mouse, in which UBR2 is not present to recycle its target proteins, there are a specific subset 
of tissues affected. This implies that UBR2 has unique functions in these tissues that cannot 
be covered by other UBR enzymes. Of these unique functions, the best studied prior to this 
thesis is its role in male fertility. I hypothesized that UBR2 is also important for female fertility 
and that both of these roles are regulated by UBR2’s N-end Rule activity, which has thus far 
not been directly shown. 
Firstly, I aimed to characterise poorly understood roles of UBR2 in female fertility. I have 
shown that UBR2 appears to regulate chromosome cohesion during egg (oocyte) production. 
All oocytes are present in the ovary during embryogenesis, and do not complete their 
development until immediately prior to ovulation, when pairs of chromosomes are divided in 
half. This can be over a period of many months in a mouse model, and during this time, 
chromosomes need to be held tightly together in order to align them and prevent 
missegregation upon division – this chromosome “cohesion” is maintained by a protein 
molecule called cohesin. In absence of UBR2, less cohesin is present and chromosomes are less 
tightly held together, increasing the risk of having the wrong number of chromosomes in the 
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resulting egg – a condition called aneuploidy which is associated with subfertility, 
miscarriage and developmental disorders such as Down Syndrome. UBR2 therefore is a 
potential candidate for protection of chromosome cohesion over time, which is especially 
associated with older women and their declining fertility in the years prior to menopause. 
While investigating aspects of chromosome behaviour during egg development, I noticed that 
Ubr2 mutant embryos were small for their gestational age, a condition that arises in around 
10% of human pregnancies and is often caused by defects in the placenta. By investigating the 
cause of this growth restriction, I have also been able to uncover a novel role of UBR2 in 
placental development in mice. 
Secondly, I wanted to investigate the mechanism behind these unique functions of UBR2; 
both male and female fertility, as well as in placental development. Instead of removing the 
Ubr2 gene, as in the mouse model used above, I introduced specific mutations in order to 
prevent N-end Rule target binding of UBR2, while preserving the enzyme itself inside cells. I 
generated this mutation in a mouse model using the CRISPR-Cas9 genome editing technology 
and hypothesized that, if UBR2 is acting through the N-end Rule, these mice would also have 
fertility problems and placental defects. Interestingly, although the N-end Rule is the main 
known functional pathway of UBR2, I did not observe any defects in the testis, ovaries or 
placenta when the ability of UBR2 to act in this pathway was specifically disrupted. This is 
the first time that a UBR protein has been identified as having functions outside the N-end 
Rule in a mouse model, and potentially outside of ubiquitination and protein recycling 
altogether.   
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1.1 Ubiquitination and Protein Turnover 
Protein turnover is an integral part of cell function and is vital for homeostasis of the 
eukaryotic proteome. In addition, there is an intrinsic requirement for turnover of certain 
proteins in essential cellular pathways involved in the cell cycle, DNA replication and stress 
responses, and in response to various stimuli in the eukaryotic system (Sadowski and Sarcevic 
2010; Bedford et al. 2010; Hicke 2001). One of the major signaling pathways involved in protein 
turnover is the ubiquitin-proteasome system (UPS). Ubiquitin is a small 9kDa protein that 
acts as a covalently-bound signalling molecule across a wide variety of functions in the cell, 
particularly in regulation of protein levels and turnover (Pickart and Eddins 2004). It is 
covalently conjugated to target substrates via Lysine residues, and polyubiquitin chains can 
be built up by ubiquitination of Lysines within the ubiquitin protein itself. There are seven 
Lysine residues within the molecule, but the most common ubiquitin chains are built up along 
K48, K33, K29, K11 or K63 residues (W Li and Ye 2008). Protein turnover is generally 
understood to act through recognition of K48 or K63 polyubiquitin chains (Ohtake et al. 2018; 
Tsuchiya et al. 2017), but the variety of different polyubiquitin chains, or even monoubiquitin 
signalling, act to carry out a diverse array of ubiquitination functions (Sadowski et al. 2012). 
In addition to polyubiquitin chains, combinations of different ubiquitin-lysine linkages can 
result in branched chains that perform specific proteostatic functions (H. T. Kim et al. 2007). 
Quality control in protein synthesis is another vital function of the UPS, and there are also 
functions for ubiquitination outside of protein degradation, for example in protein regulation 
through interaction with proteins containing UBDs (ubiquitin binding domains) (Tsuchiya 
et al. 2017). 
Ubiquitin was the first identified of a family of small ubiquitin-like proteins (Ubls), which 
share structural similarities and can be conjugated to target proteins for signalling purposes 
in a similar way to ubiquitin itself. These include SUMO and NEDD8, among many others. 
They require similar but distinct conjugating enzyme cascades as for ubiquitination, but act 
to perform a variety of signalling functions in eukaryotic cells, primarily through promoting 
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the interaction of the target with SIM (SUMO-interacting motifs) or other UBL-binding 
proteins (Hochstrasser 2009). 
 
1.1.1 The E1-E2-E3 Ubiquitination Cascade 
There are three required steps to ubiquitination of a substrate: binding to the ubiquitin 
molecule itself, binding to substrate proteins, and transfer of ubiquitin onto the substrate. For 
each function, there exists an individual class of enzymes, and together they act in a cascade 
of interactions, called the E1-E2-E3 cascade (Fig. 1.1). For preparation of the ubiquitin 
molecule itself, the E1 ubiquitin-activating enzyme undergoes ATP hydrolysis (Schulman and 
Wade Harper 2009) in order to bind specifically through a thioester bond with an active site 
cysteine residue, to the ubiquitin molecule (Fig. 1.1a). The activated ubiquitin is then 
transferred to an E2 ubiquitin-conjugating enzyme (Fig. 1.1b), again via a thioester linkage 
(Olsen and Lima 2013). Substrate specificity in this pathway is conferred through interaction 
of the target protein with an E3 ubiquitin ligase, which is the largest and most diverse group 
of the ubiquitination enzymes. Physically, these can be considered bi-substrate enzymes as 
they bind both the substrate and the E2, bringing them into the correct conformation for 
ubiquitin transfer (Fig. 1.1c). There are three major classes of E3 ubiquitin ligase, defined by 
their interaction mode with the E2 enzyme: RING (Really Interesting New Gene), HECT 
(Homologous to E6‐Associated Protein C-Terminus) or RBR (RING-between-RING) 
(Berndsen and Wolberger 2014). An interaction between a ubiquitin charged E2 and the E3 
brings the target protein in close enough proximity to the E2 for ubiquitin transfer to occur. 
There are roles for monoubiquitination or multiubiquitination in protein regulation within 
the cell (Sadowski and Sarcevic 2010) (Fig. 1.1f), but a large proportion of ubiquitinated target 
proteins are polyubiquitinated, and this requires multiple subsequent interactions between 
the E3 and charged E2 enzymes to allow building of a ubiquitin chain on the substrate (Fig. 
1.1d,e). Therefore, E2/E3 interactions must be low-affinity and transient, although long-lasting 
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enough for ubiquitin-transfer to occur. A non-ubiquitin-charged E2 has lower binding affinity 
to either the RING or HECT domains of an E3, and this aids in dissociation of the E2/E3 
complex after ubiquitin transfer (Metzger et al. 2014; Sluimer and Distel 2018). A 
polyubiquitinated substrate is then recognised by intrinsic components of the 26S 
proteasomal lid complex such as Rpn10, Rpn13 or Sem1 (Paraskevopoulos et al. 2014; 
Kragelund et al. 2016; Hamazaki, Hirayama, and Murata 2015) (Fig. 1.1g), and the target 
protein is deubiquitylated by a proteasome-associated DUB enzyme in order for it to be 
degraded within this complex (Bedford et al. 2010). Individual ubiquitin molecules and amino 


















Figure 1.1 The E1-E2-E3 Ubiquitination Cascade 
Transfer of the ubiquitin (Ub) molecule to substrate proteins occurs in a cascade of three classes 
of ubiquitination enzymes. An E1 ubiquitin activator undergoes ATP hydrolysis (a) in order to 
charge a Ub molecule, and this is transferred to an E2 ubiquitin conjugating enzyme (b). An E3 
ubiquitin ligase binds both the substrate and the Ub-charged E2 and Ub is transferred to the 
target protein (c). Ubiquitination is able to alter the function of a protein, either through 
monoubiquitination (d) or subsequent E2-E3 interactions (e) and construction of a Ub linkage 
chain (f). Either polyubiquitinated or monoubiquitinated proteins interact with UbRs (Ub 
receptors). The classical pathway of ubiquitination involves binding of polyubiquitinated 
substrates to proteasomal UbRs, and degradation in the 26S proteasome (g). The proteasome 
complex contains both deubiquitinases (DUBs) and proteases, which release the Ub molecule for 
further ubiquitination experiments and subsequently degrade the substrate protein. Released 
amino acids and Ub molecules are recycled for protein synthesis and further rounds of protein 
degradation (h). 





1.1.2 The N-end Rule Pathway for Protein Degradation 
E3 ubiquitin ligases are by far the largest and most diverse group of enzymes within the E1-
E2-E3 cascade, encoded by over 600 mammalian genes (Wei Li et al. 2008), and it is these that 
provide substrate specificity for the UPS. In contrast, there are only 2 known mammalian E1 
ubiquitin activators enzymes, UBA1 and UBA6 (Schulman and Wade Harper 2009; J. Jin et al. 
2007), which are promiscuous for binding to the mammalian E2 enzymes, of which there are 
around 40 known (Stewart et al. 2016). 
One of the earliest discovered E3 substrate binding pathways, the N-end Rule, depends on 
the N-terminal sequence of the substrate, which acts as a degron binding site for the E3 
ubiquitin ligase to carry out ubiquitination (Bachmair, Finley, and Varshavsky 1986). This 
was first discovered in S. cerevisiae, with identification of the E3 substrate recognition protein 
Ubr1 (Bartel, Wünning, and Varshavsky 1990). Multicellular eukaryotes encode a family of 
seven UBR proteins, of which UBR1 is the best characterised, which are expected to carry out 
N-end recognition (T Tasaki et al. 2005). The N-end Rule pathway, as for most E3s, also 
requires at least one internal Lysine residue in the target protein to act as the site for initial 
ubiquitin attachment by the associated E2 enzyme. 
 
1.1.2.1 Classes of N-terminal Degradation 
N-terminal degron sequences can be classified into two main subcategories: those 
that are recognised by the Arg/N-end Rule, and by the Ac/N-end Rule. Nascent 
proteins are expressed with an N-terminal methionine, encoded by the start codon 
ATG. However, N-terminal post-translational modifications are not uncommon, and 




Firstly, the Arg/N-end Rule depends on the specific modification of the N-terminus 
into either Type I or Type II N-terminal recognition sequences. These types are 
defined by the N-terminal residues on the target protein. Type I is generally basic 
residues, the most common of these being arginine (Arg) (T Tasaki et al. 2005), which 
gives the classification its name. The Type II Arg/N-end Rule is defined instead by 
bulky hydrophobic N-terminal residues, such as phenylalanine (Phe) or tryptophan 
(Trp). The Arg/N-end Rule is the more widely studied of the two categories (J. M. 
Kim and Hwang 2014), and will be considered the major pathway of N-end Rule 
ubiquitination for the remainder of this thesis. 
The Ac/N-end Rule pathway for protein degradation acts on proteins containing an 
N-terminal acetyl group; this is a cotranslational modification that occurs during 
translation of 90% of mammalian proteins (Nguyen et al. 2019; Polevoda, Arnesen, 
and Sherman 2009). This is a lesser understood category of the N-end Rule, and was 
only recently identified as a degradation signal, in 2010 (Hwang, Shemorry, and 
Varshavsky 2010). As so many Ac/N-end target proteins exist, the acetylated N-
terminus is often shielded by structural folding or interaction in a protein complex 
(Shemorry, Hwang, and Varshavsky 2013). This gives a mechanism by which E3 
ubiquitin ligases such as TEB4 (Park et al. 2015) can detect protein misfolding or 
deleterious conformational changes, so inducing degradation via the UPS and 
maintaining proteomic integrity. Acetylation at the N-terminus depends on the 
residue present in the second position, immediately after the N-terminal methionine. 
A small second residue, such as alanine or leucine, results in cleavage of methionine 
and acetylation of this second residue. However, if the second residue is large or bulky, 
the N-terminal methionine is preserved and acetylated directly. These proteins are 
classed as Met-Φ and can be degraded by either the Ac/N-end Rule or, when not yet 
acetylated, by the Arg/N-end Rule as a level of redundancy to allow quick degradation 
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of misfolded proteins. This non-acetylated Met-Φ turnover depends on components 
of the Type II Arg/N-end Rule pathway, presumably binding to the second, bulky 
residue with a similar conformation as to the bulky hydrophobic Type II N-degron (J. 
M. Kim and Hwang 2014; Nguyen et al. 2019). 
 
1.1.2.2 Type I or Type II N-terminal Modifications 
One of the first discovered, and most direct, ways in which N-terminal modification 
acts to generate an N-degron signal for the N-end Rule is through arginylation. This 
a hierarchical process, beginning with the cleavage of the N-terminal methionine and 
exposure of the second position residue, such as asparagine, glutamine and cysteine, 
which are tertiary N-terminal residues. These are modified by a group of amidase 
enzymes to generate aspartic acid, glutamic acid, or oxidised to generate CysO2(H) 
or CysO3(H) – which are substrates of the arginyltransferase ATE1 (Takafumi Tasaki 
and Kwon 2007; Yong Tae Kwon, Kashina, and Varshavsky 1999; Takafumi Tasaki et 
al. 2012; R.-G. Hu et al. 2005; M. J. Lee et al. 2005). This enzyme conjugates an arginine 
residue on the N-terminal end to generate an arginine Type I N-terminal degron 
sequence. 
Other Type I, or Type II, N-terminal sequences can arise through other cleavage or N-
terminal modifications. For example, there are also some roles for the N-end Rule in 
specific targeting of substrates under particular cellular conditions, and this can be 
achieved by generation of a neo-N-terminus through proteolysis. These include N-
end Rule degradation of the cohesin kleisin fragments during mitosis of S. cerevisiae, 
which are cleaved by separase upon removal from chromatin during chromosome 
segregation (Kim Nasmyth 2011). The neo-N-terminus generated on the C-fragment 
cleavage product bears an N-terminal arginine, so being a Type I substrate for the N-
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end Rule pathway (Rao et al. 2001). Interestingly, the meiotic REC8 kleisin is also 
cleaved by separase in this way, but this undergoes N-terminal acetylation and 
degradation by the Ac/N-end Rule pathway (Y. J. Liu et al. 2016). Other recently 
described roles for the N-end Rule in conditional protein regulation include the 
innate immune response, with the cleavage of the inflammasome component NLRP1B 
to generate a neo-N-terminal Type II degron, and DNA replication stress regulators 
such as SDE2, which has a neo-Type I N-degron upon stress-induced cleavage (H. Xu 
et al. 2019; Rageul et al. 2019). Another role for the N-end Rule has been identified in 
the regulation of hedgehog (Hh) signalling pathways in both D. melanogaster and 
mammalian systems, potentially through degradation of an N-terminally extended 
CSPP1-L ciliary protein isoform, which encodes an N-degron sequence (Kinsella et al. 
2016; Shearer et al. 2018). Ciliary function is vital for developmental patterning and 
morphogen signalling, including via the Hh pathway (Frikstad et al. 2019; He, Agbu, 







Figure 1.2 Phylogeny of the UBR N-end Rule E3 Family 
Phylogenetic tree of UBR proteins across eukaryotic systems. The RING family (yellow) is the 
largest, encompassing the originally discovered UBR protein, S. cerevisiae, and various UBR1, UBR2 
and UBR3 proteins. UBR3 has the highest sequence homology with S. cerevisiae UBR2, but this 
does not have N-end Rule activity and so is not shown here. UBR5 (orange) is the only UBR 
protein to contain a HECT domain, and together with the RING family, are the only UBR proteins 
that act in canonical E2-E3 ubiquitination interactions through their domain structures. UBR4, 
UBR6 and UBR7 have all evolved separately from the other UBR proteins and are only related 
through their shared UBR box domain structure. 
Schematic taken from (T Tasaki et al. 2005). 




1.1.2.3 Evolutionary Conservation of the UBR Protein Family 
Recognition of Type I or Type II N-end Rule substrates in mammalian systems is 
carried out by a domain called the UBR box, which is conserved between a family of 
seven E3 ubiquitin ligases called the UBR proteins (T Tasaki et al. 2005). Only four 
mammalian UBR proteins have been shown to actively bind substrates using the N-
end Rule protein recognition system: UBR1, UBR2, UBR4 and UBR5 (T Tasaki et al. 
2009). 
The UBR proteins are highly conserved across different species (Fig. 1.2), and UBR 
proteins were the first N-end Rule system discovered, with the S. cerevisiae gene UBR1 
(Bartel, Wünning, and Varshavsky 1990). This encodes UBR1 protein, which contains 
the highly conserved UBR box found in mammalian UBR proteins. 
S. cerevisiae UBR1 is a homolog of mammalian genes Ubr1 and Ubr2, which are 47% 
sequence conserved, with 68% sequence similarity to each other (T Tasaki et al. 2005). 
They each contain a UBR box, an N-domain, a RING domain which carries out 
binding to the E2 ubiquitin conjugating enzyme and a UAIN (UBR auto-inhibitory 
domain), Fig. 1.3. The S. cerevisiae UBR1 protein has substrate binding abilities in both 
the Type I and Type II N-end Rule pathways, as well as to an internal degron site in 
the transcriptional repressor CUP9 (G. C. Turner, Du, and Varshavsky 2000; Du et al. 
2002). UBR1 recognition of CUP9 depends on the C-terminus proximal UAIN, which 
has also been noted in some literature as region IV (Zenker et al. 2005). The domain 
carries out auto-inhibition in S. cerevisiae UBR1, whereby it acts to bind the N-terminal 
region of the Ubr1 protein, blocking binding of UBR1 to CUP9 (Du et al. 2002) CUP9 
functions as a transcriptional repressor of peptide import proteins such as PTR2 
(Kawai et al. 2014), and so the addition of N-end Rule peptides acts to promote CUP9 
degradation, so positively regulating their own uptake (G. C. Turner, Du, and 
Varshavsky 2000). CUP9 has an internal degron sequence, which has been limited to 
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the C-terminal 33-residue region. However, the recognition domain for CUP9 within 
UBR1 has not been identified, and so it is not understood how the UAIN acts to 
physically block CUP9 interaction (Du et al. 2002; Xia et al. 2008) (Du et al., 2002; 
Xia et al., 2008). Although the protein sequence is conserved between species, study 
of the UAIN domain has not so far been published in mammalian UBR proteins. 
Other conserved UBR proteins across different species include the fission yeast S. 
pombe proteins Ubr1 and Ubr11. These have high sequence and structural similarity to 
S. cerevisiae Ubr1, but only S. pombe Ubr11 has any documented activity in the N-end 
Rule (Fujiwara et al. 2013). Ubr11 is only required for Type II N-end Rule functions, 
and so it remains to be seen if a Type I N-end Rule E3 ligase exists in this species 
(Kitamura 2014). 
Ubr11 also appears to carry out some non-N-end Rule functions that are conserved 
with S. cerevisiae UBR1. For example, it is required for PTR2 expression, which is a 
peptide uptake transporter, and this depends on a functional UAIN domain, as in S. 
cerevisiae UBR1 (Kitamura and Fujiwara 2013). UBR1 is required in budding yeast for 
PTR2 expression through degradation of CUP9 transcriptional repressor (Du et al. 
2002), but there are as yet no known CUP9 homologs in fission yeast and so the Ubr11 
N-end Rule substrate for this function in S. pombe is unknown (Kitamura and Fujiwara 
2013; Kitamura 2014). Ubr11 is also required for degradation of misfolded kinetochore 
components via Hsp70 chaperone-assisted proteasomal degradation, so carrying out 
nuclear quality control and homeostasis (Kriegenburg et al. 2014; Kitamura 2014). 
S. pombe Ubr1 is functional as an E3 ubiquitin ligase, acting to degrade hypoxic 
transcription factor Sre1 (C.-Y. S. Lee et al. 2011) and to regulate proteasomal nuclear 
localisation by turnover of Cut8 nuclear envelope protein (Takeda and Yanagida 
2005). However, neither of these substrates are confirmed to be N-end Rule 
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substrates as both lack N-terminal degron sequences, and therefore S. pombe Ubr1 may 
not be active in the N-end Rule at all.  
There are very limited studies on non-N-end Rule mammalian UPS functions for 
UBR1 or UBR2. Studies in our group have shown that UBR2 is able to turn over the 
retrotransposon-expressed protein LINE-1 Orf1 through an unknown mechanism – 
presumably by binding to an internal degron, similarly to the CUP9 substrate of S. 
cerevisiae UBR1, as Orf1 does not contain a canonical N-degron sequence. The physical 
interaction domains between UBR2 and Orf1 have not been identified (Maclennan et 
al. 2017), and it is unknown whether this depends on activity of the UAIN domain, or 
if binding to N-end Rule sequences are required for LINE-1 Orf1 binding. 
UBR1 is the most well-studied of the mammalian UBR family and has functions in a 
variety of roles; a Ubr1-/- mouse is both viable and fertile, but has severe growth defects 
in skeletal and adipose tissues (Y. T. Kwon et al. 2001). UBR2 has specific roles in 
male meiotic progression and female embryonic survival (Y T Kwon et al. 2003; Yang 
et al. 2010), and has been implicated in the regulation of the mitotic cohesin complex 
(J Reichmann et al. 2017). Therefore, although they are highly conserved, UBR1 and 
UBR2 do appear to have distinct roles within a mammalian system. However, there 
is redundancy in some of these functions, and a double null mouse is inviable (Jee 
Young An et al. 2006); embryos do not progress past midgestation, around E11.5. 
UBR1 has been shown to bind both Type I and Type II N-terminal degron peptide 
sequences in a pulldown assay, but a Ubr1-/- N-end Rule reporter cell line has only a 
partial rescue of both classes of reporters. UBR2 specifically binds Type II peptides, 
and a double null Ubr1-/-Ubr2-/-  reporter cell line has a slightly stronger rescue, as 
compared to Ubr1-/- alone (T Tasaki et al. 2005). However, these cell lines still exhibit 
some N-end Rule activity, indicating that other N-end Rule E3 ubiquitin ligases may 
be present in these cells – potentially UBR4 or UBR5. 
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Mammalian UBR4 (also known as p600) is a very large 570kDa protein (Fig. 1.3) 
which shares highest sequence and domain homology with D. melanogaster protein 
PUSHOVER (or d-UBR4) and A. thaliana protein BIG (a-UBR4, Fig. 1.2). There is no 
known S. cerevisiae homolog, although all three homologs do share the conserved UBR 
box domain with S. cerevisiae UBR1 (T Tasaki et al. 2005). Genetic null experiments in 
mouse cell lines show that mammalian UBR4 is essential for a wide variety of 
functions across the mouse. These include oncogenic upregulation and increased 
tumour invasiveness, co-option in viral infection for innate immune response 
suppression, both placental and cardiovascular embryonic development, and 
endosome maturation in lysosomal proteolysis (S. T. Kim et al. 2018; Nakaya et al. 
2013; Sakai et al. 2011; Morrison et al. 2013). Only the latter is directly linked to 
proteolysis, although not through proteasomal degradation. Endosome maturation 
requires membrane bound UBR4 and it is currently not known whether this acts 
through ubiquitination. Neither BIG or PUSHOVER have any documented activity 
in the UPS in their respective systems (Gil et al. 2001; Richards, Hillman, and Stern 
1996; Hearn et al. 2018), and there are no previously identified ubiquitination or E2 
binding domains within the mammalian Ubr4 gene. However, mammalian UBR4 
isolated from cell lysates is able to bind both Type I and Type II N-end Rule peptide 
substrates in an in vitro peptide pulldown assay, and knockdown of UBR4 in Ubr1-/-
Ubr2-/- double null cells impairs degradation of N-end Rule reporters, which was 
partially preserved in the double null alone (T Tasaki et al. 2005), strongly implying 
that UBR4 does have some activity in the N-end Rule UPS, although in vivo substrates 
have not been identified. 
Before identification of the conserved UBR box, UBR5 was studied as an E3 ubiquitin 
ligase (called EDD/hHYD), active in, among other functions, proteasomal degradation 
of topoisomerase TopBP1, leading to cell cycle regulation. This acts via its HECT E2 
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binding domain, which recognises the protein’s C-terminal BRCA1 domain, i.e. 
TopBP1 is not an N-end Rule substrate (Honda et al. 2002; Henderson et al. 2002; 
Callaghan et al. 1998), Fig. 1.3. UBR5 is a homolog of the D. melanogaster Hyd 
(hyperplastic discs protein, or d-UBR5, Fig. 1.2) which is a tumour suppressor and E3 
ubiquitin ligase active in regulation of signalling morphogen Hh (Hedgehog) (G. 
Wang et al. 2014; Kinsella et al. 2016). Again, there is no known S. cerevisiae homolog 
for mammalian UBR5, except for the sequence similarity of the UBR box substrate 
binding domain to Ubr1 (T Tasaki et al. 2005). Within the N-end Rule, UBR5 has only 
been shown to be active in Type I N-degron binding (T Tasaki et al. 2009). 
It should be noted that the S. cerevisiae genome also encodes a UBR2 gene, which is 
unrelated to the mammalian Ubr2 gene, instead having sequence similarity to the 
mammalian Ubr3 gene; these are thought to be functional homologs (Takafumi Tasaki 
et al. 2012). Neither has activity in the N-end Rule (T Tasaki et al. 2005), although 
they both contain the sequence-conserved UBR box domain (Fig. 1.3). S. cerevisiae 
UBR2 is functional in a complex with the protein MUB1 as a RING-type E3 ubiquitin 
ligase via non-N-end Rule pathways, for example in kinetochore protein regulation 
and homeostasis of proteasomal protein transcriptional abundance (Akiyoshi et al. 
2013; L. Wang et al. 2004). The mammalian UBR3 protein is required for genomic 
stability and regulates the degradation of APE1, a DNA repair protein, again via a non-
N-end Rule pathway of the UPS. UBR3 binds E2 ubiquitin conjugating enzymes via 
a RING domain (T Tasaki et al. 2005), as does S. cerevisiae UBR2. Not much is known 
about the substrate binding domains present within the mammalian UBR3 protein 
(Meisenberg et al. 2012), but this is presumably through an internal degron. Although 
the UBR box has been identified primarily in N-end Rule degron recognition, it is 
structurally very similar to RING-like zinc finger domains, which are able to carry 
out a wide variety of functions including DNA-protein and protein-protein 
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interactions, being implicated in ubiquitin-recognition or protein-recognition (Kaur 
and Subramanian 2015; Freemont 1993). Therefore, the UBR domain could be active 
in non-N-end Rule activities in the non-N-end Rule UBR proteins such as UBR3 and 
S. cerevisiae UBR2, for example through recognition of non-N-terminal degron regions 
of substrate proteins. 
UBR6 and UBR7 are also mammalian proteins that contain a UBR box domain but 
have no documented activity in the N-end Rule. The only other characterised 
domains within these proteins are an F-box (UBR6) or a PHD (plant homeodomain, 
UBR7) (T Tasaki et al. 2005), see Fig. 1.2 and Fig. 1.3. These are both potential E2 
interaction domains that would be required for activity within the N-end Rule and/or 
the UPS. However, neither of these genes have confirmed activity either in N-terminal 
degron binding or in ubiquitination (Juliana Muñoz-Escobar, Kozlov, and Gehring 
2017; Adhikary et al. 2019; Zimmerman et al. 2014) and so cannot be assumed to act 
as N-end Rule E3 ubiquitin ligases. 
Finally, recent research has found proteins with a UBR-like ZZ domain that appear 
to act in the N-end Rule, binding the N-terminus of target proteins and directing 
them for degradation via the autophagy-lysosome pathway. For example, p62 (also 
known as SQSTM1) is a mammalian E3 ubiquitin ligase that binds the arginylated N-
terminus of ER (endoplasmic reticulum) chaperones such as BiP via its ZZ-domain 
(Cha-Molstad et al. 2015). Through this pathway, Arg-BiP mediates the degradation 
of bound, misfolded proteins. 
 
1.1.2.4 Substrate Binding Specificity in the Arg/N-end Rule 
Substrate binding specificity for the UBR proteins that act as N-end Rule E3 
ubiquitin ligases is regulated by two protein domains: the UBR box, a highly 
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conserved 70-residue zinc-finger-like motif which is shared across all UBR proteins 
(E Matta-Camacho et al. 2010), and the N-domain, which has high homology with 
the bacterial ClpS domain and is common to both mouse proteins UBR2 and UBR1. 
The UBR box alone is able to bind Type I, or arginine-containing, target peptides, but 
both this and the N-domain are required for Type II, or phenylalanine-containing, 
peptide binding by UBR1 and UBR2 (T Tasaki et al. 2009). 
There is also evidence to suggest that, at least UBR1, is also able to bind to non-
acetylated Met-Φ proteins, aiding in their degradation as a redundant role for the 
degradation of acetylated Met-Φ proteins by the Ac-N-end Rule pathway (J. M. Kim 
and Hwang 2014). This requires both the UBR box and the N-domain and, given that 
the second residue is often bulky, for example tryptophan or phenylalanine, appears 
to be most related to canonical Type II N-end Rule degradation pathways used by 
UBR proteins. 
Although UBR2 contains both a UBR box and an N-domain, the two protein domains 
required for both Type I (basic) and Type II (bulky hydrophobic/aromatic) substrate 
binding, it has strongest detectable binding to Type II substrates (T Tasaki et al. 
2005). As an isolated protein domain, the UBR2 UBR box is able to bind Type I 
peptide substrate sequences in vitro, to a similar affinity as that observed for the 
isolated UBR1 UBR box (E Matta-Camacho et al. 2010). However, this affinity 
appears to be much reduced when the whole UBR2 protein is present (T Tasaki et al. 
2005), indicating a potential structural conformation that favours Type II substrate 
binding. This could alternatively indicate a level of competitive binding between UBR 
proteins, as UBR1, UBR4 and UBR5 are all also present in these in vitro binding assays. 
It is possible that in some contexts UBR2 also binds Type I substrates in vivo. 
However, UBR1, UBR4 and UBR5 are all strongly detectable in Type I binding assays, 
are ubiquitously coexpressed in a large majority of tissues or cell types. Therefore, in 
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the majority of contexts, these are likely the primary Type I regulators of the N-end 
Rule pathway. 
These four UBR proteins, which all have similarities in their recognised substrate 
degron sites, are likely to exhibit some redundancy in their substrate binding ability. 
This has been functionally demonstrated between the two most similar UBR proteins: 
UBR1 and UBR2. Single null mutant mice for Ubr2-/- exhibit some developmental 
defects including a variably penetrant female-specific embryonic lethality (Y T Kwon 
et al. 2003). A Ubr1-/- mouse is viable but exhibits growth defects particularly in the 
skeletal or adipose tissue (Y. T. Kwon et al. 2001). However, in a double null mouse 
there is a more penetrant embryonic lethality, associated with defects in neurogenesis 
and cardiovascular development that are not linked to either of the single mutant 
phenotypes. This indicates one is able to compensate for the function of the other in 
multiple developmental pathways (Jee Young An et al. 2006). 
An example of redundancy outside these two highly conserved proteins is in the 
knockdown of Ubr4 by RNAi in cultured fibroblasts that already exhibit a  Ubr1-/- 
Ubr2-/- phenotype. Alone, the double mutant has a slight increase in both Type I and 
Type II N-end Rule reporter proteins, but additional knockdown of Ubr4 results in a 
loss of Type II N-end Rule turnover, although another component of the Type I N-
end Rule persisted in these cells – potentially UBR5. This indicates that they at least 
partially compensate for turnover of the same substrates, but as this is a reporter 
system there is no in vivo evidence that UBR1/UBR2 have overlapping biological 




Figure 1.3 The Mammalian UBR E3 Family 
The mammalian UBR family are a group of mammalian proteins that all contain the conserved 
UBR box (red), which undergoes direct interaction with the N-terminus of target proteins. 
Within the family, there is a high level of variation in the protein size, E2 binding and other 
domains. UBR1 and UBR2 are the most highly conserved within this group, each 200kDa and 
containing an N-domain (pale blue) for Type II N-end Rule activity. They each contain a RING 
domain for E2 binding activity (green-blue), and a UAIN (UBR auto-inhibitory domain, yellow). 
UBR3 has no confirmed activity as an N-end Rule ubiquitin ligase, instead acting through internal 
degron binding, but contains a UBR box, RING domain and UAIN. UBR4 is the largest of the 
UBR proteins, at 570kDa, and contains a CRD (cysteine-rich domain, orange). UBR5 is the final 
UBR protein known to be active in the N-end Rule, specifically in Type I binding. It contains the 
UBR box for Type I binding, and has a HECT E2 binding and ubiquitin transfer domain (purple). 
UBR6 and UBR7 are the smallest of the UBR family and neither have any documented roles in the 
N-end Rule or in ubiquitination. 




















1.1.3 E2/E3 Interaction Dynamics and the E3 RING Domain  
There are three major classes for E3s: those containing either the RING, HECT or RBR 
domains. These domains determine specificity to the E2 ubiquitin-conjugating enzyme and 
dictate the mechanism by which ubiquitin is transferred to the target protein. E3 ligases 
within the UBR family, although they are conserved in their substrate binding domain, are 
variable in this instance and so are expected to interact with a varied array of E2 enzymes. 
UBR5 contains a HECT domain, which undergoes temporary ubiquitination as a proximal 
transfer point for build-up of ubiquitin chains before transfer to the substrate (M. Wang and 
Pickart 2005; Sluimer and Distel 2018). Additionally, UBR5 does not undergo canonical 
interaction with its associated E2 enzyme UBCH4 and is able to carry out E2-independent 
ubiquitin-transfer (Edna Matta-Camacho et al. 2012; Shen et al. 2018). There are no known 
UBR proteins with an RBR domain, which is a highly specialised E2 binding domain that is 
also able to catalyse ubiquitin transfer in an E2-independent manner (Spratt, Walden, and 
Shaw 2014). 
UBR1 and UBR2 both contain a RING domain, which interacts with E2 enzymes through 
sequence-specific contacts at the RING domain surface (Deshaies and Joazeiro 2009). E2-E3 
interactions are highly variable, but there are three known E2 proteins that have been shown 
to interact with UBR2 and act in its ubiquitination of substrates: UBE2A/B, USE1 (C. W. P. 
Lee et al. 2011) and UBE2O (H. Xu et al. 2019). The coding regions of human UBE2A and UBE2B 
paralogues share 80%  identity and the proteins have 96% amino acid identity (Koken et al. 
1991); they are distinctly expressed and have different but overlapping functions in the mouse 
(Roest et al. 2004, 1996), but are biochemically indistinguishable and so are assumed to be 
functionally indistinct. They are both documented in complex with E1 ubiquitin activator 
UBA1 (Y T Kwon et al. 2003; C. W. P. Lee et al. 2011). USE1 is an E2 known to participate in 
a ubiquitination cascade with the E1 ubiquitin activator UBA6 (J. Jin et al. 2007; Groettrup et 
al. 2008). This E1 is present in mammalian cells, but not many lower eukaryotes such as S. 
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cerevisiae, and so the UBA6-USE1 cascade is not as well studied as the other major E1 protein 
UBA1. Finally, UBE2O was most recently identified as a potential interactor of UBR2, both 
being required for the N-end Rule-mediated proteolysis of the NLRP1B inflammasome (H. Xu 
et al. 2019). UBE2O is an E2/E3 hybrid protein that has been implicated in the turnover of 
orphan proteins that are misfolded as a result of loss of their protein complex (Yanagitani, 
Juszkiewicz, and Hegde 2017). This function appears to be independent of any canonical E3 
ligase, but it appears that UBE2O is able to carry out the role of an E2 alongside the UBR2 E3 
as well. 
There are 300 human genes encoding RING domain-containing proteins, most of which are 
expected to be at least partially active as E3 ubiquitin ligases (Wei Li et al. 2008). In S. 
cerevisiae, there are around 50 RING-encoding genes (Finley et al. 2012), and this increase in 
absolute gene number between species is generally attributed to evolutionary conservation 
and duplication, generating families of orthologous proteins that have overlapping functions 
(Deshaies and Joazeiro 2009). This gives a level of assumed redundancy within higher 
eukaryotes which indicates the importance of the UPS for proteome homeostasis and 
regulation in mammalian systems and could be extended to the existence of both UBR1 and 
UBR2 as mammalian homologs of S. cerevisiae UBR1.The canonical RING domain is a cysteine-
rich protein domain with conserved histidine residues that coordinate two zinc molecules in 
the core of their structure. This is similar, but structurally and functionally distinct, to the 
zinc finger DNA-binding structure (Freemont 1993; Freemont, Hanson, and Trowsdale 1991). 
Outwith these core residues, the intervening amino acids in the RING domain sequence can 
be variable, although there are several conserved residues across a variety of RING domain 
containing proteins that, through structural and mutational studies, have been shown to be 
important for physical contacts to the E2 ubiquitin ligase structures. For example, bulky 
hydrophobic residue, such as W408 (Tryptophan) in c-Cbl, is often found on the exposed 
49 
 
surface of the RING domain and the sidechain of this residue sits in the binding cleft of the 
E2 enzyme (C. W. P. Lee et al. 2011; Deshaies and Joazeiro 2009). 
E2-E3 interaction tends to be highly dynamic and transient, allowing quick replacement with 
newly ubiquitin-charged E2 enzymes, and efficient extension of the substrate ubiquitin chain. 
E3 enzymes often interact with more than one E2, which could depend on the substrate or 
the type of ubiquitination chain being constructed. Therefore, it is difficult to reliably predict 
E2-E3 pairs. In addition, it is generally thought that E2 enzymes will only bind to the RING 
domain after thioesterification and ubiquitin-charging, and that the uncharged E2 
competitively binds between the E1 enzyme and the E3 RING domain. Binding of the RING 
domain to the E2-Ub thioester complex promotes discharge of the Ub to an acceptor – i.e. 
lysine residues in the target protein, as well as other ubiquitin molecules. The E2 and the 
substrate for ubiquitination in complex with an E3 ligase are generally far apart when in 
complex with the RING E3 enzyme. Some RING proteins require additional modifications to 
stabilise the E2 interaction and promote ubiquitin transfer across this distance, for example 
linkage proteins (J. Liu and Nussinov 2010) or even autoubiquitination of either the E2 or E3 
proteins themselves (Patel, Sibbet, and Huang 2019). 
Given the highly variable dynamics of E2-E3 interactions, this gives an even higher level of 
variability in the UPS than even conferred by the large number and diversity of ubiquitin 
ligase-encoding genes (W Li and Ye 2008). Therefore, caution must be taken in the study of 
RING-E3 and E2 protein pairs. Introduction of specific mutations into the RING domain in 
an attempt to prevent binding to E2’s and generate a functionally “catalytically dead” E3 
protein,  must take into account potential variation in binding conformation  and at least some 




1.1.4 The 26S Proteasome 
After substrate proteins are tagged via the E1-E2-E3 cascade of ubiquitination, they are 
targeted to the proteasome for degradation. This is a 26S protein complex that acts as the 
major eukaryotic protease to degrade proteins tagged with ubiquitin in both the cytosol and 
the nucleus. It is an AAA+ ATPase motor and acts to unravel the higher order structure of 
target proteins through ATP hydrolysis. It has very low selectivity, acting to deubiquitinate 
and degrade a wide variety of eukaryotic proteins that have been polyubiquitinated (Bedford 
et al. 2010). 
The complex consists of a 20S hollow core, a base complex, and a lid complex. The base and 
lid together are a 19S protein complex and act as the ubiquitin-recognition site (Tanaka 
2009). Within this complex, subunits Rpn10, Rpn13 or Sem1 act to bind ubiquitin-conjugated 
proteins, and are the first binding point for ubiquitinated substrates (Shi et al. 2016; 
Rosenzweig et al. 2012; Hamazaki, Hirayama, and Murata 2015; Kragelund et al. 2016; 
Paraskevopoulos et al. 2014). These intrinsic proteasomal ubiquitin receptors do not exhibit 
exclusive recognition for particular ubiquitin chains as a signal for degradation at the 
proteasome, although there is a bias towards K48-ubiquitin chains (Tsuchiya et al. 2017). 
The Rpn11 subunit is an example of the stably associated deubiquitinases (DUBs) in the 
proteasome, which act to remove the poly-ubiquitin chain from substrates and allow 
unfolding and translocation of the substrate itself into the proteasome core. In addition to 
ubiquitin chains, substrates also require an unstructured initiation region which can act as a 
starting point for unfolding in the 20S core. Components of the proteasome avoid degradation 
while close to the AAA+ ATPase core by lacking this unstructured or flexible region (Bedford 





1.1.4.1 Regulatory Functions of Proteasomal Degradation 
Given the high specificity of E3 substrate binding, the proteasomal protein 
degradation pathway can act to specifically degrade proteins that are required to be 
short-lived, for example in response to cellular conditions. One such example of this 
is the necessity for proteasomal activity in NLRP1 inflammasome activation in the 
innate immune response, which is a response to bacterial infection by B. anthracis and 
subsequent exposure to anthrax lethal toxin (LT) (Sandstrom et al. 2019; Chui et al. 
2019). In fact, the N-end Rule E3 ubiquitin ligase UBR2 was recently identified in 
NLRP1 inflammasome activation (H. Xu et al. 2019). LT exposure in mammalian 
macrophage cells induces cleavage of NLRP1B, generating a neo-Type II N-degron 
sequence on the C-terminal fragment. Caspase-1, which stimulates the immune 
response in these cells, is activated by the cleaved N-terminal fragment of NLRP1B, 
and this response depends on degradation of the C-terminal fragment by the N-end 
Rule. siRNA knockdown of either UBR2 or the E2 ubiquitin conjugating enzyme 
UBE2O results in a vulnerability of macrophages to the B. anthracis infection and a loss 
of the immune response, implying that UBR2 specifically binds the C-terminal 
fragment for proteasomal degradation. 
Another recently identified role of the Arg/N-end Rule in a regulatory function of 
proteasomal degradation is the conditional degradation of the genome surveillance 
protein SDE2 (Rageul et al. 2019). This protein is endolytically cleaved in response to 
DNA replication stress in order to negatively regulate monoubiquitination of PCNA 
(proliferating cell nuclear antigen), which is a cell stress response that prevents 
progression of DNA replication forks. Thus, SDE2 acts to protect against cellular 
stress and promotes progression of DNA replication and S-phase (Jo et al. 2016). After 
cleavage of SDE2, the neo-N-terminus of the C-fragment encodes a Type I N-degron 
which has been shown to be turned over through proteolysis. Stable siRNA 
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knockdown of either N-end Rule E3-encoding genes Ubr1 or Ubr2 results in a 
significant stabilization of the SDE2 C-terminal fragment, and both of these are 
required for the DNA stress response to UV irradiation. UBR1 and UBR2 are 
redundant in this capacity, and both must be removed to fully stabilise the C-terminal 
SDE2 protein (Rageul et al. 2019). The activity of the Type I Arg/N-end Rule in this 
capacity acts alongside CRL4CDT2 E3 ubiquitin ligase under stressed conditions, 
adding another layer of redundancy to an essential cellular process (Jo et al. 2016). 
Interestingly, this is an in vivo Type I function of UBR2, although peptide pulldown 
assays do not show a particular affinity for Type I peptide sequences by UBR2 protein 
(T Tasaki et al. 2005). This shows that there are in vivo roles for proteins such as UBR2 
that cannot necessarily be predicted by in vitro pulldown or binding assays.t 
1.1.4.2 Misfolded or Orphan Protein Turnover 
As described, degradation of specific proteins can be important for the functioning of 
pathways under various conditions in the cell, but a much more diverse function of 
the UPS is in the recycling of misfolded or denatured proteins. This acts in 
partnership with the lysosomal mode of protein degradation, which in itself is vital 
for turnover of proteins (Jackson and Hewitt 2016). Partial denaturation of cellular 
proteins can be caused by a variety of conditions – either in the initial folding process, 
which has been estimated to result in misfolding errors from 5-30% of the time (U. 
Schubert et al. 2000; Hartl and Hayer-Hartl 2002), or in destabilisation of complex 
components leading to orphan proteins that have exposed and vulnerable interaction 
sites (Juszkiewicz and Hegde 2018). Defects in either of these pathways has been 
associated with a large variety of disorders, including aggregation of misfolded 
proteins as in Parkinson’s or Alzheimer’s disease (Q. Zheng et al. 2016), and 
degradation of misfolded but still healthy proteins, such as the binding of CHIP 
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chaperones to immature CFTR in some mutational backgrounds of cystic fibrosis 
(Meacham et al. 2001). 
Misfolded proteins are targeted to the proteasome in a two-step process. First, 
molecular chaperones act to protect exposed areas of misfolded or orphan proteins, 
allowing them to refold without aggregation. At this point, chaperones can either 
commit to refolding, or degradation of the protein in question. One of the determining 
factors at this step is the co-chaperone protein CHIP, which has E3 ubiquitin ligase 
activity and binds to Hsp70 or Hsp90 (heat shock proteins, known protein folding 
chaperones) in order to target bound proteins to the UPS, recycling amino acid 
components for new protein synthesis (Marques et al. 2006).  
However, in addition to the activity of E3 ligase CHIP, there is some implication for 
the N-end Rule in these pathways, which have historically been associated with 
sequence-specific binding at the N-terminus of target proteins (Tasaki et al., 2012, and 
section 1.1.2). As discussed in section 1.1.2.1, UBR proteins have a recently identified 
role as a compensatory pathway for the Ac/N-end Rule to turnover misfolded 
proteins, both in S. cerevisiae (Eisele 2008) and in mammalian systems (J. M. Kim and 
Hwang 2014; Nguyen et al. 2019; Shemorry, Hwang, and Varshavsky 2013). 
Outside of the N-end Rule, a non-canonical role in protein quality control has been 
identified for S. cerevisiae Ubr1 (Heck, Cheung, and Hampton 2010; Nillegoda et al. 
2010; Eisele and Wolf 2008), as well as S. pombe Ubr11 (Kriegenburg et al. 2014). In 
both species, this is dependent on the interaction of the protein chaperone Hsp70 to 
misfolded proteins in the cytoplasm (Summers et al. 2013; Kriegenburg et al. 2014), 
similarly to mammalian CHIP E3 (Marques et al. 2006). No such pathway has thus 
far been identified for mammalian UBR proteins, but it should be noted that CHIP E3 
ubiquitin ligase is not encoded in the S. cerevisiae genome (Heck, Cheung, and 
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Hampton 2010), and so UBR proteins may not be required for non-N-end Rule 
chaperone-assisted cytoplasmic proteostasis in the mammalian system. 
Additionally, the ZZ-domain N-end-like pathway is implicated in turnover of 
misfolded proteins via the autophagy-lysosome pathway, potentially through K63 
ubiquitination; p62 binds the arginylated N-terminus of ER chaperone BiP to mediate 
turnover of misfolded ER proteins (Cha-Molstad et al. 2015). 
 
1.1.5 Non-Proteasomal Functions of Ubiquitination 
Although the best studied function of ubiquitination is in the turnover of proteins tagged with 
polyubiquitin chains, there are a variety of different ubiquitin configurations that encode 
different signaling functions in a eukaryotic cell. While a straight polyubiquitin chain is made 
up of a series of ubiquitin proteins typically ubiquitinated at the K48 residue, K33, K29, or 
K63 are all also common ubiquitination sites on the ubiquitin molecule and this indicates 
roles for a variety of differently structured polyubiquitin chains (W Li and Ye 2008). K63 
ubiquitin chains have been implicated in induction of autophagy through recognition by p62 
(Seibenhener et al. 2004; Pankiv et al. 2007) and therefore an alternative protein degradation 
pathway through the autophagosome, which can be active in degradation of protein 
aggregates that are too large for regular proteolytic activity (Reggiori and Klionsky 2005). 
K29 and K33 ubiquitin-linkages have been implicated in specialised polyubiquitin chains in 
the regulation of AMPK kinase activity, in balance with the deubiquitination enzyme USP9X 
(Al-Hakim et al. 2008). 
Aside from variants in polyubiquitin chains, monoubiquitination and multiubiquitination are 
the conjugation of single ubiquitin molecules across the surface of the substrate. These have 
been generally associated with regulation of protein interactions, acting to promote binding 
to proteins containing ubiquitin-binding domains (Hicke 2001). Monoubiquitination is 
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sufficient to promote internalization and lysosomal endocytosis of ubiquitinated membrane-
bound substrate RTKs (receptor tyrosine kinases) (Haglund et al. 2003). 
The specific combination of substrate protein, E2 ubiquitin conjugating enzyme and E3 
ubiquitin ligase confers the ubiquitin modification that is carried out. RING-type E3 
ubiquitin ligases bind to a variety of E2’s and these determine the ubiquitin chain formation 
(Christensen, Brzovic, and Klevit 2007; H. T. Kim et al. 2007). HECT-type E3’s however 
usually confer Ub chain linkages directly via a variable N-terminal region of the domain (M. 
Wang and Pickart 2005). There is also evidence to suggest that sequence-specific interactions 
take place between the catalytic core of the E2 and the surrounding residues in either the 
substrate or the ubiquitin molecule being ubiquitinated, which regulates the length of the 
ubiquitin chain and depends on both the substrate and the E2 present (Sadowski et al. 2012; 
Sadowski and Sarcevic 2010). Without knowing the structural conformation of their three-
way transient interaction or which individual E2/E3 pair is involved in a ubiquitination 
reaction, it is difficult to predict which ubiquitin modification is utilised. Therefore, it is 
possible that individual E2 or E3 proteins are able to carry out multiple different 
ubiquitination activities, depending on the substrates bound and E2/E3 interaction utilised, 
so targeting individual substrates for any number of degradation or regulatory functions in 
the cell. 
The N-end Rule E3 ubiquitin ligase UBR proteins are generally implicated in protein 
turnover, whether through N-end Rule or non-N-end Rule substrate binding pathways. This 
is reflected in the known ubiquitin linkages they carry out. For example, UBR2 acts alongside 
either E2 ubiquitin conjugating enzymes USE1 or UBE2A in order to deposit K48-linked Ub 
chains on RGS4/5 substrates, which have an N-terminal Type I degron sequence (C. W. P. 
Lee et al. 2011; M. J. Lee et al. 2005). UBR4 and UBR5 have been shown to recognise K63-Ub 
chains deposited by other E3’s such as ITCH, and deposit Ub at K48 in order to generate 
56 
 
forked Ub chains, which have also been associated with proteasomal degradation (Ohtake et 
al. 2018). 
Additionally, UBR2 has been implicated in a regulatory role for ubiquitination of histones in 
meiotic spermatocytes, by monoubiquitination of histone H2A. In somatic cells, this is 
mediated by Polycomb complex component and E3 ubiquitin ligase RING1B (D. E. Cohen and 
Lee 2002) and is a repressive chromatin mark which is important for X-inactivation or 
transcriptional silencing (D. E. Cohen and Lee 2002). The sex chromosomes of spermatocytes 
are only synapsed at the PAR during prophase I, and so they must be transcriptionally 
silenced in what is called meiotic sex chromosome inactivation (MSCI) (J. M. A. Turner 2007). 
This is mediated by monoubiquitination at H2A, but instead of RING1B, UBR2 localises to 
the XY body in the pachytene nucleus, and acts to ubiquitinate H2A alongside the E2 
ubiquitin conjugating enzyme HR6B (J Y An et al. 2010). There is no clear N-terminal degron 
sequence in histone H2A, and so it has been hypothesised that this acts through either non-
canonical internal degron binding, potentially through the UAIN domain, or as-yet undefined 




1.2 UBR2 and TEX19.1 
The mammalian UBR family is highly diverse, only united by the common UBR box domain 
that is able to physically bind to the N-terminus of target proteins for substrate 
ubiquitination (E Matta-Camacho et al. 2010; J Muñoz-Escobar et al. 2017). The UPS is a 
versatile system and covers a wide variety of proteome homeostasis functions, as well as 
regulation of short-lived proteins in context-specific pathways. Furthermore, the ubiquitin 
signalling system is much more diverse than simple canonical UPS-related degradation 
(Sadowski et al. 2012; W Li and Ye 2008; Hicke 2001). These revelations have implications in 
the study of UBR2’s known roles across male meiotic progression, female embryonic survival 
(Y T Kwon et al. 2003) or its recently uncovered role in cohesin regulation (J Reichmann et al. 
2017). 
The N-end Rule E3 ubiquitin ligase UBR2 is encoded by the gene Ubr2, conserved between 
both human and mouse genomes. Mouse Ubr2 is a 46 exon gene that encodes a 200kDa protein, 
which is one of four E3 ubiquitin ligase UBR proteins that have been shown to be active in 
the N-end Rule (T Tasaki et al. 2005), and is particularly prominent in Type II N-end Rule 
binding, although some Type I ability has been identified in vivo genetic studies (T Tasaki et 
al. 2009; Takafumi Tasaki et al. 2012; Rageul et al. 2019). A wide variety of roles for the UBR2 
protein have been identified, involving degradation of N-end Rule targets such as 
inflammasome NLRPB1 and stress regulator SDE2 (see section 1.1.4.1 and Rageul et al., 2019; 
Xu et al., 2019). These have not been identified as prominent phenotypes in a Ubr2-/- context 
and the latter can also be regulated by UBR1. Given that there is so much potential for 
redundancy between the UBR proteins in the N-end Rule, discussed in detail in section 1.1.2.4, 
it is interesting that a Ubr2-/- mouse has a very specific subset of phenotypes, indicating 
essential functions of the gene in the testis and in embryonic development (Y T Kwon et al. 




A Ubr2-/- embryonic stem cell (ESC) line also has a phenotype, indicating a role for the N-end 
Rule in cohesin regulation in these cells, which may be related to the role in cohesin regulation 
in the mouse (Reichmann et al. 2017), as well as in retrotransposon derepression (unpublished 
data, Karen Dobie, MRC HGU – discussed in more detail in Chapter 5). 
Tex19.1 is a gene primarily expressed in hypomethylated tissues, including the testes, ovaries 
and placenta (Ollinger et al. 2008). The TEX19.1 protein interacts with UBR2 (Maclennan et 
al. 2017), and its expression pattern broadly overlaps the tisues which exhibit phenotypes in 
the Ubr2-/- mouse (Ollinger et al. 2008; Y T Kwon et al. 2003; Yang et al. 2010). Ectopic 
expression of Tex19.1 in a Flp-In-293 cell line results in specific protection of GFP Type II N-
end Rule reporters implying that its interaction with UBR2 may antagonise UBR2 N-end 
Rule activities (J Reichmann et al. 2017). 
 
1.2.1 Similarities between Ubr2-/- and Tex19.1-/- Phenotypes 
There are two major phenotypes of a Ubr2-/- mouse model that appear to confer specific roles 
of the UBR2 protein that cannot be compensated for by other UBR proteins. The most well 
characterised of these is in male meiotic progression (Yang et al. 2010), and there is also an 
embryonic lethality that appears to be of variable penetrance depending on the genetic 
background (Y T Kwon et al. 2003). These wild type processes are described in detail in 
sections 1.4 and 1.5, respectively. 
Meiosis is a continuous process in males, occurring asynchronously throughout adult life. 
Recombination and crossing over of genetic material is a vital part of this, giving rise to genetic 
variation and diversity in the population (Cole, Keeney, and Jasin 2012). With a lack of Ubr2, 
there is an asynapsis of chromosomes during prophase I, which is associated with loss of 
recombination foci and defects in the homology search (Crichton et al. 2017). This leads to 
gross spermatocyte apoptosis and male infertility, which can be characterised by gross 
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morphological changes in the seminiferous tubules of the testis, low testis weight and a lack 
of mature sperm (Y T Kwon et al. 2003). This phenotype is very similar to that characterised 
in the infertile Tex19.1-/- male, which has an asynaptic arrest and reduction in recombination 
rates (Crichton et al. 2017). Indeed, TEX19.1 protein is destabilised in the Ubr2-/- testis (Yang 
et al. 2010), indicating that their interaction is vital for normal spermatogenesis. However, it 
remains unclear whether the phenotype is a result of lack a functional TEX19.1-UBR2 
complex, perhaps through TEX19.1’s regulation of N-end Rule activity, or if UBR2 is simply 
required for TEX19.1 stabilisation in this tissue, producing such a stark phenocopy between 
these male mice. Aside from UBR2, the UBR protein with the highest Type II N-end Rule 
affinity is UBR1 (T Tasaki et al. 2005), and these are expressed to similar levels in the testes 
(Fig. 5.1). However, there is a difference in the cell types that express UBR1 and UBR2 in this 
tissue; UBR1 is highly expressed in spermatogonia, whereas UBR2 is specifically expressed in 
spermatocytes (Y T Kwon et al. 2003). This implies that the Ubr2-/- testis may have lost a 
specific Type II N-end Rule function in spermatocytes that cannot be compensated by UBR1 
redundancy, resulting in the observed phenotypes. 
The embryonic lethality present in Ubr2-/- mice is also similar to that observed in the Tex19.1-/- 
mouse. TEX19.1 is expressed in the trophoblast-derived tissues of the placenta, and in a  
Tex19.1-/- there are embryonic growth restrictions and a placental defect that arises around 
E12.5 days of development (J Reichmann et al. 2013; Tarabay et al. 2013). This has been linked 
to derepression of retrotransposons, particularly LINE-1, as well as increased expression of 
placental imprinted genes (Reichmann et al., 2013 and Playfoot et al. 2019, manuscript 
submitted, MRC HGU). We are thus far unaware of any placental defects in a Ubr2-/- context, 
but embryonic growth restriction and partially penetrant female-biased lethality in these 
mice (Y T Kwon et al. 2003) leads to my hypothesis that TEX19.1 and UBR2 are working 
together in placental development and support of embryonic growth. 
60 
 
Finally, surviving Ubr2-/- females are reported to be subfertile, but due to female-biased 
embryonic lethality the role for UBR2 or the N-end Rule in female meiotic processes has not 
been extensively studied (Y T Kwon et al. 2003). Tex19.1-/- females have a subfertility associated 
with chromosome missegregation and aneuploidy in the oocyte. This results from a 
misregulation of an acetylated subunit of the cohesin complex, SMC3, and chromosome 
cohesion defects (J Reichmann et al. 2017). The dynamics of the cohesin complex are 
discussed further in section 1.3, but in brief: acetylation of the SMC3 cohesin subunit, present 
in every known cohesin complex, is associated with a “cohesive” subpopulation of the 
complex. SMC3 acetylation is most well understood in mitosis, and it acts to recruit cohesin 
maintenance factor sororin (Ben-Shahar et al. 2008) to “lock” cohesin onto the chromosome 
axis. There are key differences in this dynamic in meiotic cells, as sororin appears to localise 
to chromosome axes independently of cohesin or SMC3 acetylation (Gómez et al. 2016; Jordan 
et al. 2017). Additionally, Tex19.1 is not expressed in the majority of mitotic cell types, 
indicating that it acts in a meiosis-specific AcSMC3 regulatory pathway. Regardless, 
AcSMC3 appears to be required for normal chromosome segregation (J Reichmann et al. 2017), 
and so study of how TEX19.1 protein is able to regulate this cohesin subpopulation, 
potentially through its interaction with UBR2, will give insights into the importance of SMC3 
acetylation in the oocyte.  
1.2.2 A Model for TEX19.1-UBR2 Complex Function 
Although Ubr2 is ubiquitously expressed, the only prevalent phenotypes in a Ubr2-/- mouse at 
least partially phenocopy the Tex19.1 phenotypes in these tissues. Therefore, the TEX19.1-
UBR2 complex appears to be important for N-end Rule functions in the testis, the placenta 
and, potentially, in the meiotic oocyte. 
UBR2 has recently been implicated in chromosomal stability and regulation of the cohesin 
complex in mitotic tissues (Jee Young An et al. 2012; J Reichmann et al. 2017) and so this could 
imply a previously unidentified role for TEX19.1-dependent N-end Rule regulation of cohesin 
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during oogenesis.  The Ubr2-/- mouse has a TEX19.1-independent role in mitotic AcSMC3 
regulation – in the spleen, in absence of Ubr2, chromosome-bound AcSMC3 is specifically 
increased, and other cohesin subunits including total SMC3 levels are unaffected (J 
Reichmann et al. 2017). This implies that UBR2 is able to negatively regulate the acetylated 
cohesin complex, whether this acts through direct turnover via the N-end Rule or through an 
indirect pathway (Fig. 1.4A). Ubr2-/- ESCs also have a specific increase in AcSMC3 
(unpublished data, Karen Dobie, MRC HGU). Tex19.1 is expressed in this cell type, and a 
Tex19.1-/- ESC line has a reduction in chromatin-associated AcSMC3, similarly to that observed 
in the Tex19.1-/- oocyte. Therefore, our group has hypothesised that TEX19.1 protein binds to 
UBR2 and acts to protect AcSMC3, potentially by inhibiting its role in the N-end Rule (Fig. 























Figure 1.4 The TEX19.1-UBR2 Complex 
A. In the mitotic mouse spleen, in absence of TEX19.1, the E3 ubiquitin ligase UBR2 is able to 
specifically (but not necessarily directly) turn over AcSMC3, i.e. the acetylated subpopulation of 
cohesin. B. In presence of TEX19.1, in both mitotic mESCs (mouse embryonic stem cells) and 
meiotic oocytes, TEX19.1 binds to UBR2 and inhibits its turnover of AcSMC3, so protecting the 























1.3 Chromosome Cohesion in the Mitotic Cell Cycle 
Among many other molecular functions, the N-end Rule E3 ubiquitin ligase UBR2 has been 
shown to play a role in genomic stability (Ouyang et al. 2006) and our lab have recently shown 
that UBR2 regulates cohesin complexes in the mitotic spleen (J Reichmann et al. 2017). 
Sister chromatid cohesion, and the protein complex that carries it out – cohesin – is essential 
for genomic stability during the DNA synthesis and mitotic phases of the cell cycle (K 
Nasmyth and Haering 2009). The cohesin complex also plays a major role in interphase 
chromatin organisation, being instrumental alongside CCCTC-binding factor (CTCF) in the 
formation and maintenance of loops and TADs (topologically associated domains) that have 
been associated with chromatin compartmentalisation and long-range transcriptional 
regulation (Schwarzer et al. 2017; G. Wutz et al. 2017). Misregulation of the cohesin complex 
in a meiotic context, particularly in oocytes, has been associated with chromosome 
missegregation, aneuploidy and subfertility (Jessberger 2012; Herbert et al. 2015). Little is 
understood about meiotic cohesin, and so insights from the study of UBR2’s role in mitotic 
cohesin regulation may tell us more about the regulation of the complex in a meiotic context. 
 
1.3.1 The Cohesin Complex 
Cohesins are a group of protein complexes that associate with the chromosome axes during 
S phase and both mitotic and meiotic cycles, acting to hold sister chromatids together until 
chromosome division in mitotic anaphase or meiotic anaphase II. There are also regulatory 
roles for the cohesin complex during interphase of both cell cycles. Structurally, the complex 
is made up of three subunits that make up a tripartite ring: two SMCs (structural 
maintenance of chromosomes) and a kleisin. Accessory proteins such as SA1 or SA2 and other 
interactors also bind and regulate the complex’s behaviour (Nasmyth, 2009), see Fig. 1.5. 
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SMC (structural maintenance of chromosomes) proteins form the core of the cohesin complex. 
These are highly conserved large 110-170kDa proteins which consist of a globular ATPase, that 
encompasses both the N- and C-terminal domains, a long anti-parallel coiled-coil domain and 
a globular hinge domain, which interacts with the hinge domain of other SMC proteins 
(Haering et al. 2002). The ATPase domain has recently been shown to mediate interaction 
between cohesin and its host DNA molecule (Çamdere, Carlborg, and Koshland 2018; 
Chapard et al. 2019; Hirano 2002), acting to entrap two strands of DNA between the kleisin 
and SMC ATPase heads. This activity has been implicated in the interaction of the cohesin 
complex with chromatin motor proteins, for cohesin translocation in the loop extrusion 
model of chromatin organisation (Ladurner et al., 2016; Nuebler et al., 2018). However, there 
are no implications for roles of the ATPase in sister chromatid cohesion itself. 
There are 6 known mammalian SMC proteins, and these form the basis of three major known 
complexes: cohesin (SMC1/3), condensin (SMC2/4) and the SMC5/6 complex (Skibbens 
2019). Within cohesin, the canonical mitotic complex is made up of SMC3 and SMC1α. SMC3 
is present in all known cohesin complexes, but SMC1β can form also complexes in a meiotic 
context (Anderson et al. 1999). 
Kleisin proteins are a highly evolutionary conserved family, and the major mammalian cohesin 
kleisin is RAD21, which is homologous to the S. cerevisiae kleisin SCC1 (Richardson, Morell, 
and Faulkner 2014). There are meiosis-specific cohesin kleisins REC8 and RAD21L, which act 
to form a variety of different cohesin complexes in a meiotic context (Anderson et al. 1999). 
The only conserved domains between these proteins, and the kleisins involved in the 
condensin complex, are the N- and C-terminal interaction domains with either SMC protein, 
and so is has been surmised that the major function of this protein class is to close the cohesin 
ring and hold the complex together, so holding cohesed DNA molecules together (Richardson, 
Morell, and Faulkner 2014), as well as to recruit the final component of the complex, an SA 
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protein. These differences in structure may, however, result in differences in function between 








Figure 1.5 The Cohesin Complex 
Cohesin is a large multiprotein complex that is made up of two SMC proteins (SMC3 and 
SMC1α), which each have an ATPase head and interact through their globular hinge domains. 
Canonical mitotic subunits are shown in bold, and meiotic alternatives in brackets. The canonical 
kleisin subunit is RAD21, and this links the ATPase heads of the two SMC subunits via its N- and 
C-terminal ends. The kleisin recruits accessory proteins SA1 or SA2, which in turn are the binding 
site for WAPL, a cohesin removal factor. Binding of sororin to WAPL-cofactor PDS5A/B inhibits 





The accessory proteins SA1 or SA2, also known as STAG1 or STAG2 (stromal antigens 1 and 
2) specifically bind to the kleisin subunit (Zhang et al. 2013). These are highly functionally 
redundant, but are the most implicated of all cohesin complex components in oncogenic 
mutations associated with chromosome cohesion (J. S. Smith et al. 2016). These are differently 
localised during meiosis; SA1 is required for telomeric stability, and depletion of the protein 
results in aneuploidy during mitotic cell cycle (Kostova et al. 2009). SA2 is required for 
maintenance of centromeric sister chromatid cohesion, as well as chromatin structure and 
replication fork integrity during S-phase (Canudas and Smith 2009; Mondal et al. 2019). SA2 
is also important for cohesin-mediated DNA damage repair during S/G2 phase, although both 
SA1 and SA2 are necessary for the S phase DNA damage checkpoint (Kong et al. 2014). Meiotic 
SA3, or STAG3 (stromal antigen 3), is specifically expressed in meiotic cells and localises 
along the chromosome axes during meiosis (Prieto et al. 2001). Indeed, SA3 is required for 
formation of the axis and synapsis of meiotic homologs during prophase I (Winters, McNicoll, 
and Jessberger 2014). Both SA1 and SA2-cohesin complexes are also present along the 
chromosome axis during meiosis (Prieto et al. 2002); the variation in different cohesin 
complexes during this specialised cell division indicates the highly varied roles for different 
cohesins. 
The interaction between the cohesin complex and chromatin is thought to be topological, 
meaning that the ring structure doesn’t directly interact with DNA through a specific 
sequence (Haering et al. 2002). There are two major models for how this interaction takes 
place: the ring model, or the handcuff model. The ring model utilises a single cohesin ring to 
hold two strands of DNA in close conformation; either pairs of sister chromatids during cell 
division, or cis-acting DNA strands in chromatin structural regulation. The handcuff model 
instead suggests that each DNA strand is held by a single cohesin ring, which then interact 
together in a dimeric complex to bring the strands together. This dimer may be mediated 
through anti-parallel interaction of two RAD21 kleisin subunits, the structure of which 
requires direct interaction of the kleisin with either SA1 or SA2 (Zhang et al. 2008, 2013). This 
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‘handcuff’ model would be advantageous in adaptability of cohesin-regulated interactions of 
regions, for example in loop formation, without unloading and reassembly of the cohesin 
complex. 
 
1.3.2 Cohesin Dynamics in the Mitotic Cell Cycle 
The mammalian mitotic cell cycle is made up of four stages. G1, or the first growth phase, is 
followed by S phase, when DNA synthesis occurs. After this, the cell enters a second growth 
phase, G2, before entry into mitosis (M phase). During this, chromosomal alignment and cell 
division occur. The cell cycle, and the dynamics of the cohesin complex through these stages, 
are summarised in Fig. 1.6. 
After DNA replication in S-phase, pairs of sister chromatids need to be physically connected 
throughout G2 and early mitosis. Correct segregation of chromosomes into balanced euploid 
daughter cells is one of the most important processes of the cell cycle, and so this physical 
connection must be maintained up until separation at anaphase of the mitotic division. This, 
at least in part, is mediated by the cohesin complex, which holds pairs of sister chromatids 
together. Cohesin is first associated with chromatin during G1, which is a process which 
requires ATPase activity and  the heterodimeric chaperone complex NIPBL-MAU2, 
homologous to the S. cerevisiae complex SCC2/SCC4 (Watrin et al. 2006; Visnes et al. 2014; 
Rhodes et al. 2017). The complex assembles fully before association with chromatin (Losada 
2014), and is loaded onto DNA through an ‘entry’ gate between the two SMC subunits (Fig. 
1.5). Throughout G1, the cohesin complex is dynamically loaded and unloaded, as cohesin 
release factor WAPL associates with the kleisin subunit (Fig. 1.6) and catalyses dissociation 
of the kleisin with SMC3, opening an ‘exit’ gate (Tedeschi et al. 2013). Once S-phase 
commences, acetyltransferases ESCO1 and ESCO2 are able to acetylate the SMC3 subunit at 
two lysine residues towards the protein’s N-terminus (K105 and K106 in both mouse and 
human SMC3), which acts to ‘lock’ cohesin onto chromatin during DNA replication (Ben-
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Shahar et al. 2008). This acetylation recruits the cohesin maintenance factor sororin (Fig. 1.6), 
which is antagonistic of WAPL activity, so maintaining the cohesin complex by blocking 
opening of the ‘exit’ gate (Nishiyama et al. 2010). The WAPL accessory proteins PDS5A or 
PDS5B (Fig. 1.6) have been associated both with cohesin removal (G. Wutz et al. 2017; 
Nishiyama et al. 2010) and with establishment of the cohesin complex potentially through 
promotion of SMC3 acetylation by the acetyltransferases ESCO1 or ESCO2 (Hons et al. 2016; 
Carretero et al. 2013). This indicates an essential cohesin regulatory function of PDS5 proteins, 
beyond simply acting as WAPL cofactors. 
There are two phases of cohesin dissociation during mitosis: in prophase, and during 
anaphase. Prophase dissociation occurs along the chromosome arms as sororin is 
phosphorylated by Aurora B and Cdk1 kinases (Borton et al. 2016; Nishiyama et al. 2013). This 
allows WAPL activity and opening of the ‘exit’ gate between the SMC3 and kleisin subunit. 
Centromeric cohesin molecules are protected from this dissociation step by the centromeric 
localisation of SGO1 (Shugoshin) and PP2A (Protein Phosphatase 2A), which act to 
dephosphorylate sororin and maintain the WAPL antagonism that was established earlier in 
the cell cycle (Fig. 1.6). There is also evidence to suggest that SGO1 and WAPL act as a second 
layer of regulation, directly competing for binding sites on the SA1 or SA2 subunit and 
enhancing the protection of cohesin from WAPL-mediated removal at the centromere (Hara 
et al. 2014). 
Centromeric cohesion must be maintained until the spindle fibres have properly attached to 
kinetochores at the centromeres, ensuring even division of chromosomes during segregation 
and cell division. Once the spindle assembly checkpoint (SAC) has been satisfied, anaphase 
commences, during which SGO1 and PP2A dissociate from the centromere (Fig. 1.6). This has 
been hypothesised to be in part due to the physical forces put onto bioriented sister chromatid 
kinetochores as they are pulled away from each other during spindle depolymerisation 
(Nerusheva et al. 2014). SGO1 and PP2A inhibit the enzyme separase (Sun et al. 2009; Clift, 
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Bizzari, and Marston 2009; Holland et al. 2007; Lianga et al. 2018), and upon SGO1-PP2A 
dissociation, separase cleaves the RAD21 kleisin (Uhlmann, Lottspelch, and Nasmyth 1999). 
Another mechanism for regulation of separase-mediated kleisin cleavage is in the APC/C 
(anaphase-promoting complex, or cyclosome) itself, which is a component of the SAC. 
Separase is bound by a chaperone protein called securin, which prevents its enzymatic 
activity, until the SAC is satisfied (Luo and Tong 2018; Holland et al. 2007). At this point, 
APC/C phosphorylates securin (Toda et al. 2012), allowing activity of separase and so 
promoting cohesin dissociation and allowing the chromosomes to divide. Cohesin 
components are recycled and SMC3 is deacetylated by the histone deacetylase HDAC8 (Fig. 
1.6), and these protein subunits can then form new cohesin complexes in the new G1 phase 
daughter cells (Dasgupta et al. 2016). 
Aside from sister chromatid cohesin during the cell cycle, the interphase roles of cohesin also 
require association and disassociation with chromatin. With loss of CTCF, which is 
associated with cohesin in formation of TADs and TAD boundaries (Hansen et al. 2017), 
cohesin is still associated with interphase chromosomes (Wendt et al. 2008), implying that 
CTCF acts to organise cohesin’s ability to restructure chromatin, but the loading and 
regulation of cohesin itself involves other mechanisms. This is at least in part regulated by the 
binding of WAPL cohesin removal factor, which has been associated with the size of 
chromatin loop structures and regulation of cohesin’s hypothesised ability in loop extrusion 
(G. Wutz et al. 2017). PDS5 proteins appear to be involved in regulating CTCF and the 
boundaries of loop extrusion in a WAPL-independent manner (G. Wutz et al. 2017). 
Maintenance of cohesin complexes via SMC3 acetylation has also been associated with 
interphase chromatin architecture (Kawasumi et al. 2017), and the role of PDS5 proteins in 







Figure 1.6 Cohesin Dynamics in the Mitotic Cell Cycle 
Cohesin complexes are dynamically loaded and unloaded throughout G1-phase, via an entry gate 
between the hinge regions of the two SMC subunits and an exit gate between SMC3 and the 
kleisin subunit, as a result of WAPL activity. In S-phase, the SMC3 subunit is acetylated, 
recruiting cohesin maintenance factor sororin, which inhibits WAPL activity and maintains 
chromosome cohesion. Mitotic progression involves both a prophase and an anaphase dissociation 
step, which involve sororin phosphorylation and WAPL activity, and separase activity, 
respectively. Cohesin components are recycled into G1 of the daughter cells’ cycle. Taken from 




Somatic mutations in cohesin subunits or regulatory pathways result in a group of 
pathologies known as cohesinopathies. One of the most well-studied human cohesinopathies 
is Cornelia de Lange syndrome (CdLS), which is characterised by intellectual disability and 
distinctive craniofacial and limb developmental morphologies (Kline et al. 2018). This has 
been associated with human mutations in cohesin chaperone NIPBL, the SMC subunits and 
the kleisin RAD21 (Deardorff et al. 2012). Other cohesinopathies include Roberts syndrome 
(RBS) and Warsaw Breakage syndrome (WABS). RBS patients have growth and mental 
retardation, limb deformities and craniofacial defects. These are thought to be a result of 
widespread translational errors, stemming from defects in chromatin architecture and 
pericentromeric heterochromatin morphology (Whelan et al. 2012), as well as widespread 
mitotic aneuploidies and cell apoptosis (Banerji, Skibbens, and Iovine 2017). These symptoms 
are associated with a loss of cohesin acetylation as a result of mutations in ESCO2, which is 
specifically localised to pericentromeres and acts to acetylate the SMC3 subunit (Dupont et 
al. 2014; Kawasumi et al. 2017), so promoting dissociation of sister chromatids and potential 
chromosome missegregation during the mitotic cell division. Both null Esco1 or Esco2 mice are 
embryonic lethal and there are no documented human ESCO1 mutations, possibly because this 
would also be embryonic lethal (Gordillo et al. 2008; Banerji, Skibbens, and Iovine 2017). 
WABS is a rare cohesinopathy associated with congenital microcephaly and sensorineural 
hearing loss, alongside a wide range of developmental abnormalities (Alkhunaizi et al. 2019). 
This is associated with mutations in the DNA helicase DDX11/ChIR1 required for DNA repair 
and replication fork stabilization. Lack of functional DDX11 results in chromosomal breakages 
and disorganization of heterochromatin (Pisani et al. 2018). DDX11 is required for 
establishment of chromosome cohesion during DNA replication by association with 
replication fork protection factors and has recently been shown to interact with cohesin 
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complexes in vitro (Cortone et al. 2018), indicating that it has a vital role in cohesin loading 
and functions during S phase. 
Given the widely varied roles for cohesin in the mitotic cell, both in interphase and during 
mitosis, molecular consequences of these mutations can vary from global transcriptional 
changes as a result of chromatin remodeling, associated with CdLS, to mitotic cell cycle failure 
as a result of aneuploidy and apoptosis, which is associated with RBS (Banerji, Skibbens, and 
Iovine 2017). 
In addition to the wide array of developmental disorders associated with defects in the 
cohesin complex, there is also an association between cohesin defects during meiosis, 
particularly in oocytes from older women, and reduced fertility or increased incidence of 
miscarriage as a result of chromosome missegregation and aneuploidy (Herbert et al. 2015). 





1.4 Meiosis and Genomic Stability during Reproduction 
1.4.1 Aneuploidy and Fertility 
Aneuploidy is an imbalance in the number of chromosomes in a given cell type; aneuploidy 
arising during gametogenesis, as a result of chromosome missegregation during the two 
meiotic divisions, leads to a variety of reproductive or developmental disorders. The outcome 
of chromosome missegregation can be highly variable depending on the chromosomes 
involved in the aneuploidy. For example, one of the most common cases of aneuploidy 
documented in human gametes is trisomy 21: a third copy of chromosome 21, which leads to 
the developmental disorder Down Syndrome (Xing et al. 2016). However, the vast majority of 
embryonic aneuploidies involving whole chromosomes are incompatible with live birth and 
undergo either spontaneous early onset miscarriage or cannot lead to pregnancy at all, 
resulting in subfertility of the ovulating female. Subfertility or pregnancy complications as a 
result of meiotic aneuploidy arise in 10-30% of human pregnancies and, interestingly, over 95% 
of these are a result of meiotic errors during oogenesis – i.e. chromosome missegregation 
during female meiosis, as opposed to chromosome missegregation in the male meiotic cells 
(Hassold and Hunt 2001). 
The incidence of meiotic aneuploidy increases exponentially with maternal age; at the age of 
20, women are likely to experience aneuploid pregnancies 5% of the time, but at the age of 40, 
this incidence increases to 35%. This rate is estimated to be higher than even this, but early 
spontaneous abortion is often missed and not always linked directly to aneuploidy (Hassold 
and Hunt 2001). This is exacerbated in society by the growing social trend that women wait 
until they are older to have children; in the USA, for example, there was an 8-fold increase in 
the number of women choosing to have their first child over the age of 35 between 1970 and 
2006 (Matthews and Hamilton 2009). 
In addition to meiotic segregation errors, mitotic chromosome instability can lead to 
chromosome missegregation in the first few mitotic divisions, giving rise to mosaic 
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aneuploidy in the early embryo (Daughtry and Chavez 2016; Magli 2000). A large proportion 
of these early embryos undergo spontaneous abortion before the blastocyst stage (Bielanska 
2002). However, these are not significantly associated with maternal age, and instead are 
thought to arise as a result of relaxed checkpoint controls during the first few mitotic 
divisions (McCoy et al. 2015; Mantikou et al. 2012). 
Meiotic aneuploidy is a leading cause of birth defects or miscarriage (Hassold and Hunt 2001), 
and although we are able to diagnose it during both natural pregnancies and IVF (in vitro 
fertilisation), potentially avoiding it by selecting for healthy oocytes in the latter, there are no 
current clinical strategies for prevention during oogenesis (Nagaoka, Hassold, and Hunt 
2012). This means that study of aneuploidy is vital to improving fertility technology and 
increasing the ability of people to have children at a wider range of life stages, to align with 
their own social and reproductive priorities. 
Laboratory mice are not often maintained beyond their standard reproductive lifespan (8 to 
11 months), roughly equivalent to those of human women with increased aneuploidy 
incidence, and at this age there is not an equivalent aneuploidy rate recorded (Koehler et al. 
2006). However, 16-month aged mice have been associated with increased chromosome 
missegregation rates (Sakakibara et al. 2015). 
 
1.4.2 The Two Meiotic Divisions 
Mammalian meiosis is a two-stage specialised cell division in which four copies of each 
chromosome, generated by DNA replication in S phase, are segregated into haploid gametes, 
first by separation of the pairs of homologous chromosomes in Meiosis I (MI), and the 
segregation of the two sister chromatids within each homolog pair in Meiosis II (MII). 
Haploid gametes then combine during fertilisation to produce a diploid zygote, which will 
then proceed through development. These are largely similar between oogenesis and 
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spermatogenesis, but there are key differences between male and female reproductive systems 
that result in specific adaptations in either spermatogenesis or oogenesis. 
1.4.2.1 Prophase I: Synapsis and Recombination 
Prophase I is a stage of meiosis that encompasses the processes of homology searching, 
chromosome synapsis and homolog recombination during MI (Soh et al. 2017). After 
DNA replication in S phase, chromosomes enter what is called leptotene of prophase 
I (Fig. 1.7). They undergo widespread double-strand break (DSB) formation by 
topoisomerase-like SPO11 protein (Keeney 2008), and then 5’ DNA resection occurs 
to yield 3’ single-stranded tails (Neale, Pan, and Keeney 2005; Neale and Keeney 2006). 
This facilitates a homology search within the nucleus, and 3’ tails undergo strand 
invasion of their intact homolog, leading to recombinant products that can resolve 
into either crossover or non-crossovers of genetic material (Allers and Lichten 2001; 
Baudat and de Massy 2007). These recombinant repair events are able to act either 
with the homolog, or the sister chromatid – but in meiotic cells, there is thought to 
be a bias towards homolog-repair, leading to genetic crossovers (Humphryes and 
Hochwagen 2014). 
During this process, chromosome synapsis occurs – and this depends on formation of 
the synaptonemal complex (SC), a proteinaceous scaffold that forms an axis along 
which the homologous chromosomes are able to align. The SC is made up of three 
component parts. First, the lateral element made up of proteins such as SYCP2 and 
SYCP3, which localise to chromosomes in the leptotene stage of prophase I (Fig. 1.7). 
It forms individual axes by polymerisation (Baier, Alsheimer, and Benavente 2007; 
Syrjänen, Pellegrini, and Davies 2014) along each homolog, and as they align during 
homolog DSB repair, the cell enters zygotene (Fig. 1.7). Transverse filaments and the 
central element of the SC such as the proteins SYCE1, SYCE2 and SYCP1 form a 
ladder-like structure that holds the two homologs together in a long axis (Y. Costa et 
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al. 2005; Bolcun-Filas et al. 2007; Hernández-Hernández et al. 2016; Dunne and Davies 
2019). The next and longest stage of prophase I, pachytene (Fig. 1.7), is defined as 
when all chromosomes in a prophase I nucleus are fully synapsed and the SC has 
“zipped” together, i.e. the LE and CE are fully formed along the length of the SC. DSB 
repair occurs primarily in this stage, in which homologs recombine and either 
produce crossover or non-crossover events (Baudat and de Massy 2007). The 
mismatch repair heterodimer MLH1/MLH3 localises and carries out crossover repair 
(Falque et al. 2007; Rogacheva et al. 2014). The final stage of prophase I is diplotene 
(Fig. 1.7), in which the SC begins to “unzip” and homologous chromosomes are only 
held together at their recombination points. At this point, the SC dissociates and 
genetic crossovers mature into chiasmata, marking the onset of prometaphase I. 
Chiasmata are physical connections between genetic material at crossover points that 
act to maintain bivalent structure without proteinaceous scaffolds such as the SC or 
cohesin complexes (Bascom-Slack, Ross, and Dawson 1997). 
Throughout prophase I, sister chromatids are held together by the cohesin complex 
(Fig. 1.8), which is a tripartite protein ring complex. The structure of this complex 
was discussed in further detail in section 1.3.1. There are multiple meiosis-specific 
cohesin subunits, including SMC1β and kleisin proteins such as REC8 and RAD21L 
(Fig. 1.5). Given that all mitotic subunits are also present during meiosis, this gives a 
huge variability in the potential cohesin complexes that are present in the meiotic cell. 
These are thought to carry out a variety of different functions in the organisation of 
chromatin and sister chromatid cohesion during MI. SMC1α and SMC1β-containing 
cohesins share a role in SC axial length regulation during meiosis, but SMC1β is 
specifically required to prevent a DNA damage response at telomeres (Hodges et al. 
2005; Ekaterina Revenkova et al. 2004; Biswas, Stevense, and Jessberger 2018). 
Additionally, REC8 and RAD21L-containing cohesin complexes are spatially distinct 
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along the chromosome axis in prophase I (Rong et al. 2016), and these have been 
shown to be required for distinct roles in SC formation and chromosome synapsis 
(Ishiguro et al. 2011; Herrán et al. 2011; Fukuda et al. 2014; Ward et al. 2016). Therefore, 
it seems that dynamics of different cohesin complexes are tightly regulated 








Figure 1.7 Meiotic Prophase I Progression 
The four stages of meiotic Prophase I. Pairs of sister chromatids are aligned and held together by 
cohesin rings (black bars), and double strand breaks (DSBs) form in leptotene. Each pair of 
homologous chromosomes begins to line up as a result of the homology search in zygotene, and 
once the full lengths of the homologs are aligned and synapsed, the cell progresses into pachytene. 
DNA recombination and crossing over occur here, and then the synaptonemal complex begins to 
break down, allowing desynapsis except for the crossover points in diplotene. 




1.4.2.2 Metaphase I: Chiasmata Stability and Homolog Segregation 
After crossover maturation into chiasmata, the two homologs of each chromosome 
are maintained in their bivalent complex via sister chromatid cohesion within each 
homolog, carried out by cohesion complexes (Brooker and Berkowitz 2014). Cohesin 
complexes downstream of the crossover hold together the original sister chromatids, 
so holding the two homologs together and stabilising the position of the chiasma (Fig. 
1.8). Bivalents align on spindle fibres in metaphase I, and chiasmata act to provide 
tension against the spindle forces until chromosomes are fully aligned, so reducing 
the incidence of premature chromosome separation. 
The majority of aneuploidies detected in oogenesis are a result of non-disjunction or 
missegregation events that occur during the first meiotic division (Pellestor et al. 
2002), although there are missegregation events that arise during MII as well 
(MacLennan et al. 2015). Maintenance of MI chromosome cohesion is vital for normal 
segregation at both these stages, and so it is key that chromosome cohesion is 
protected throughout Metaphase I to allow proper attachment of spindle fibres, so 
chromosome segregation can occur. 
Kinetochores are large proteinaceous structures that form at the centromere of each 
sister chromatid and act, among many other regulatory functions, as attachment 
points for the spindle microtubules (Thomas, Renjith, and Manna 2017; Joglekar and 
Kukreja 2017). Attachment of the spindle occurs in mitotic cells in a bipolar 
orientation, allowing segregation of the two sisters to either end of the cell. Meiotic 
kinetochores instead align in a monopolar orientation in MI, allowing segregation of 
the sisters within each homolog pair towards the same direction, and then in a bipolar 
orientation in MII, generating a haploid cell upon division (Sakuno, Tada, and 
Watanabe 2009; MacLennan et al. 2015). 
79 
 
Oocytes are among very few cell types that lack a specific centriole structure for 
spindle nucleation, having disassembled it during prophase I, and instead have 
multiple aMTOCs (acentriolar microtubule-organizing centres), which are protein 
complexes essential for normal cell division and production of euploid cells 
(Baumann et al. 2017; Szollosi, Calarco, and Donahue 1972). Via the RAN-GTPase 
pathway, spindle fibres extend towards the kinetochore centromeric structures of 
meiotic bivalent chromosomes, and attach. After arm cohesion has degraded, 
microtubules rapidly depolymerise in order to pull the homologous chromosomes 
apart, and centromeric cohesion holds each pair of sisters together. During oogenesis, 
the meiotic spindle is asymmetrically positioned by activity of actin filaments in order 
to carry out the unequal divisions and polar body extrusion (PBE) that maintain 
maternal cytoplasmic resources (Mogessie, Scheffler, and Schuh 2018). 
To ensure maintenance of sister chromatid cohesion throughout formation of the 
spindle, so preventing premature separation and missegregation of chromosomes, 
eukaryotes have evolved the spindle assembly complex (SAC), in which the APC/C 
(Polanski 2013) signals for removal of arm cohesion along each bivalent through 
cohesin complex cleavage and depolymerisation of the microtubule filaments, so 
pulling the homologous pairs apart and towards each end of the dividing cell 
















Figure 1.8 Meiotic Cohesin Establishment 
The cohesin complex (red) holds sister chromatids together along their full axis length and, after 
crossovers occur and resolve into chiasmata during Prophase I, hold the bivalent structure of the 
two homologs (blue and yellow) together, downstream of the chiasma. Oocytes go into dictyate 
arrest and, upon ovulation in adulthood, resume meiosis and progress into pro-Metaphase I. After 
a short dictyate arrest, cohesin complexes are present in abundance on the chromosome arms, 
holding the chiasmata in place while the chromosomes align on spindle fibres in Metaphase I. 
However, a longer dictyate arrest (i.e. an older female) is associated with a reduction in the 
number of cohesin complexes present along the chromosome arms, which destabilises the 
Metaphase I bivalent structure and increases the chance of premature separation before proper 






















1.4.2.3 Meiosis II: Segregation of Sister Chromatids 
After the first meiotic division is complete, meiocytes then progress into MII. This 
stage is shorter, as there is no need for further exchange of genetic material. Pairs of 
sister chromatids are held together by centromeric cohesin complexes, and the 
kinetochores are bi-orientated on spindle fibres, much like in Metaphase I. 
Spermatocytes progress through cell division, but oocytes arrest at Metaphase II until 
fertilisation with mature sperm, upon which time centromeric cohesion breaks down 
(MacLennan et al. 2015; Perry and Verlhac 2008). Again, only in oocytes, asymmetric 
positioning of the spindle is achieved by actin anchoring against the egg’s surface, this 
time parallel to the oocyte membrane (Mogessie, Scheffler, and Schuh 2018). When 
cell division occurs, the second polar body is extruded and half of each pair of sister 
chromatids is left in the oocyte, giving a haploid female nucleus which can then fuse 
with the haploid sperm nucleus to produce a diploid single-cell zygote. 
 
1.4.3 Gendered Gametogenesis 
The stark difference between male and female incidence of aneuploidy could be attributed to 
sexual dimorphism between male and female meiosis itself. One of the key differences 
between these is the timing of gametogenesis; spermatogenesis begins at puberty and occurs 
continuously throughout adulthood. However, oogenesis is not a continuous process and 
begins during embryonic development of the ovary, undergoing two arrests: dictyate, at the 
end of prophase I (MacLennan et al. 2015), and the metaphase II arrest (Perry and Verlhac 
2008). Prophase I, involving synaptonemal complex formation and pairing of homologous 
chromosomes in an aligned conformation (see section 1.4.2.1), proceeds synchronously in the 
embryonic ovary between E14.5-E18.5 in the mouse embryo (Dietrich and Mulder 1983; 
Reichman, Alleva, and Smolikove 2017). After crossovers have occurred, the cells go into an 
extended arrest phase, known as dictyate arrest (Fig. 1.8). Meiosis does not resume until 
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immediately prior to ovulation; in humans this is after puberty and could be anything from 15 
to 40 years later, and in laboratory mice this is between 2 and 12 months later, assuming a 
normal reproductive lifespan. Therefore, the dictyate arrest needs to be stable and able to 
maintain crossovers over this long period of time, allowing sufficient tension between the 
spindle and chiasmata on the bivalent in metaphase I. 
 
1.4.4 Hypotheses for Oocyte Aneuploidy 
Increased maternal age has long been associated with a decline in fertility, long before the 
onset of menopause. The underlying molecular cause is not fully understood, although there 
are a few prominent hypotheses. One of the original hypotheses centered on a ‘production line’ 
of oocytes that entered foetal meiosis stages in the same order that they then exited the 
dictyate arrest at ovulation, and that the number of crossovers established during the foetal 
period decline as development progresses. Therefore, oocytes ovulated later in life would have 
been produced later in embryogenesis, have less crossovers and less chiasmata, and so 
chromosomes would be more likely to prematurely dissociate during meiotic progression, 
resulting in aneuploidy (Polani and Crolla 1991). However, this have been repeatedly 
disproved, as oocytes isolated from different foetal stages show no difference in crossover 
frequency (Rowsey et al. 2014; Polani and Crolla 1991; Tease and Fisher 1986; Speed and 
Chandley 1983). 
Aside from chromosome aneuploidies, another theory to explain the maternal age effect 
includes a decrease in mitochondrial DNA (mtDNA) copy number. Mitochondria are the 
powerhouse of the cell; they are highly specialised organelles that generate ATP to provide 
energy for essential cellular functions via the electron transport chain. The mitochondria 
encode their own mtDNA, of which there are between 1 and 15 copies per organelle. Control 
of this copy number is vital for normal cellular function and oocyte cell division is associated 
with an asymmetric division in mitochondria; the majority of the organelles are retained in 
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the oocyte nucleus to promote ATP production during preimplantation development. It has 
been shown that polar bodies isolated from older women contain mitochondria with lower 
copy numbers (C. C. W. Chan et al. 2006; Konstantinidis et al. 2014). However, surprisingly, 
early embryo and blastocyst mtDNA copy number are increased from older women, and so 
there appears to be a recovery of mitochondrial mtDNA replication in the early stages of 
development (Elpida Fragouli et al. 2015). Interestingly, lower mtDNA copy numbers at this 
stage of development are associated with embryonic survival (Diez-Juan et al. 2015), and 
higher copy number has been associated with lower oocyte quality and increased aneuploidy 
rate (Elpida Fragouli et al. 2015). This indicates that although mtDNA copy number may 
decline with age, this does not have a direct link to the increase in aneuploidy associated with 
older oocytes. 
Of the currently debated hypotheses behind age-related oocyte aneuploidy, those with the 
most molecular basis are: an increased chance of chromosome missegregation as a result of 
failed maintenance of chromosome cohesion at crossovers, or lower stringency at the spindle 
assembly checkpoint (SAC), resulting in premature depolymerisation of the meiotic spindle 
before proper attachment of each chromosome. These are discussed in detail in sections 1.4.4.1 
and 1.4.4.2. 
Aside from chromosomal or molecular changes over time, the age and health of the 
surrounding tissue environment may play a role, and these are not necessarily mutually 
exclusive with some of the prevailing molecular theories. Indeed, it is likely that aneuploidy 
is actually a consequence of multiple overlapping factors, both on a molecular and systemic 




1.4.4.1 Meiotic Chromosome Cohesion 
Chromosome cohesion and regulation of the cohesin complex during meiosis shares 
some similarities with regulation of mitotic cohesin, although there are major 
adaptations for the differences in cell cycle progression. There are two meiotic 
divisions, and so cohesins are maintained on sister chromatid centromeres through 
the first division of homologous pairs, and then cohesin at sister centromeres is 
removed prior to segregation in the second division (Brooker and Berkowitz 2014). 
Both chromosome arm and centromeric cohesion are established in S-phase and 
intact throughout Prophase I, and arm cohesion acts to stabilise chiasmata, holding 
the bivalent together through alignment of the spindle in metaphase I. At the first 
metaphase-anaphase transition, cohesin complexes are removed along the 
chromosome arms, but maintained at the pericentromeric region. Changes in 
chromosome arm cohesion have been linked to chromosome missegregation during 
Meiosis I. Live imaging experiments on young and old mouse oocytes shows that 
bivalents separate into univalents during metaphase I more frequently in older 
oocytes, then bi-orient on the MI spindle, so being more susceptible to 
missegregation (Sakakibara et al. 2015). 
Loss of chromosome cohesion at metaphase I is often linked to the loss of 
chromosome-bound cohesin complexes, which act to hold sister chromosomes 
together during prophase I homology repair and recombination. Senescence-
accelerated mice (SAM), which have a natural premature ageing phenotype, show a 
marked decrease in cohesin subunits including REC8 and SMC1β on oocyte 
chromosomes and reduced cohesion of chromatids at MI and MII compared to wild 
type mice (L. Liu and Keefe 2008). Meiotic cohesin subunit REC8 is depleted with 
age – immunofluorescence shows a of chromosome-associated protein in aged wild 
type prometaphase I oocytes (isolated from 14 month old female mice), alongside a 
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reduction in chromosome arm cohesion (Lister et al. 2010; Chiang et al. 2010; 
Tachibana-Konwalski et al. 2010) – and there is no apparent mechanism for 
replenishment of the protein after removal from the chromosome axes (Burkhardt et 
al. 2016). Similarly, Smc1β expression only in prophase I provides sufficient protein for 
normal sister chromatid cohesion and chromosome segregation in MI and MII (E 
Revenkova et al. 2010), as opposed to a full Smc1β-/- which results in defects in MI 
oocyte sister chromatid cohesion (Hodges et al. 2005). Finally, the most recently 
identified kleisin subunit, RAD21L, is necessary for female fertility only with age, 
implying a dependence on these complexes when REC8-containing complexes are 
depleted in later life (Herrán et al. 2011). Loss of both chromosome cohesion and 
chromosome-associated cohesin complexes has also been observed in oocytes 
isolated from older human women; in particular, the subunits REC8 and SMC1β were 
decreased in the oocytes isolated from otherwise healthy women around the age of 40 
years or over, as compared to 20 year old controls (Tsutsumi et al. 2014). 
Together, these data point to the idea that cohesin is maintained without further gene 
expression in prophase I and later stages, resulting in a slow depletion of the 
complexes from chromosomes in dictyate arrest. This is illustrated in Fig. 1.8, in 
which a longer dictyate arrest (in an older woman) results in a decreased abundance 
of cohesin rings associated with the chromatin, allowing premature chromosome 
separation to occur upon commencement of Metaphase I. 
As discussed above, it is thought that different meiosis-specific cohesin complexes 
carry out different functions (Ward et al. 2016; Anderson et al. 1999; Wolf et al. 2018; 
Biswas, Stevense, and Jessberger 2018). Cohesin depletion with age occurs primarily 
with REC8-containing complexes, although RAD21L and SMC1β-containing 
complexes are necessary with age (Herrán et al. 2011; Biswas, Stevense, and Jessberger 
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2018), indicating that different complexes are able to at least partially carry out the 
function of REC8-containing complexes if required. 
 
1.4.4.2 SAC Stringency 
The spindle assembly checkpoint (SAC) operates prior to anaphase I and ensures that 
chromosomes are correctly attached to the meiotic spindle before segregation. It is 
thought that, unlike in spermatocytes, the oocyte SAC triggers the metaphase-
anaphase transition when only a threshold of microtubule-kinetochore attachments 
are achieved, leaving room for error in a small proportion of sisters that may not be 
correctly attached as the chromosomes begin to separate (Polanski 2013; Kolano et al. 
2012). Transcriptional analysis in the human pro-metaphase II oocyte shows an age-
related decrease in spindle checkpoint-associated genes such as BUB1B (BubR1 
protein) and CDK1 (D. J. Baker et al. 2004; E Fragouli et al. 2010; Riris, Webster, and 
Homer 2014). In the GV-stage (germinal vesicle) mouse oocyte, expression of Atrx is 
decreased between old and young mice (Pan et al. 2008). This is a heterochromatin 
remodeler but is not required for spindle organisation until metaphase II (De La 
Fuente et al. 2004). These transcriptional changes offer no clear explanation for the 
increasing incidence of aneuploidy as a woman gets older, as the majority of 
chromosome missegregation occurs in MI (Sakakibara et al. 2015) and there appear 
to be no functional consequences at this stage as a result of loss of expression. Timing 
of anaphase I in old (16-19 month) mouse oocytes is unchanged, indicating no 
perturbation of the SAC (Duncan et al. 2009) and, furthermore, there are no 
differences in the timing of polar body extrusion of germinal vesicle breakdown onset 
in old or young mice, even when aneuploidy rates are increased (Lister et al. 2010). 
This indicates that, although there are changes in SAC regulators between old and 
young mice, there does not appear to be a particular perturbation of the SAC itself, 
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and so these changes are not sufficient to be solely causative of ageing oocyte 
missegregation. 
  
1.4.4.3 Ovarian Tissue Environment 
The traditional view of the ovarian tissue environment during the ageing process is 
that there is a generic oocyte pool that is slowly depleted over time (Warburton 
2005), as dictyate arrested oocytes resume meiosis and are ovulated individually. This 
has been the prevailing theory of oogenesis since its conception in the 1950s 
(Zuckerman 1951). However, new evidence implies that there may be a small ovarian 
stem cell pool, although the biological significance is as yet unknown (Johnson et al. 
2004; Bukovsky et al. 2004; Telfer and Anderson 2019). This could point to a 
depletion of stem cell environment with age (H. Ye et al. 2017), contributing to a 
declining molecular environment and poor oocyte quality later in life. These cells can 
be cultured in vitro and differentiated into oocyte-like meiocytes, with the distinctive 
large cytoplasmic area and expression of germ cell-specific marker genes such as 
DAZL and SYCP3 (Parte et al. 2014). 
However, there is much debate surrounding the existence of this stem cell pool, and 
whether they differentiate during adulthood into oocytes for ovulation, which has not 
thus far been shown in vivo. Oocytes actively going through prophase I have only been 
detected in embryonic ovaries (Reichman, Alleva, and Smolikove 2017) and genetic 
experiments show that oocytes that are ovulated during adulthood are maintained 
from embryonic prophase I. Depletion of cohesin molecules during adulthood but 
before ovulation results in aneuploid oocytes, which are unable to correctly segregate 
their chromosomes during the meiotic divisions (Tachibana-Konwalski et al. 2010) – 
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indicating that there is no cohesin turnover or replacement after the initial loading 
period in embryonic prophase I. 
Instead of acting to directly supplement the oocyte population, it has been suggested 
that this ovarian stem cell pool may play a role in maintaining the follicular cell 
environment (Eppig and Wigglesworth 2000; Kerr et al. 2006; Albertini 2004), or 
could exist as a quiescent ‘backup’ pool that is not functional under normal 
reproductive conditions (Yuan et al. 2013). Regardless, the majority of ovulated 
oocytes do not appear to be derived from this stem cell population, instead being 
maintained in a stable state since embryonic prophase I. 
With reproductive age and repeated instances of ovulation, the ovarian tissue goes 
through many physical and molecular changes and there is a documented increase in 
tissue fibrosis and degradation of surrounding support cells over time (Briley et al. 
2016). Young women with reproductive conditions such as PCOS (polycystic ovarian 
syndrome) that result in ovarian scarring or cysts do not exhibit an increased risk of 
meiotic aneuploidy (Weghofer et al. 2007), although they exhibit reduced fertility 
due to hormonal or ovulatory defects. Therefore, there is no direct link between the 
scarring prevalent in older women and aneuploidy or subfertility. 
 
1.4.4.4 Systemic Ageing 
The ovary is not an isolated tissue, and female meiosis is very responsive to systemic 
changes in hormonal balance and interaction of different tissues together (Nelson, 
Telfer, and Anderson 2013). With age, pre-menopausal human female hormonal levels 
can fluctuate (Musey et al. 1987), and low AMH (anti-Mullerian hormone) and high 
FSH (follicle stimulating hormone) in women have been associated with increased 
incidence of embryo aneuploidy (Thum, Abdalla, and Taylor 2008; X. Jiang et al. 2018). 
Human studies on the long-term effects of hormonal contraceptive-induced ovulation 
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arrest are limited, but there is a potential link between this and increased fertility in 
later life (Farrow et al. 2002; Ford and MacCormac 1995), implying that the reduced 
number of ovulation events or menstrual cycles can play a role in ovarian health. 
However, this has not been directly linked to oocyte aneuploidy rates, and there are 
many other factors including uterine environment and maternal health that can play 
a role in the balance of female fertility rates. Additionally, hormonal effect is not 
clearly separated from wider issues of maternal age; high FSH alone cannot induce 
meiotic aneuploidy (Thum, Abdalla, and Taylor 2008) and there are factors other than 
hormonal levels at play in age-related aneuploidy and subfertility (Warburton 2005), 
including depletion in oocyte number with age, depletion of chromosome-associated 
cohesin complexes and decreasing stringency of the SAC. 
 
There are multiple prevailing theories on the molecular origins of oocyte aneuploidy and it is 
important to consider them all in tandem. However, the hypothesis with the most direct 
evidence behind it is the changes in chromosome cohesion, linked to declining levels of 
cohesin complex components. Aside from chromosome cohesion, the cohesin complex has 
been linked to genomic stability and large-scale chromatin structure (G. Wutz et al. 2017; 
Hansen et al. 2017), and so I would hypothesise that this is a causative molecular deficiency. 
Even oxidative stress and loss of SAC stringency have been linked to decline in function of 
the cohesin complex (Miao et al. 2017; Perkins et al. 2016), and so investigation of oocyte 







1.5 Placentation and its Role in IUGR 
The Ubr2-/- mouse has been documented to exhibit a variable perinatal lethality across 
different genetic strain backgrounds. This is more penetrant in females than males andthe few 
surviving Ubr2-/- females are much smaller than control animals, indicating a potential growth 
restriction during either development or adulthood as a result of the loss of UBR2 function (Y 
T Kwon et al. 2003). 
Growth restriction during development, or intrauterine growth restriction (IUGR), has long 
been associated with defects in placental development, restricting the availability of oxygen 
and/or nutrients to the foetus. This is a developmental condition defined in the smallest 10% 
of human foetuses (Scifres and Nelson 2009), and has been linked extensively to development 
of adult diseases. The placenta is one of the first organs to develop during embryogenesis, and 
is vital for embryo growth and survival, acting as the conduit for nutrient delivery from the 
maternal blood stream (Rossant and Cross 2001). In humans, placental defects are associated 
with intrauterine growth restriction (IUGR), where the foetus does not receive enough 
nutrients for a normal growth rate (Scifres and Nelson 2009). This can result in lower 
birthweight and perinatal morbidity, impacting respiratory and cardiovascular health in 
neonatal stages. This also leads to health complications later in life, increasing the risk of 
hypertension, heart disease and respiratory disease. There has also been an association 
between placental insufficiency and neurodevelopmental disorders, among many other health 
risks and a shortened life span (Malhotra et al. 2019). Therefore, the study of genes involved 
in healthy placental development is important to understand this process. 
One of the most highly adapted tissues between species is the placenta; humans have a large, 
extensively villus placenta, with many folds in the trophoblast labyrinth surface that provide 
a large surface area for maternal-embryonic nutrient transfer. The mouse is much smaller and 
has less contact space between maternal and embryonic blood supplies, although vilification 
is still present (Fig. 1.9A). Both humans and rodents have cotyledons, which are bundles of 
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villus tissue, but mice have only a single cotyledon (also known as a discoid placenta), 
whereas humans have multiple cotyledons, arranged into a larger cluster (Fig. 1.9B) (Rossant 
and Cross 2001; Woods, Perez-Garcia, and Hemberger 2018). Some of the major differences 
between human and murine placental morphology have been attributed to the requirement 
for mouse pregnancies to support, on average, 8-12 foetuses at the same time. This indicates 
an evolutionary need to limit maternal resource input and ensure equal support of all embryos, 
which can be observed in the limited maternal vascularisation in the murine placenta, as 
compared to the more extensive vasculature and of human decidua. 
While the murine and human placentas are largely different in morphology and caution must 
be taken in the extrapolation of data between the species (Malassine, Frendo, and Evain-Brion 
2003), animal models are an invaluable tool to study the largely conserved genetic and 
molecular events that take place during placental development. Mouse phenotyping data, 
gene expression profiles, and physical protein interaction networks give a huge array of 










Figure 1.9 Differences in Mammalian Placental Development 
Mammalian placental development is generally defined by the extent of vilification into maternal 
tissues, increasing the surface area of nutrient and oxygen transfer. A. The mouse placenta is a 
distinct tissue, with junctional zone (blue) and labyrinth (pink) trophoblast-derived tissue layers. 
The maternal blood supply extends into the space (white) around the villus labyrinth. Inset: 
Foetal blood vessels sit alongside the trophoblast-surrounded maternal blood supply, where 
nutrients pass across the syncytiotrophoblast-derived interhaemal membrane. B. The human 
placenta is made up of multiple coletydons, which are bundles of villus labyrinth tissue arranged 
together to form a high surface are contact to the maternal tissues. Inset: Foetal blood vessels sit 
within the maternal blood stream, allowing for maximal nutrient transfer without the need for a 
distinct interhaemal membrane. 




1.5.1 The Murine Placenta 
The murine placenta is a layered tissue made up of maternal, extraembryonic and embryonic 
cell lineages which is highly specialised for its function; to act as a conduit for nutrients 
between the maternal and embryonic blood supplies. The maternal contribution to placental 
development makes up the maternal decidua (Md) tissue, which is a highly vascularised 
extension of the uterine decidual wall, providing a conduit for maternal blood flow and 
nutrient transfer. The two other cell layers are the junctional zone (Jz), which directly borders 
the Md, and the labyrinth (Lb) – these are made up of a combination of extraembryonic and 
embryonic components, and act as the connection point to the maternal blood stream. The Jz 
is vital for many of the endocrine functions of the placenta, and the Lb is adapted to be highly 
villus, increasing the surface area of contacts with the maternal blood stream. A majority of 
cells in both layers are from the extraembryonic trophoblast cell lineage, and successful 
signalling between the embryonic/foetal tissues, the trophoblast tissues and the maternal 
decidua and vascular tissues are vital for normal placental functioning, in which the 
trophoblast acts as an intermediary between the embryonic and maternal cells (Rossant and 
Cross 2001; J. C. Cross et al. 2002). 
 During embryonic development, formation of trophoblast cells and the trophectodermal 
tissue layer is one of the first distinct specialisation events. It arises from the outer 
trophectoderm layer of the blastocyst (E3.5, Fig. 1.10A) and, around the time of implantation 
(E6.0), differentiates into the ectoplacental cone and the extraembryonic ectoderm (Fig. 
1.10B). Away from the inner cell mass, a layer of trophoblast giant cells develop through 
endoreduplication, which is a specialised DNA replication event that results in polyploid 
nuclei. It has been hypothesised that this allows increased gene expression and quick tissue 
growth for large maternal-embryonic contact surface areas, but this is not clearly understood 
(Larkins et al. 2001; James C. Cross 2014). The ectoderm develops (among other structures) 
into the chorionic membrane and the allantois (E7.5, Fig. 1.10C), which undergo 
chorioallantoic fusion to develop into the villus Lb, and the ectoplacental cone develops into 
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a spongiotrophoblast layer that forms the bulk of the Jz (E12.5, Fig. 1.10D). The 
spongiotrophoblast and trophoblast giant cells (TGCs) are the first structure of the placenta 
proper to form, providing a framework upon which chorioallantoic cells can undergo 
extensive folding and villous branching to form the high surface area labyrinth structure 
(Rossant and Cross 2001). This provides ample membrane surface area for transfer of 
nutrients through into the foetal vasculature. While the major function of trophoblast tissues 
is acting as a junction between maternal and foetal blood systems, they also act in a variety of 
hormonal and signalling contexts between maternal and embryonic tissues, which are 
essential for successful pregnancy (M. A. Costa 2016; Malassine, Frendo, and Evain-Brion 
2003; Linzer and Fisher 1999). For example, Jz TGCs secrete lactogen into the maternal blood 
stream, where it acts to moderate maternal metabolic rate and divert an energy supply for 
foetal growth, as well as prepare mammary tissues for growth and milk production 
(Malassine, Frendo, and Evain-Brion 2003; Nieder and Jennes 1990; Walker et al. 1991). 
By E10.5, the full placental structure has formed, supporting the complex processes that 
happen in the latter half of murine development. The Jz and Lb layers (Fig. 1.10D) are made 
up of a variety of specific trophoblast-derived cell types that carry out specific functions in 
the placenta. For example, spongiotrophoblast glycogen-rich cells (SGCs) are present in the 
Jz, and these migrate and invade the Md between E13.5 and E18.5, lysing to release glycogen 
stores as an energy source towards the end of development, when embryonic growth rate is 
the highest (P. M. M. Coan et al. 2006). TGCs in the Jz are responsible for hormone secretion, 
as discussed above (Malassine, Frendo, and Evain-Brion 2003) and also function to aid the Jz 
invasion of the Md during late development (D. Hu and Cross 2010). Labyrinth-specific 
syncytiotrophoblasts (SynTs) are required along villus surfaces in this tissue layer for 
formation of the ‘interhaemal membrane’, which is the membrane over which nutrients will 
pass between maternal and embryonic blood supplies (Woods, Perez-Garcia, and Hemberger 
2018). Finally, embryonic epithelial cells in the labyrinth make up the distinct compartments 



















Figure 1.10 Murine Trophoectoderm Lineage Development 
The trophoblast lineage (blue) is derived from the blastomeric trophectoderm (A) and develops 
into the ectoplacental cone and extraembryonic ectoderm, as well as trophoblast giant cells (B, 
C). The ectoplacental cone itself develops into the bulk of the placental junctional zone at E12.5 
(Jz, blue), which borders the maternal decidua (Md, yellow) with a layer of trophoblast giant 
cells in D. This forms a scaffold on which the chorionic ectoderm and allantois (C), which 
developed from the extraembryonic ectoderm, can fuse (chorioallantoic fusion) and become villus, 
forming the high surface area labyrinth (Lb, pink) layer seen at E12.5 (D). 
Taken from (Rossant and Cross 2001). 
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1.5.2 Roles for Tex19.1 in Placental Development 
The Tex19.1-/- placenta is small, preceding an embryonic growth restriction that arises between 
E12.5 and E14.5 (J Reichmann et al. 2013; Tarabay et al. 2013 and Playfoot et al. 2019, manuscript 
submitted, MRC HGU). This is particularly characterised by a reduction in the size of the Jz 
tissue layer, alongside compositional differences in this tissue, including a reduction in the 
abundance of spongiotrophoblast cells and SGCs (J Reichmann et al. 2013). Previous 
published and unpublished work in our lab has shown that this gene has a range of known 
roles in the murine placental trophoblast tissues, such as retrotransposon inhibition (J 
Reichmann et al. 2013) and transcriptional repression through histone H3K9 trimethylation. 
The latter is a function of TEX19.1’s interaction with KAP1, an E3 ligase that interacts with a 
subset of ZFP proteins and is involved in recruitment of the histone methyltransferase 
SETDB1 and transcriptionally repressive H3K9me3 histone methylation marks to multiple 
genomic locations including retrotransposons and imprinted genes (Playfoot et al. 2019, 
manuscript submitted, and unpublished work by Chris Playfoot, MRC HGU). The placental 
defects in Tex19.1-/- mice bear some resemblance to those seen in human pregnancies that 
exhibit IUGR, which has been independently associated with changes in methylation states 
and changes in expression levels of both imprinted genes and retrotransposon-encoded 
proteins (Frost and Moore 2010; Michels, Harris, and Barault 2011). 
 
1.5.2.1 Genomic Imprinting in the Placenta 
As a consequence of methylation reprogramming during reproduction and 
development, the trophectoderm-derived components of the placenta are 
hypomethylated (Crichton et al. 2014; Oda et al. 2013). Monoallelic gene expression, 
leading to asymmetrical maternal and paternal genetic contributions, arises as a result 
of methylation of single alleles at specific loci. This phenomenon was first discovered 
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using pronuclear oocyte transfer and generation of  uniparental embryos, which 
exhibit growth defects and embryonic lethality whether paternal or maternal alleles 
are missing (Kaufman, Barton, and Surani 1977; Barton, Surani, and Norris 1984; 
Surani, Barton, and Norris 1984). Allele imprinting, and a dependence on either the 
paternal or maternal allele of certain genes, is often associated with dose-dependent 
expression of genes regulating development and growth, and so is particularly 
important in the placenta to regulate growth and proliferation during development. 
Paternal expression has been linked to maximal input of maternal resources in the 
placenta, whereas maternal expression is more associated with limiting maternal 
input, and a combination of both creates a delicate balance of resources and finely 
tunes nutrient availability and growth throughout development (Frost and Moore 
2010). Indeed, IUGR is a major phenotype of the human imprinting disorder SRS 
(Silver Russell syndrome), in which around half of cases have loss of expression of 
growth factors such as IGF2 as a result of imprinting misregulation (Tunster, Jensen, 
and John 2013). IGF2 is a paternally expressed gene that is thought to be important 
for angiogenesis and vascularisation in placental tissue (Harris et al. 2011; Chao and 
D’Amore 2008), and so loss of this function could lead to a restricted ability to transfer 
oxygen or nutrients to the foetus. Derepression of imprinted alleles has also been 
linked to this disorder in humans, such as hypomethylation of the gene MEST, which 
is prevalent in 7-10% of SRS cases (Hannula et al. 2001). MEST, and the mouse 
homolog Mest, is a paternally expressed gene involved in angiogenesis in both the 
decidua and trophoblast tissues within the placenta (Mayer et al. 2000). Female mice 
deficient in Mest are growth restricted both pre- and postnatally (Lefebvre et al. 1998). 
Interestingly, both upregulation and loss of gene expression as a result of imprinting 
defects can lead to placental defects and growth disorders. Both Jz increases and 
decreases in size have been linked to embryonic growth defects (Woods, Perez-
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Garcia, and Hemberger 2018), as placental size alone is not a true indicator of 
placental function – cell localisation and abundance are important factors for 
placental development. Therefore, imprinting misregulation in either direction, as a 
result of hypo- or hypermethylation, can be deleterious to the developing embryo. 
Imprinting disorders in the human placenta have also been associated with 
preeclampsia (Zadora et al. 2017; Carney 2017), indicating the importance of 
imprinting in this tissue and a need for a further understanding of the regulatory 
processes protecting the methylation of these loci in an otherwise widely 
hypomethylated context. There are widespread differences in the methylation of 
imprinted loci between human and murine placental epigenomes, reflecting the high 
level of variability between the placentation and pregnancy requirements of different 
mammalian species. However, most of these differences are additional paternally 
imprinted loci in the mouse, and subsequent maternal expression of these genes. This 
indicates a push towards limitation of maternal input into developmental energy 
expenditure, possibly as a result of the requirement to support 8-12 embryos during 
the same pregnancy (Monk et al. 2006). This is known as parental conflict theory, 
and involves the balance of maternal and paternal gene expression levels (Moore and 
Reik 1996; Haig 1999). As a model for human placental imprinting disorders, the 
murine placenta is still useful; human genes such as MEST, and the mouse homolog, 
Mest, have been shown to have similar roles in both species (Mayer et al. 2000). 
Alongside the documented IUGR and placental growth defects, the Tex19.1-/- placentas 
exhibit reduced amounts of H3K9me3 at specific imprinted genes (Mest, Mcts2 and 
Impact) and transcriptionally de-repress Mest and Mcts2 around 2-fold in the labyrinth 
layer (Playfoot et al. 2019, manuscript submitted, MRC HGU). This is thought to act 
through TEX19.1’s interaction with KAP1, which is a transcriptional corepressor 
involved in deposition of H3K9me3, but also implicates UBR2 in this tissue for a 
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potential interaction with the TEX19.1-KAP1 complex and a subsequent role in 
imprinting. 
 
1.5.2.2 Retrotransposons and the Placental Immune Response 
Transposable elements (TEs) are mobile elements which make up around 40% of the 
sequenced mammalian genome and were first described nearly 70 years ago 
(McClintock 1956, 1950). There are only two classes of TEs: firstly, transposons 
which move around the genome in a “cut and paste” method and are quite rare, only 
taking up 3% of the genome. The other type, retrotransposons, make up the majority 
of mammalian TEs and act to “jump” around the genome in a “copy and paste” method, 
being transcribed as RNA and reintegrating into new loci by reverse transcription 
and recombination, inducing chromosomal deletions or rearrangements (Goodier 
2016). Although this activity is generally deleterious and contributes to genomic 
instability, retrotransposons are maintained in the germline in order to contribute to 
a healthy mutation rate and genetic variation throughout multiple generations. 
In the majority of somatic tissues, a wide variety of genetic silencing mechanisms are 
in place to ensure retrotransposons do not actively damage the genome. One of these 
is epigenetic modifications, which are able to directly repress retrotransposition 
through DNA methylation and histone marks (Slotkin and Martienssen 2007; Walter 
et al. 2016). However, within placental tissue, there are functional advantages to the 
expression of some retrotransposons (Garcia-Perez, Widmann, and Adams 2016). 
Therefore, a balance in repression at some retrotransposon loci must be struck in 
order to limit mutational activity and maintain genomic integrity. 
There are two classes of retrotransposons: LTRs (long terminal repeats, including 
ERVs, endogenous retroviruses) and non-LTRs, which do not contain the repeat 
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sections. One of the most commonly found families of retrotransposons in the 
mammalian genome is the non-LTR-class element LINE-1 (long interspersed element 
1), copies of which make up 17% of genetic material (Lander et al. 2001; Slotkin and 
Martienssen 2007). LINE-1 encodes its own mobilisation machinery, made up of a 5’ 
UTR promoter region, two protein-coding regions Orf1 and Orf2, and a long 3’ poly-A 
tail. ORF1p has activity in RNA-binding, and ORF2p acts as an endonuclease and 
reverse transcriptase; both proteins are essential for retrotransposition of LINE-1, 
acting to regulate and reintegrate the expressed RNA into new genomic loci (Mita et 
al. 2018; Martin 2006; Feng et al. 1996). Placental and cord blood supply misregulation 
of LINE-1-expressed proteins Orf1 and Orf2 have been associated with changes in 
birth weight in humans, ranging from IUGR to higher than normal birth weights 
(Michels, Harris, and Barault 2011). 
Tex19.1 has previously been shown to regulate expression of different retrotransposon 
RNAs in both testis tissue (Ollinger et al. 2008; Judith Reichmann et al. 2012) and 
trophoblast-derived placental tissue layers (J Reichmann et al. 2013; Tarabay et al. 
2013), including LINE-1 Orf1 RNA, and TEX19.1 protein has been implicated in 
regulation of LINE-1 Orf1 protein levels as well (Maclennan et al. 2017), so indicating 
a dual mechanism to protect the genome against retrotransposition both at an RNA 
and a protein level. Both Tex19.1-/- and Ubr2-/- embryonic stem cells (ESCs) have an 
upregulation of LINE-1 RNA levels, indicating a role for both of these genes in 
retrotransposon repression (Maclennan et al., 2017 and unpublished data, Karen 
Dobie, MRC HGU). 
Finally, upregulated expression of retrotransposons has been associated with an 
interferon (IFN) immune response in a variety of tissue contexts (Yu et al. 2015; 
Mavragani et al. 2016; Kosumi et al. 2019), and this is hypothesised to be a molecular 
response to the danger to genomic stability that retrotransposition poses, so acting 
102 
 
as an additional defence mechanism. As such, interferon responses have been shown 
to be a vital component of the placental immune system for both embryonic and 
maternal survival (Racicot et al. 2016; J. Y. Kwon et al. 2018). In particular, the IFNβ 
response acts in response to LINE-1 retrotransposition (Yu et al. 2015). IFNβ is an 
established cellular defence mechanism against viral infection (Taniguchi and 
Takaoka 2002), which involves upregulation of a wide variety of interferon response 
genes via the JAK-STAT signalling pathway such as IFITMs (interferon-induced 
transmembrane proteins) that act to carry out viral endocytosis and inhibit various 
stages of the viral life cycle (Schneider, Chevillotte, and Rice 2014; Zhao et al. 2019). 
Unpublished data in our group show that the Tex19.1-/- placenta exhibits an IFNβ 
response alongside derepression of LINE-1, so indicating a potential link between 







The mammalian UBR family is highly diverse, only united by the common UBR box domain 
that is able to physically bind to the N-terminus of target proteins (E Matta-Camacho et al. 
2010; J Muñoz-Escobar et al. 2017). They are historically implicated as E3 ubiquitin ligases in 
the N-end Rule pathway of the UPS (T Tasaki et al. 2005, 2009; Bartel, Wünning, and 
Varshavsky 1990), using this substrate binding domain to target proteins for proteasomal 
degradation. However, there are roles for UBR box containing proteins outside of this 
canonical pathway. 
Perturbation of UBR2 in a variety of tissues can lead to a plethora of defects, and so the study 
of these roles, and the molecular basis of UBR2 function, is vital to understanding these 
protein regulatory pathways and how they impact highly specialized tissue or cell types. A 
recently identified novel role for UBR2 in the regulation of the cohesin complex has 
implications in the vulnerability for misregulation of meiotic cohesins in the oocyte (J 
Reichmann et al. 2017). Spermatocytes also depend on UBR2 for genetic recombination, 
chromosomal synapsis and meiotic progression (Akera et al. 2017; Crichton et al. 2017). In 
addition, UBR2 appears to be specifically important for embryonic survival (Y T Kwon et al. 
2003), although the molecular basis of this has not yet been described. 
UBR2 has a strong interaction with the protein TEX19.1, which is involved in cohesin complex 
regulation in meiotic oocytes. Both UBR2 and TEX19.1 are also important for embryonic 
survival, the latter through regulation of placental development. These phenotypes indicate a 
potential link between UBR2 and TEX19.1, a protein expressed in hypomethylated tissues 








1.7 Thesis Objectives 
I hypothesised that the TEX19.1-UBR2 complex has a role in regulation of both oocyte meiotic 
chromosome cohesion and placental development, and the first objective of this thesis was to 
investigate these processes using a Ubr2-/- mouse. There is evidence that TEX19.1 is able to 
regulate the Type II N-end Rule substrate binding ability of UBR2, and so the second 
objective of this work is to investigate the molecular basis of the known Ubr2-/- phenotypes, 
using a genetic approach to perturb the canonical N-end Rule pathway. 
In this thesis, I will address the following research questions, across three chapters of 
independent research. 
− Is Ubr2 important for oocyte development and chromosome cohesin during female 
meiosis? 
 
























2.1 Animal Work 
Animals were maintained in a heterozygous colony with Ubr2+/- x Ubr2+/- or Ubr2+/T2 x Ubr2+/T2 
crosses. Unless stated, animals used for experiments were 2-6 months old, with age-matched 
wild type (Ubr2+/+) controls from the same colony. All animal work was carried out after 
ethical approval by the University of Edinburgh Animal Welfare and Ethical Review Body, 
under UK Home Office Project Licences PPL60/4424 or P3900/7F29. Husbandry and animal 
care followed local institutional guidelines (University of Edinburgh, Central Bioresearch 
Services). 
 
2.1.1 Dissection and tissue retrieval 
All animals were culled by Schedule 1 termination, in accordance with UK Home Office 
regulations. Adults were culled by cervical dislocation, and embryos beyond developmental 
stage E14.5 were culled by decapitation. 
 
2.1.2 Embryo tissue retrieval 
For embryo experiments, heterozygous pairs (either Ubr2+/- x Ubr2+/- or Ubr2+/T2 x Ubr2+/T2) 
crosses were set up and checked for plugs every 24 hours. The day that the plug was found 
was designated E0.5, and development was measured as E10.5 (10 days after plug), E12.5, E18.5, 
and so on. As a secondary measure of development, to ensure timing from plug dates were 
accurately representative of developmental stages, I observed limb and craniofacial 
development; E10.5 was designated as embryos having a lens indentation around the eye 
primordia but no nasal pits, E12.5 as embryos with developed and webbed digits, and E18.5 
with having fully developed but closed eyes, developed whiskers and nail primordia. 
Parturition occurs around E19.5-20.5, upon which mouse age is designated in days post 
parturition (dpp), with the day of birth designated as 0dpp. 
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At the required embryonic stage, pregnant females were culled as in section 2.1.1, and the 
uterus was dissected. Prior to weighing, extraembryonic membranes (amnion and chorion) 
were dissected away from the embryo and placenta itself. Embryos post-E14.5 were 
immediately decapitated after dissection in compliance with UK Home Office regulations, 
then the head and body were weighed separately and combined to give the total embryo 
weight. Late stage embryos weighed in this manner will have lost some fluid weight, but 
should be comparable between genotypes treated in the same way in these experiments. For 
isolation of internal embryonic tissues at E18.5, embryos were opened across the abdomen in 
an antero-posterior direction under a dissection microscope. Embryonic ovaries were isolated 
and stored in 5% FCS (foetal calf serum) in PBS at 4°C until chromosome spreading (see 
section 2.4.1). 
 
2.1.3 CRISPR-HDR by zygotic injection 
Ubr2-/- mice were as described previously (Crichton et al. 2017; Maclennan et al. 2017); the 
design and implementation of which was carried out using CRISPR-Cas9 by Karen Dobie 
(MRC HGU). This mouse has a premature STOP codon in exon 3 (at position Cys-121) of the 
Ubr2 gene; UBR2 protein cannot be detected in either the brain or the testes (Crichton et al. 
2017). For genotyping purposes, a silent XbaI restriction enzyme site (5’−T^CTAGA−3’, NEB 
CutSmart, R0145) was also introduced in exon 3. 
To generate a Ubr2T2/T2 mouse line, wild type Cas9 mRNA (0.25μg/μl, Tebu-Bio CleanCap Cas9 
L-7206), both wild type (with mutant PAM) and point mutant (D233A) dsDNA repair 
templates (1.5 μg/μl), and an RNA guide construct (250ng/μl, cloned from Addgene pX330, 
see section 2.8.1.3) specific to the target site were injected together into a single-celled mouse 
zygote on the C57BL/6J background. These were then transferred into the uterus of a host 
mother on a CD-1 background, to ensure all pups born into the Ubr2T2/T2 were on the C57BL/6J 
111 
 
background and had been edited by CRISPR. Injections and embryo transfer were carried out 
by Bioresearch and Veterinary Services (BVS) at the University of Edinburgh. There were 9 
pups produced; three were successfully edited and used for subsequent matings and 
generation of the Ubr2T2/T2 mouse line used in all experiments in Chapter 5. 
 
2.1.4 Genotyping assays 
All mice used in this thesis were genotyped by earclipping at weaning (3 weeks post-partum, 
pp) or, for embryo experiments, using tail tips. DNA was extracted using the DNAreleasy™ 
standard protocol (Anachem LS02), in which tissue was submerged in 20µl DNAreleasy™ 
reagent and incubated on a thermocycler at 75°C for 5 minutes, 96°C for 2 minutes and 20°C 
for 10 minutes. After one freeze-thaw cycle (-20°C), the tissue was spun down using a micro-
centrifuge at maximum speed and the supernatant used in subsequent PCR experiments. For 
all genotyping assays, PCR products were observed using gel electrophoresis, as per standard 
protocols and as follows. 1.5% agarose gel in TBE (Tris/Borate/EDTA) buffer with 0.5 µg/ml 
ethidium bromide for visualisation (Electran®, VWR). Samples were combined with loading 
buffer (5X Orange G, Sigma Aldrich O3756, in 30% glycerol), loaded alongside either 1kb 
(NEB, N3232L) or 100bp (NEB, N3231S) DNA ladder, as appropriate for expected sizes, and 
run at 150V/cm. DNA bands were visualised using a UV SynGene U:Genius 3 Geldoc system. 
For all embryo experiments, sex genotyping was used to separate male and female embryos. 
Sex genotyping was carried out by PCR against the X-encoded Ube1X gene and the Y-encoded 
paralog Ube1Y (Chuma and Nakatsuji 2001); primer sequences are noted in Table 2.1. For each 
20µl PCR reaction: 2µl 10X Platinum Taq buffer, 0.8µl 50mM MgCl2, 0.16µl 25µM dNTP mix, 
0.8µl each primer at 100µM, 0.16µl Platinum Taq DNA polymerase (Invitrogen, 10966034) and 
13.92µl dH2O, with 2µl DNA. PCR protocol as in Table 2.2. 
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The Ubr2-/- mouse was genotyped using a two-step protocol: PCR amplification of Ubr2 exon 
3, with primers as in Table 2.1, and digestion using XbaI restriction enzyme (NEB CutSmart, 
R0145). This was then assayed by gel electrophoresis, see Table 2.1 for expected band sizes. 
For each 50µl PCR reaction: 5µl 10X Plat. Taq buffer, 1.5µl 50mM MgCl2, 1µl 10µM dNTP mix, 
1µl each primer at 100µM, 1µl Platinum Taq DNA polymerase (Invitrogen, 10966034) and 
37.5µl dH2O, with 2µl DNA. PCR protocol as in Table 2.3. The majority of routine genotyping 
assays for the Ubr2-/- colony were carried out initially by David Read, Mary Taggart or Jennifer 
Lawson (MRC HGU), and later outsourced to Transnetyx Inc. 
The Ubr2T2/T2 mouse was initially genotyped by tetra-primer ARMS (amplification-refractory 
mutation system) PCR, which utilises two pairs of primers (inner and outer, sequences in 
Table 2.2) to detect specific point mutations in the sequence (Medrano and De Oliveira 2014; 
S. Ye et al. 2001). These products could then be assayed by gel electrophoresis, as outlined in 
Table 2.2. For each 20µl PCR reaction: 2µl 10X Platinum Taq buffer, 0.8µl 50mM MgCl2, 0.4µl 
10µM dNTP mix, 0.2µl each inner primer at 100µM, 1µl each outer primer at 100µM (1:5 ratio 
inner:outer primers), 0.2µl Platinum Taq DNA polymerase (Invitrogen, 10966034) and 14µl 
dH2O, with 0.2µl DNA. PCR protocol as in Table 2.3. The details of the ARMS-PCR are 
outlined in Chapter 5 (Fig. 5.7) (S. Ye et al. 2001; Medrano and De Oliveira 2014). In order to 
confirm mutation, Sanger sequencing was implemented as in section 2.8.2. Upon 
establishment of the Ubr2T2/T2 colony, routine genotyping of mice at weaning was outsourced 












2 bands: 220bp, 200bp 
Female (XX): 








Single band at 310bp 
+/-: 
3 bands: 310bp, 205bp, 
100bp 
-/-: 















Control band at 476bp 
present in all reactions, plus: 
 
+/+: 
Single band at 242bp 
+/T2: 
2 bands: 242bp, 292bp 
T2/T2: 
Single band at 292bp 
Tetra-primer 
ARMS PCR 
(S. Ye et al. 
2001) 
 
Table 2.1 Primers for mouse colony genotyping 
 
 
Step Ube1X/Ube1Y Ubr2-/- Ubr2T2/T2 
1) Initial Denaturation 94°C, 7 minutes 95°C, 7 minutes 95°C, 2 minutes 
2) Denaturation 94°C, 30 seconds 95°C, 30 seconds 95°C, 1 minute 
3) Annealing 66°C, 30 seconds 65°C, 30 seconds 63°C, 1 minute 
4) Extension 72°C, 30 seconds 72°C, 1 minute 72°C, 1 minute 
Cycles 
40 cycles 
Return to (2) 39 times 
40 cycles 
Return to (2) 39 times 
35 cycles 
Return to (2) 34 times 
5) Final Extension 72°C, 5 minutes 72°C, 2 minutes 72°C, 2 minutes 
 







2.2 Tissue culture 
2.2.1 Cell storage and general culture conditions 
Cells were stored at -150°C in a liquid nitrogen facility, in DMSO+serum supplemented 
freezing media (culture media for each cell line, as in sections 2.2.2 and 2.23, was 
supplemented with 20% DMSO and 25% FCS). For retrieval, cells were quickly thawed in a 
37°C waterbath and added to 9ml of pre-warmed media, then pelleted by centrifugation (200g, 
5 minutes) and resuspended in fresh pre-warmed media. They were seeded into either T25 or 
T75 culture flasks (Corning, 25cm2 and 75cm2) at 2x105 cells/ml, unless stated; HEK293T cells 
were seeded on uncoated flasks, and for mESCs flasks were first coated in 0.2% gelatin (Sigma) 
in PBS (phosphate buffered saline), which was removed by aspiration prior to addition of cell 
suspension in media. 
All cells were cultured in their respective media at 37°C and 5% CO2. Standard passaging 
protocol was used for all cell lines: a 1x pre-warmed (37°C) PBS wash, then trypsinisation 
using pre-warmed trypsin-EDTA (1% trypsin/0.4% EDTA, Sigma Aldrich T4174) in PBS for 5 
minutes at 37°C, 5% CO2. Trypsin was inactivated using 10 volumes of the appropriate pre-
warmed media, and cells transferred to a 15ml falcon tube to pellet by centrifugation (200g, 5 
minutes). Cells were then resuspended in fresh pre-warmed media and reseeded as above. 
 
2.2.2 HEK293T cells 
Wild type HEK293T cells were used primarily as a vehicle for protein overexpression through 
transfection of plasmids. HEK293T cells were cultured in serum-supplemented DMEM 
(Dulbecco’s Modified Eagle’s Medium, Gibco 41965-039) (10% foetal calf serum/FCS, 
200µg/ml penicillin-streptomycin, P/S, 8mM L-Glutamine) and allowed to grow for 48-72 
hours between passaging. For overexpression experiments, cells were seeded at 1x105cells/ml 
in 6-well plates (9.6cm2) and allowed to grow for 24 hours. Then, the plasmids outlined in 
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Table 2.5 were transfected using the Lipofectamine 2000 (LF2000, Invitrogen 11668-019) 
standard protocol, as follows. 1µg of plasmid (or 0.5µg each if cotransfecting two plasmids), 
as measured by Nanodrop spectrophotometry (ThermoFisher Scientific), was added to 50µl 
Opti-MEM Reduced Serum Media (Invitrogen 31985-092) and a master mix of 3µl LF2000 
per 50µl Opti-MEM was made up. Both were incubated at room temperature for 5 minutes, 
then combined (total volume 100µl), gently mixed and incubated again at room temperature 
for 5 minutes. This mixture was then added dropwise to each well of the 6-well plate and the 
cells incubated for 24 hours as normal. Cells were harvested at 24 hours post-transfection, by 
either trypsinisation or in-well cell lysis, as determined by experimental protocol. 
 
2.2.3 Mouse Embryonic Stem Cells 
Feeder-independent E14 mouse embryonic stem cells (mESCs) were used in this thesis as a 
cell culture model in which both UBR2 and TEX19.1 are expressed, primarily to investigate 
the role of UBR2 in cohesin regulation. mESCs were cultured on 0.2% gelatin-coated flasks 
in serum/LIF-supplemented GMEM (Glasgow Minimal Essential Medium, Gibco 21710-025) 
(10% FCS, 100µg/ml P/S, 2mM Gibco L-Glutamine, 1mM Sigma Aldrich sodium pyruvate, 1x 
Sigma MEM non-essential amino acids, 50μM Gibco β-mercaptoethanol and Leukaemia 
inhibitory factor, or LIF) and passaged at maximum every 48 hours. 
 
2.2.3.1 CRISPR-Cas9 HDR for UBR2-T1 mES cell generation 
I generated a stable UBR2-T1 line on the E14 background with the point mutation 
D118A by CRISPR-Cas9 HDR. E14 mESCs were transfected with the dsDNA repair 
oligo with 50bp homology arms encoding the mutant repair template containing both 
the point mutation and the mutant PAM sequence, alongside a Cas9 expressing 
plasmid and pX330 plasmid with the specific guide sequence cloned into it; see 
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section 2.8.1.3 and Fig. 5.16. Transfection and picking of clonal colonies was carried 
out by Fiona Kilanowski (MRC HGU). To genotype successful clones of the UBR2-
T1 line, I designed tetra-primer ARMS PCR, as detailed in section 2.4.1 and in Chapter 
5, and confirmed this by Sanger sequencing of the outer fragment alone; genotyping 
primer sequences in Table 2.4. Wild type untransfected E14 mESCs were used as a 
control comparison to the UBR2-T1 line. 
 
Genotyping Assay Primers Expected Results 
ARMS-PCR 








Control band at 362bp present in 
all reactions, plus: 
+/+: 
Single band at 235bp 
+/T1: 
2 bands: 180bp, 235bp 
T1/T1: 






+/+       GAC 
+/T1     GNC 
T1/T1   GCC 
 
Table 2.3 – Primer sequences for UBR2-T1-D118A mESC genotyping (both ARMS and Sanger) 
 
Step UBR2-D118A-T1 
1) Initial Denaturation 95°C, 2 minutes 
2) Denaturation 95°C, 1 minute 
3) Annealing 61°C, 1 minute 
4) Extension 72°C, 1 minute 
Cycles 
35 cycles 
Return to (2) 34 times 
5) Final Extension 72°C, 2 minutes 
 





2.2.3.2 mESC synchronisation and sorting 
To synchronise UBR2-T1 or E14 mES cells into G2/M, cells were seeded at 
0.5x105cells/ml in a T25 flask, and after 24 hours of growth, media was changed to 
fresh GMEM+serum/LIF (see section 2.2.3) supplemented with 1.25mM thymidine 
(Sigma Aldrich T9250) to a final concentration of 1.25mM. Cells were cultured for 17 
hours under thymidine treatment, then released for 5 hours and cultured in a second 
thymidine block at 1.25mM. A double thymidine block arrests the cell cycle at the 
G1/S phase transition (Chen and Deng 2018), and so in order to collect cells enriched 
at G2/M, cells were released into growth media for 4 hours and then harvested for 
subsequent experiments. 
FACS (fluorescence-associated cell sorting) analysis for cell cycle tracking was 
carried out as follows. Cells were seeded in a 6-well plate at 1x105cells/ml and, at 
various timepoints of the double thymidine block detailed above, harvested by 
trypsinisation (as in section 2.2.1) and the cell pellet washed in 1x PBS. The 
suspension was spun down at maximum speed in a tabletop centrifuge and 
resuspended in 50% FCS in PBS. Cells were fixed by dropwise addition of 450µl ice 
cold 70% EtOH over a vortex and incubated for a minimum 24 hours at 4°C. To stain 
for FACS, cells were centrifuged at 1000rcf at 4°C for 5 minutes, washed twice in ice 
cold PBS, then resuspended in 50µg/ml propidium iodide, 100µg/ml RNase A in PBS 
and incubated at room temperature for 1 hour, protected from the light. Cells were 
stored on ice, protected from light, until analysis on a BD Biosciences LSR Fortessa™ 




2.3 Histology and tissue analysis 
2.3.1 Fixation and tissue preparation 
For histological analysis, isolated mouse tissues were fixed in either 4% paraformaldehyde 
(PFA) or Bouins fixative solution overnight at 4°C under continuous movement. They were 
then washed twice overnight at 4°C in 1x PBS, and dehydrated through an alcohol (ethanol, 
EtOH) increasing series into 70% EtOH. Tissues were embedded through 100% xylene and 
into 100% paraffin wax using the Tissue-Tek VIP vacuum infiltration processor (Sakura) and 
hand embedding into 100% paraffin wax molds using the Tissue-Tek Embedding Console 
System (Sakura). Tissue was sectioned into 5µm sections using a microtome (Thermo Fisher), 
stretched by floating on a 47°C water bath, and baked onto glass slides overnight in a 65°C 
histology oven. 
Prior to staining, tissue sections were dewaxed in 100% xylene for 5 minutes three times, and 
then rehydrated through a step-wise decreasing EtOH series into tap water, as has been 
previously described (Puchtler, Meloan, and Waldrop 1986). 
 
2.3.2 H&E tissue staining 
Haematoxylin and eosin staining is a broadly used tissue stain that is useful for identifying 
major morphological features in tissue sections. This was carried out on tissue section as 
described (Fischer et al. 2008), and summarized as follows. Slides were stained in 
haematoxylin for 4 minutes, washed in running tap water and differentiated in acid/alcohol 
(1% HCl in 70% EtOH) for a few seconds. After another wash in running tap water, slides 
were blued by immersion in saturated lithium carbonate solution for 10 seconds, stained in 
eosin for 2 minutes then washed again. Slides were dehydrated by rinsing in 100% EtOH, then 
three subsequent 2 minute washes in 100% EtOH and then cleared in 3 washes of xylene for 
5 minutes each. They were then mounted using DPX mountant solution (Sigma Aldrich) and 
allowed to set in a fume hood overnight before imaging. 
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2.3.3 Periodic Acid Schiff-Haematoxylin (PAS-H) tissue staining 
Alternatively, in order to stain glycogen-rich tissue sections, Periodic acid Schiff staining was 
carried out on slides by oxidation in 0.5% periodic acid solution for 5 minutes. Slides were 
then washed in running tap water and stained in Schiff reagent for 15 minutes. After washing, 
slides were counterstained in Meyers haematoxylin for 1 minute, washed in running tap water 
then dehydrated in xylene and mounted as in section 2.3.2. 
Both H&E and PAS-H stained tissue sections were visualised using brightfield microscopy, 
outlined in section 2.5.1. 
 
2.4 Meiotic chromosome spreads 
Chromosome spreads are a method by which cells can be spread on glass slides in order to 
count chromosomes and visualise chromatin-bound proteins by immunofluorescence. All 
culture media and wash steps were carried out on oocytes using documented embryo-safe 
solutions, acquired from the companies stated. 
 
2.4.1 Prophase I oocyte spreads 
In order to isolate oocytes at pachytene, I dissected out E18.5 ovaries as detailed in section 
2.1.2, and incubated each pair of ovaries in hypotonic extraction buffer (30mM Tris, 50mM 
sucrose, 17mM trisodium citrate dehydrate, 5mM EDTA, 0.5mM DTT and 0.5mM PMSF at 
pH8.2) for 15-30 minutes. Pairs of ovaries were transferred into 20μl 500mM sucrose solution 
in a PCR tube, then pierced with a needle for approximately 5 minutes. During this time, 
tissue was macerated against the side of the tube in order to release oocytes from the ovarian 
tissue. Sterilised glass slides were pre-soaked in 1% PFA fixative (1% paraformaldehyde, 0.15% 
Triton X-100 detergent at pH 9.2 – pH was set using titration of 1M boric acid) and 10µl of 
the sucrose-oocyte suspension was dropped onto the slide and zig-zagged down the slide in 
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order to spread the material out for ease of imaging. In this way, 2 glass slides could be 
generated for each pair of ovaries isolated from one embryo. Slides were incubated in a humid 
chamber overnight at room temperature, then allowed to air-dry the following day. Once dry, 
these slides were stored short-term at 4°C, or long-term at -80°C, before immunofluorescent 
staining as described in section 2.4.4. 
 
2.4.2 Prometaphase I oocyte culture and spreads 
In order to isolate oocytes at prometaphase I, pairs of age-matched female mice between 9-14 
weeks old (2-3 months) were intraperitoneally injected, staggered one hour apart, with 0.1ml 
5IU PMSG (pregnant mare serum gonadotrophin) in order to induce ovarian follicular 
development. After 42 hours, ovaries were dissected into warm (37°C) M2 media (Sigma 
Aldrich). Within 30 minutes of mouse cull, oocytes were isolated from whole ovaries and 
transferred into pre-gassed M16 (Sigma) culture under embryo-safe filtered mineral oil 
(Sigma Aldrich BioXtra, M3510) at 37°C and 5% CO2 – due to superovulation around 15-20 
oocytes can be isolated from one pair of ovaries. Oocytes were cultured for 2 hours and those 
that developed through germinal vesicle breakdown (GVBD) in that time were separated and 
further cultured as above for 3 hours post-GVBD. 
After culture, chromosome spreads were performed 3 hours post-GVBD. Oocytes were 
washed into fresh M2 media, then the zona pellucida (ZP) was removed using a 5-10 second 
wash in Acidic Tyrode’s solution (Sigma Aldrich, T1788) and the oocytes were washed 
through fresh M2 four times. Oocytes were individually incubated in 0.5% sodium citrate, 
continuously moving, for 2 minutes, then dropped onto a fixative-soaked glass slide (1% 
paraformaldehyde/PFA, 0.14% Triton X-100 detergent, 3mM dithiothreitol/DTT at pH 9.2 – 
pH was adjusted with 1M boric acid) and air-dried for around 1 hour. These slides were 
previously scored with a 1cm2 area in order to quickly locate the individual oocytes on each 
slide. After air-drying, 50µl of 0.4% Tween-20 was added to each slide and allowed to air-dry 
122 
 
overnight. All slides were stored at 4°C short-term or -80°C long-term until 
immunofluorescent staining, as described in section 2.4.4. 
 
2.4.3 Metaphase II oocyte culture and spreads 
For prometaphase II oocyte spreads, female mice were treated with PMSG as in section 2.4.2, 
but 48 hours after follicle stimulation, mice were intraperitoneally injected with 0.1ml 5IU 
hCG (human chorionic gonadotrophin) to induce ovulation. Oocytes were isolated from the 
ampulla 18 hours post-hCG treatment into 37°C M16 (Sigma Aldrich) media. They were 
treated in 0.5mg/ml hyaluronidase in M2 media (Sigma Aldrich) for 5 minutes to remove 
cumulus cells, and then washed three times in fresh M2. Chromosomes were spread in 1% 
PFA fixative as described in section 2.4.2. All slides were stored at 4°C short-term or -80°C 
long-term until immunofluorescent staining, as described in section 2.4.4. 
 
2.4.4 Immunofluorescent staining 
Glass slides with fixed chromosome spreads were rehydrated in room temperature 1x PBS 
from either 4°C short-term or -80°C long-term storage. 50µl blocking solution (0.15% BSA, 
0.1% Tween-20, 5% goat serum in PBS) was added to each slide in a humid chamber and a 
flexible plastic coverslip added to spread the block over the surface of the slide. Slides were 
blocked in a sealed humid chamber for 1 hour at room temperature. Primary antibodies were 
then added at the concentration described in Table 2.11, in 50µl blocking solution per slide. 
Primary antibodies spread with a disposable coverslip again and incubated either overnight 
at 4°C or for 3 hours at room temperature, in a sealed humid chamber. After primary antibody 
incubation, slides were washed three times in PBS for 5 minutes and then incubated with 
secondary fluorescent (Alexa Fluor®, Invitrogen) antibodies (again, in 50µl blocking solution 
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at the indicated concentration, Table 2.11) and 20µg/ml DAPI (Biotium, 40043, stock at 
10mg/ml) for 1 hour in a humid chamber, protected from the light. 
Slides were then mounted in PD mountant solution (1mg/ml p-phenylene diamine in 90% 
glycerol), gently compressed under a glass coverslip for approximately 15 minutes, then sealed 
with clear nail varnish and stored at 4°C, protected from light, until imaging using 








2.5 Microscopy and analysis 
2.5.1 Brightfield microscopy 
Brightfield images were acquired using a Micropublisher 5MP cooled colour CCD camera 
(Qimaging, Surrey, BC, Canada) mounted on a Zeiss Axioplan II fluorescence microscope 
with Plan Apochromat objectives (Carl Zeiss, Cambridge, UK). Image capture was performed 
using scripts written by the IGMM-AIR (Advanced Imaging Resource) facility for 
Micromanager (https://open-imaging.com/). Objectives and magnifications used were set on 
Micromanager prior to image capture, so this was captured in the image metadata and scale 
could be directly applied to images during analysis. 
 
2.5.1.1 Tiled brightfield imaging and analysis 
Tiled whole tissue scanning for whole placenta measurements was carried out using 
an Olympus BX51 upright microscope (Olympus KeyMed, Southend on Sea, UK) 
with Marzhauser motorized stage (Marzhauser Wetzlar GmbH & Co, Wetzlar, 
Germany).  The system uses Olympus plan Apochromat and UplanS Apochromat 
objective lenses with magnifications from 2x-40x.  Images are acquired using an 
Olympus XC10 colour CCD camera.  Batch scanning of slides is carried out by the 
attached SL50 slide loader unit.  All hardware and tissue measurements were 
controlled through the Olympus Dotslide VS-ASW software, maintained by the 
IGMM-AIR facility. 
 
2.5.2 Epifluorescence microscopy 
After immunofluorescent staining, epifluorescent images were acquired using a Photometrics 
Coolsnap HQ2 CCD camera and a Zeiss Axioplan II fluorescence microscope with Plan-
neofluar objectives (Carl Zeiss, Cambridge, UK), a Mercury Halide fluorescent light source 
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(Exfo Excite 120, Excelitas Technologies) and Chroma #83000 triple band pass filter set 
(Chroma Technology Corp., Rockingham, VT) with the excitation filters installed in a 
motorised filter wheel (Ludl Electronic Products, Hawthorne, NY). Image capture was 
performed using scripts written by the IGMM-AIR (Advanced Imaging Resource) facility for 
Micromanager (https://open-imaging.com/). Objectives and magnifications used were set on 
Micromanager prior to image capture, so this was captured in the image metadata and scale 
could be directly applied to images during analysis. 
 
2.5.2.1 Z-stack epifluorescent microscopy 
Where required, z-stack images were taken using a Photometrics Coolsnap HQ2 
CCD camera and a Zeiss AxioImager A1 fluorescence microscope with a Plan 
Apochromat 100x 1.4NA objective, a Lumen 200W metal halide light source (Prior 
Scientific Instruments, Cambridge, UK) and Chroma #89014ET single excitation and 
emission filters (Chroma Technology Corp., Rockingham, VT) with the excitation 
and emission filters installed in Prior motorised filter wheels. A piezoelectrically 
driven objective mount (PIFOC model P-721, Physik Instrumente GmbH & Co, 
Karlsruhe) was used to control movement in the z dimension. Hardware control, 
image capture and analysis were performed using Volocity (Perkinelmer Inc., 
Waltham, MA) or Micromanager. 
Deconvolution, and subsequent 3-dimensional measurements between foci, were 
carried out using a calculated PSF in either Volocity (Perkinelmer Inc., Waltham, MA) 
or Imaris v9.0 (Bitplane, Oxford Instruments plc). Centromeric antibody signals were 
designated as “spots” at which co-ordinates could be recorded, and 3-dimensional 
Pythagorean Theorem was implemented in order to measure distances between these 




2.5.3 Image analysis and quantification 
Unless specified, all 2-dimensional image analysis and quantifications were carried out using 
FIJI (Image J) with 64bit Java8. In order to avoid scoring bias, image names were randomized 
using a FIJI macro script written by James Crichton (MRC HGU), and analysed blind. 
For axial distance measurements in prophase I images, 3-colour stack images were converted 
to 8bit and analysed using the NeuronJ FIJI plugin, developed by ImageScience (Meijering et 
al. 2004). 
For antibody stain intensity quantification in stacked 3-colour prometaphase I cell images, 
each individual bivalent was thresholded by condensed DAPI signal, and fluorescent antibody 
signal intensity measured, then normalised against other protein levels within the same 
bivalent. Median bivalent protein intensity was calculated across each nucleus, then the mean 
of these medians was calculated for all nuclei from each mouse. For comparison between 
genotypes, these relative signal intensities were normalised again the mean for control 








2.6 Protein analysis 
2.6.1 Preparation from cell culture 
2.6.1.1 Chromatin preparation 
mESCs were cultured in 6-well plates and enriched at G2/M using double thymidine 
treatment as in sections 2.2.3 and 2.2.3.2. At the DT+4 (G2/M) timepoint, cells were 
washed in ice-cold PBS and harvested by scraping, then resuspended in 200μl Buffer 
A+ (10mM HEPES, 10mM KCl, 1.5mM MgCl2, 0.34M sucrose, 0.1% Triton-X100, 1mM 
DTT, 5mM sodium butyrate to prevent deacetylation of proteins, 1X Roche Complete 
Mini protease inhibitor and 10% glycerol in dH2O) and lysed on ice for 5 minutes. 
Nuclei were separated by centrifugation at 1300g for 4 minutes at 4°C, then washed 
in 500μl Buffer A (as Buffer A+, but with no Triton-X100 detergent). Nuclei were 
separated by centrifugation as above, and resuspended in 200μl Buffer B (3mM EDTA, 
0.2mM EGTA, 1mM DTT, 5mM sodium butyrate to prevent deacetylation of proteins 
and 1X Roche Complete Mini protease inhibitor in dH2O); this was incubated on ice 
for 30 minutes in order to lyse nuclei. Chromatin was separated by centrifugation at 
1700g for 4 minutes at 4°C, then washed in 500μl Buffer B and pelleted as above. 
Chromatin was then resuspended in 100μl Laemmli 2x sample buffer, sonicated to 
shear chromatin for 20 cycles (30 seconds on, 30 seconds off – BioRuptor®, Diagenode) 
and then the protein sample was denatured at >95°C in a heat block for 10 minutes. 
Protein was then used for Western blotting, or stored at -20°C until later use. 
 
2.6.1.2 Co-immunoprecipitation 
HEK293T cells were transformed with combinations of UBR2-FLAG, TEX19.1-GFP 
or GFP expression plasmids, as described in section 2.2.2 and Table 2.6 and harvested 
by trypsinisation 24 hours later (section 2.2.1). Anti-FLAG M2 beads (Millipore, 
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M8823) were provided in glycerol to preserve the antibody structure, and so were 
equilibrated in Dilution Buffer (DB: 10mM Tris pH7.5, 0.15M NaCl, 0.5mM EDTA, 
1mM PMSF and 1% Roche Complete Mini protease inhibitor in dH2O) by washing 
30μl beads per experiment three times in 500μl DB, with centrifugation at 13,000g 
between each wash, and then stored on ice until use. 
Transfected HEK293T cells were washed in ice-cold PBS, then resuspended in 200μl 
Lysis Buffer (as Dilution Buffer above, but with 0.5% NP40 detergent) and lysed on 
ice for 30 minutes – during this time, the cells were occasionally gently mixed to avoid 
settling and ensure full cell lysis. Cell debris was pelleted by centrifugation at 16,000g 
for 10 minutes at 4°C, and then the protein supernatant was transferred to a pre-
cooled tube and diluted in 800μl DB to a total volume of 1ml. An aliquot of this was 
taken and added to Laemmli sample buffer to act as the input sample for each co-
immunoprecipitation experiment. The diluted lysate was then combined with 30μl 
equilibrated FLAG-M2 beads and mixed by inversion at room temperature for 1 hour. 
Beads, and bound proteins, were then kept on ice throughout three washes in 500μl 
ice-cold DB, then denatured and dissociated in Laemmli sample buffer at >95°C for 10 
minutes. Protein samples were used immediately for Western blotting, or stored at -
20°C until later use. 
 
2.6.1.3 Peptide pulldown assays 
Peptides specific to the N-terminal sequence of Type I (Arginine) or Type II 
(Phenylalanine) target proteins  in the N-end Rule (see Chapter 5, Fig. 5.3A) were 
conjugated to resin via a C-terminal Cysteine using the Sulfolink® Peptide 




Briefly, each peptide Type I (R), Type II (F) and -ve (G, negative control) diluted to 
0.5mg/ml in 2ml of Sulfolink Coupling Buffer (50mM Tris pH 8.5, 5mM EDTA-Na) 
and reduced by addition of 100µl TCEP (0.5M Tris(2-carboxlethyl)phosphine, 
Sulfolink BondBreaker®) and incubation at room temperature for 30 minutes. Resin 
was equilibrated by three washes in Sulfolink Coupling Buffer, then peptide solution 
added and incubated end-over-end at room temperature for 15 minutes, and upright 
for an additional 30 minutes to allow coupling of peptide to resin beads. Resin was 
washed four times in Sulfolink Wash Solution (1M NaCl, 0.05% NaN3), and two 
additional times in Sulfolink Coupling Buffer. Resin then incubated end-over-end in 
7.9mg/ml L-Cysteine-HCl in Sulfolink Coupling Buffer for 15 minutes at room 
temperature, and for an additional 30 minutes upright. Resin washed twice with 
storage buffer (0.05% sodium azide in 1x PBS) and stored at 4°C upright in 2ml fresh 
storage buffer – this should be maintained at 50% resin, 50% storage buffer. 
Peptide coupling efficiency was calculated by comparison of protein content of 
peptide solution before and after coupling (i.e. flowthrough), measured by Nanodrop 
spectrophotometry. Generally, ≥80% coupling efficiency was deemed sufficient for 
peptide pulldown assays. 
Immediately prior to pulldown assay, resin was aliquoted – three 110µl aliquots of 
preclear and one 220µl aliquot of each Type I, Type II and -ve peptide per condition – 
and then prepared by removal of storage buffer and washed in 1ml ice cold dilution 
buffer (10mM Tris pH7.5, 150mM NaCl, 0.5mM EDTA, 1x Roche Protease Inhibitor 
in dH2O). All centrifugation of resin performed at 8200g and 4°C for 30 seconds. All 
resin was stored in 100µl dilution buffer on ice until use. 
For peptide pulldowns, HEK293T cells were seeded at 1x105cells/ml in 3 wells of a 6-
well plate and, after 24 hours were transfected for protein overexpression with either 
pCMV10-UBR2-T1-FLAG or pCMV10-UBR2-T2-FLAG, alongside the wild type 
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control plasmid pCMV10-UBR2-FLAG, as in section 2.2.2. At 48 hours, cells were 
washed with ice cold 1x PBS and cells were lysed in-well with 200µl ice cold lysis 
buffer (10mM Tris pH7.5, 150mM NaCl, 0.5mM EDTA, 0.5% NP-40, 1x Roche 
Protease Inhibitor in dH2O) and incubated for 30 minutes at 4°C with continuous 
movement. Lysates from three wells were combined and centrifuged at 16,000g for 10 
minutes at 4°C to separate out cell debris. Supernatant was transferred into a new 
tube and diluted to 3ml with ice cold dilution buffer to reduce the concentration of 
NP-40 detergent. At this stage, a 50µl aliquot of each sample was taken to be the input 
control - 50µl Laemmli sample buffer (Sigma-Aldrich, S3401) was added and the 
sample heated at 95°C for 5 minutes prior to Western blotting. Each sample was split 
(1ml x3) across 3 preclear resin tubes (after removal of excess dilution buffer) and 
incubated end-over-end at 4°C for 1 hour. Supernatant was then recombined, and 
then split again into Type I, Type II and -ve peptide-conjugated resin (1ml per tube). 
Incubated end-over-end at 4°C overnight. Supernatant was removed and resin 
washed 3 times in 750µl ice cold wash buffer (10mM Tris pH7.5, 150mM NaCl, 0.5mM 
EDTA, 0.1% NP-40, 1x Roche Protease Inhibitor in dH2O). Beads were resuspended 
in 50µl Laemmli sample buffer and heated at 95°C for 5 minutes while pulse-vortexing 
to mix every 1-2 minutes. Finally, resin was then centrifuged and supernatant (in 
Laemmli buffer) isolated for analysis by Western blotting. 
 
2.6.2 Preparation from animal tissues 
2.6.2.1 Chromatin preparation 
Spleens were dissected from adult males and homogenised using razor blades and 
filtered through a 100µm nylon cell strainer into 1.5ml PBS. Cells were pelleted at 100g 
for 4 minutes at 4°C, washed in ice-cold PBS and then resuspended in 200μl Buffer 
A+ (see section 2.6.1.1) – from this point, chromatin preparation carried out exactly 
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as in section 2.6.1.1. As spleen tissue has high cell number compared to cell pellet 
isolated from cell culture, protein isolated from spleen chromatin was diluted 1:100 in 
Laemmli after sonication and denaturation at >95°C in order to produce accurate 
Western blots. Protein samples were then stored at -20°C until analysis by Western 
blotting. 
 
2.6.2.2 Peptide pulldown 
For peptide pulldowns, whole testes were dissected from adult males and 
homogenized using razor blades and 100µm nylon cell strainers, as above, into PBS. 
Cells were spun down, and then incubated with continuous movement in lysis buffer 
at 4°C, as in section 2.6.1.3. Peptide pulldowns carried out as above, and protein 
samples analysed using Tris-Acetate Western blotting, described in section 2.6.3. 
 
2.6.3 Western blotting and quantification 
For most Western blotting experiments, samples were heated in Laemmli buffer >95°C for 5 
minutes, then 15µl loaded into wells of a 4-12% Bis-Tris gel (Invitrogen NuPAGE system) 
alongside a broad range Color Protein Standard (NEB, P7719S) marker. Gels were run in SDS-
MOPS buffer (NuPAGETM, Invitrogen NP0001) at 150 volts (V/cm) in order to separate 
proteins by molecular weight. Gels were transferred onto nitrocellulose blotting membranes 
using the iBlot2 dry transfer system (ThermoFisher, IB21001). The membranes were washed 
in PBS-T (0.1% Tween-20 in 1x PBS); membrane block and all antibody incubations were in 
5% milk (Marvel milk powder) in PBS-T. Primary and HRP-conjugated (horseradish 
peroxidase) secondary antibodies are all noted in Table 2.10. 
For high molecular weight proteins (above 200kDa, i.e. UBR proteins), such as in peptide 
pulldown assays, Western blotting was modified to use 3-8% Tris-Acetate gels (Invitrogen 
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NuPAGE), which have a higher resolution of protein separation at high molecular weights 
and either broad range Color Protein Standard (NEB, P7719S) or high molecular weight 
HiMark Protein Standard (Life Technologies, LC5699) marker in Tris-Acetate SDS running 
buffer (Invitrogen NuPAGE, LA0041). For these experiments, proteins were transferred onto 
PVDF (polyvinylidene fluoride) membranes and blocking/antibody staining was carried out 
in 3% BSA (bovine serum albumin) in 1x PBS-T. 
For visualisation of Western blotting, membranes were incubated in ECL (enhanced 
chemiluminescent reagent, Thermo Fisher SuperSignal system, 34577) and visualised using 
photosensitive film in a dark room (SLS Amersham Hyperfilm). 
If quantification was required, developed film was scanned as a TIFF image file and protein 





2.7 RNA analysis 
2.7.1 RNA preparation 
RNA was prepared from whole mouse tissue by homogenization in 500μl TRIzol™ reagent 
(Invitrogen, 15596026), and dilution to 1ml of TRIzol. RNA was precipitated by 
chloroform:isopropanol, as per the manufacturer’s instructions, and then washed in EtOH 
and resuspended in RNase-free dH2O. Isolated nucleic acid was then subjected to DNase 
treatment to isolate only RNA, using the TURBO DNA-free kit (Invitrogen, AM1907), and 
then purified using the RNeasy Mini kit (Qiagen, 74104).  For RNA preparation from cell 
culture samples, RNA was directly isolated and purified using the RNeasy Plus Mini kit 
(Qiagen, 74134), which does not require a separate DNase step. 
After RNA purification, cDNA synthesis was carried out using the SuperScript™ First-Strand 
Synthesis System (Thermo Scientific, 11904018), in which 1µg purified RNA was added to 1µl 
dNTPs and 0.2µl random primers in a 13µl reaction, then incubated at 65°C for 5 minutes and 
chilled on ice for 2 minutes. Random primers were used to maximise transcript coverage and 
to ensure no genomic DNA contamination was present. The reverse transcription mix was set 
up as follows: 13μl prepared RNA, 4μl 5x First Strand Synthesis buffer, 1μl 0.1M DTT, 1μM 
RNAse Inhibitor, 1μl Superscript III Reverse Transcriptase enzyme. This was incubated at 
25°C for 5 minutes, 50°C for 60 minutes and 70°C for 15 minutes. For a negative control (no 
reverse transcriptase, NRT), reactions were performed without reverse transcriptase enzyme. 
cDNA samples were diluted 1:50 for use in qRT-PCR and stored at -20°C until use. 
 
2.7.2 qRT-PCR 
Quantitative real-time PCR (qRT-PCR) is an assay by which the level of expression of a gene 
in a cell or tissue can be measured by looking at the amplification rate of cDNA produced from 
the mRNA complement of that sample, so giving the level of mRNA transcripts present, and 
comparing to the amplification rate of known housekeeping genes that have constant 
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expression level. 1:50 cDNA samples were used, and a control sample was generated by 
combining a small amount of each of the neat samples and creating a dilution series 1:10, 1:50, 
1:100 and 1:1000. This was used to generate a standard amplification curve for each primer pair, 
and so only primer pairs with an R2 value of >0.98 in their standard curve were used. 
Primers, as noted in Table 2.4, were ordered from Sigma Aldrich with desalting purification, 
and were reconstituted to 100µM stocks, diluted to 1µM working solutions and stored at -
20°C. Each 20µl reaction was made up with 2.5µl of each 1μM primer, 10μl of SYBR™ qPCR 
master mix (Applied Biosystems, 4472908) and 5µl of 1:50 cDNA sample. A minimum of three 
biological repeat samples were used and, for every sample, three technical repeats were 
carried out. For controls, an NTC (no template control) was set up with 5µl dH2O instead of 
the cDNA sample, and an NRT (no reverse transcriptase control) was used as detailed in 
section 2.7.1. These reactions were carried out in 96-well opaque qRT-PCR plates (Applied 
BioSystems) on a Roche Lightcycler 480. Samples were pre-incubated at 50°C for 2 minutes, 
then 95°C for 2 minutes. 50 PCR cycles were carried out, which consisted of: an amplification 
step at 95°C for 5 seconds, then 60°C for 30 seconds. 
qRT-PCR output is a Cp (crossing point) value, which indicates the number of cycles taken 
to reach a plateau level of transcript amplification. The quantity of transcripts present was 
determined using the slope of the standard curve calculated for each primer pair. This 
quantity was normalised to reference gene β-actin and then calculated for each genotype as 
relative to wild type control samples. A two tailed Student’s T-test was used to determine if 




Target Gene/Locus Forward Reverse Notes 
Cdx2 5’–GGGTGGGGGTAGCAATACTT 5’–CCCTTCCTGATTTGTGGAGA Trophoblast 
Ctsq 5’–AGAACAGCTGGGGTAGACG 5’–GCCACATGCTTTCTTGTGAA Trophoblast 
Ifi44 5’–ATGGAGACCTGGTTCAGCAA 5’–ACTGTCATCCTTGGCCTTGA IFN response 
Ifitm2 5’–CTCTTCTTCAACGCCTGCTG 5’–TGGGGTGTTCTTTGTGCAAA IFN response 
Ifitm3 5’–TATGAGGTGGCTGAGATGGG 5’–TCACCCACCATCTTCCGATC IFN response 
Impact 5’–TTTATGGCGAGGAGTGGTGT 5’–GTTCGATAAGTCTGCGCGTT Imprinted 
Irf7 5’–GTGTACTGGGAGGTAGGCAG 5’–TGCCCAAAACCCAGGTAGAT IFN response 
LINE-1 ORF2 5’–GGAGGGACATTTCATTCTCATC 5’–GCTGCTCTTGTATTTGGAGCATAGA Retrotransposon 
Mcts2 5’–TGCAAATATCATGTGCCCGG 5’–TTCTCAATGCCGATCCCCTT Imprinted 
Mest 5’–AAGATCTGGGAAGGGCTGAC 5’–GGTTGATTCTGCGGTTCTGG Imprinted 
MMERVK10C 5’–AACTGGTCGCAGGAGCTG 5’–GGTAAAGTCTCCGAGGGTCA Retrotransposon 
Oasl1 5’–CTGCTCCAGGATCATGAGCT 5’–TTCTGCCACATTGTTGGTGG IFN response 
Oasl2 5’–CCGGCAATCTACGAGACTCT 5’–GCTCTCTGTACCCATCTCCC IFN response 
Peg3 5’–CCAAGAGAACTGCCTACCCA 5’–TCCCTTGCTCTTCCGGATTT Imprinted 
Prl8a8 5’–AAATTATGTGGGTGCCTGGA 5’–TCACGCAGAATTTGTCTGTTG Trophoblast 
Psg21 5’–ATAGGGACCCGTTGCTGTAC 5’–TGTCACCATCCAGTCACCAA Trophoblast 
Psg23 5’–TCCAGTCACCACAACACGTA 5’–ATCCTGTGTCCTCCTGTGTG Trophoblast 
Tmem173 5’–CCTCAGTTGGATGTTTGGCC 5’–CCTCAGTTGGATGTTTGGCC IFN response 
VL30 5’–CAGCCTTGGCCTGAGAGTTT 5’–CTTTCTGGGCTGAAGTCCCT Retrotransposon 
β-actin 5’–GGCTGTATTCCCCTCCATCG 5’–ACATGGCATTGTTACCAACTGG Housekeeping 
 









2.8 DNA analysis 
2.8.1 Plasmids 
Various plasmids were used for overexpression of proteins in cell culture (see section 2.2.2), 
as well as conduction of CRISPR-Cas9 in ESCs (section 2.2.3) and in generation of a mutant 
mouse (section 2.1.3); all are noted in Table 2.6. 
 
Plasmid Features Antibiotic Resistance Source 
p3xFLAG-CMV-10-UBR2 
N-terminal 3xFLAG epitope tag 
Mouse Ubr2 CDS 
Ampicillin Adams lab (MRC HGU) 
pCAAGS-TEX19.1 
GFP epitope tag 
Mouse Tex19.1 CDS 
CAG promoter 
Kanamycin Adams lab (MRC HGU) 
pX330-U6-Chimeric_BB-
CBh-hSpCas9 




Table 2.6 – Plasmids used in various molecular biology assays 
 
2.8.1.1 Bacterial culture and DNA extraction 
Plasmids were amplified by transforming into subcloning efficiency DH5α competent 
E. coli cells (Invitrogen, 18265017) as per the manufacturer’s instructions. Cells were 
stored at -80°C and thawed on ice prior to use. These were gently mixed and aliquoted 
into 50µl, then incubated on one with 5-10ng of DNA for 30 minutes. The cells were 
heat shocked for 20 seconds at 42°C, cooled on ice for 2 minutes and then 50µl 
prewarmed SOC medium was added. Cells were incubated with 1g shaking at 37°C 
for 1 hour, then mixed with 150µl LB () medium and plated onto pre-poured LB agar 
plates (10g/L NaCl, 10g/L Bacto-tryptone, 5g/L, Yeast extract, 15g/L Difco Agar) with 
either Ampicillin or Kanamycin antibiotic treatment for selection of successful 
transformants. Plates were inverted and incubated overnight at 37°C then colonies 
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were picked the following morning. These were then outgrown over the following 
night in 5ml LB medium with 50µg/L of the appropriate antibiotic (Ampicillin or 
Kanamycin) at 1g. DNA was isolated using the MiniPrep column spin kit (Qiagen) 
and yield was quantified using Nanodrop spectrophotometry (ThermoFisher 
Scientific). 
2.8.1.2 Site directed mutagenesis 
In order to introduce the D118A and D233A point mutations into the pCMV10-UBR2 
plasmid, I used Phusion Site-Directed Mutagenesis (Thermo Scientific F-541) as per 
manufacturer’s instructions. Briefly, a forward and reverse primer pair were designed 
to meet at their 5’ end (Table 2.6), with the intended point mutation in the centre of 
primer F. They were ordered from Sigma Aldrich with 5’ phosphorylation in order to 






UBR2-D118A 5’–[Phos]GACTGTGCAGTTGCCCCCACCTGTG 5’-[Phos]TCTGCAGGAGTATGTAGGTTCCCCCAC 
UBR2-D233A 5’–[Phos]GCTGTTTAATGCTGAGGTTCACACC 5’-[Phos]ATGCAGTAGTAGGTGTCACTCTTCT 
 
Table 2.7 – Site-directed mutagenesis primers. The introduced point mutation is marked in 
red. 
 
The intact 11kb plasmid was added to the following PCR reaction; 31.7µl dH2O, 10µl 
5x Phusion buffer, 2.5µl of each primer at 10µM, 0.3µl pCMV10-UBR2 (10ng total 
plasmid DNA), 1µl 10mM dNTPs, 1.5µl DMSO (final concentration at 3%) and 0.5µl 
Phusion HotStart DNA polymerase. As pCMV10-UBR2-FLAG is a large (11kb) GC-
rich plasmid, DMSO was added outwith the standard Phusion protocol. The 
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extension time was calculated at 30 seconds/kb of plasmid. The PCR protocol was 
followed as outlined in Table 2.7. A negative control with no Phusion polymerase was 
also used to ensure no contamination was present in the sample and all plasmid was 
incorporated into the PCR reaction. 
 
Step D118A D233A 
1) Initial Denaturation 98°C, 30 seconds 98°C, 30 seconds 
2) Denaturation 98°C, 10 seconds 98°C, 10 seconds 
3) Annealing 64°C, 30 seconds 70°C, 30 seconds 
4) Extension 72°C, 6 minutes 72°C, 6 minutes 
Cycles 
25 cycles 
Return to (2) 24 times 
25 cycles 
Return to (2) 24 times 
5) Final Extension 72°C, 10 minutes 72°C, 10 minutes 
 
Table 2.8 – PCR protocols for site-directed mutagenesis. 
 
 
After PCR amplification, the linear product was treated with 1µl FastDigest DpnI per 
reaction and incubated at 37°C for 15 minutes to digest the methylated parental 
plasmid DNA, and then the product was circularised using T4 DNA ligase; 2µl DpnI-
treated PCR product was combined with 2µl 5x T4 buffer, 5.5µl dH2O and 0.5µl T4 
ligase, then incubated at room temperature for 5 minutes. 
The mutated plasmids were then amplified using DH5α competent E. coli cells, as 
outlined in section 2.8.1.1, and screened for successful clones by Sanger sequencing of 
the whole ORF (open reading frame) to verify that no unintended mutation of the 




2.8.1.3 RNA guide cloning for CRISPR-Cas9 
In order to generate the CRISPR gRNA guide for injection into zygotes as detailed in 
section 2.1.3, and for generation of mESCs as in section 2.2.3.1, I introduced the guide 
sequence in Figures 5.5 or 5.16 into the plasmid pX330 (Table 2.5). This plasmid 
encodes the wild type CRISPR-Cas9 guide machinery required for binding of the 
guide to wtCas9 protein and successful CRISPR mutational activity. 
Both sense and antisense guide sequences were ordered as 5’-phosphorylated single 





Table 2.9 CRISPR gRNA generation constructs. Additional bases indicated in red for 
generation of sticky ends required for cloning into pX330. [Phos] indicates a 
phosphate group on the 5’ end of the next base in the sequence. 
 
 
The pX330 plasmid was digested with BbsI restriction enzyme (consensus 5’–
GAAGAC(N)2^ –3’) in a 150μl reaction, as follows: 6μg pX330 plasmid, 6U/ml BbsI 
(NEB), 3U/ml Fast AP (NEB), 10X NEB RE CutSmart buffer and dH2O up to a total 
volume of 150µl. This was combined with alkaline phosphatase treatment (Fast AP, 
NEB), incubated at 37°C for 30 minutes, and then the linearized plasmid was gel 
purified using the QIAquick column gel extraction kit (Qiagen). During this, the 
sense and antisense oligos were diluted in dH2O to 100µM, combined in a 10µl 
reaction, denatured at 95°C for 5 minutes and allowed to slowly cool to room 
temperature to anneal into a dsDNA structure. This was diluted 1:200 to a final 
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concentration of 0.5µM. The ligation reaction was carried out overnight at room 
temperature using T4 ligase, as follows: 50ng linearized pX330, 1µl 0.5µM dsDNA 
guide, 10X Roche ligation buffer, 1µl T4 DNA ligase (Roche), and dH2O to a total 
volume of 20µl. 
The ligation reactions were then used to transform into DH5α competent E. coli cells 
for amplification, as outlined in section 2.8.1.1, and selected using Ampicillin 
antibiotic resistance. Plasmid DNA was isolated using the MiniPrep column spin kit 
(Qiagen) and verified using Sanger sequencing with a primer specific to the sequence 
of the U6 promoter. 
For CRISPR-Cas9 in mESCs, this plasmid could be direct transfected into cells, as 
detailed in section 2.2.3.1. For injection into mouse zygotes, the gDNA construct 
including the inserted guide sequence was amplified by PCR with a primer pair 
specific to both the sequence of the T7 promoter and the guide, and this product was 
used in in vitro RNA synthesis of the gRNA construct including the cloned guide 
sequence using the T7 Quick High Yield RNA Synthesis kit (NEB), as per 
manufacturer’s instructions. The RNA template was purified using the RNeasy Mini 
column purification kit (Qiagen) and used in the injection mix described in section 
2.1.3. 
 
Primer Sequence Application 
U6 sequencing 5’–ACTATCATATGCTTACCGTA Sanger sequencing 
T7 Forward (guide) 5’–TGTAATACGACTCACTATAGGGCTGCATGCTGTTTAATGATG PCR amplification 
T7 Reverse (pX330 universal) 5’–AAAAGCACCGACTCGGTGCC PCR amplification 
 






Step T7-guide PCR 
1) Initial Denaturation 95°C, 30 seconds 
2) Denaturation 95°C, 30 seconds 
3) Annealing 50°C, 60 seconds 
4) Extension 68°C, 45 seconds 
Cycles 
35 cycles 
Return to (2) 34 times 
5) Final Extension 68°C, 5 minutes 
 





2.8.2 DNA sequencing 
All DNA Sanger sequencing was carried out using either a 3130XL or 3730 Genetic Analyser 
(Applied BioSystems, MRC HGU, Core DNA Sequencing Facility). This was used primarily 
for genotyping of point mutations in either CRISPR-Cas9 generated mice or cell lines, or for 






Biological Target Level Application, Dilution Species Reference/Source 
ACA 
(anti-centromere) 




Gift from J. M. Peters 
(Nishiyama et al. 2010) Western Blotting, 1:1,000 
FLAG-M2 Primary Western Blotting, 1:5,000 Mo Millipore F1804 
GFP Primary Western Blotting, 1:2,500 Rb Abcam, ab290 
Histone H3 Primary Western Blotting, 1:10,000 Rb Abcam, ab1791 
Lamin B1 Primary Western Blotting, 1:5,000 Rb Abcam ab16048 





Rb Abcam, ab128919 
Western Blotting, 1:1,000 
SYCP3 Primary Immunofluorescence 
1:500 Rb LS-Bio, LS-B175 
1:200 Mo 
Santa Cruz Antibodies 
D-1 sc-74569 
TEX19.1 Primary Western Blotting, 1:5000 Rb 
Gift from J. Wang 
(Yang et al. 2010) 
UBR2 Primary Western Blotting, 1:500 Gt Aviva, OAEB 00482 





Secondary Immunofluorescence, 1:500 Gt 
Alexa Fluor® 
Invitrogen, A11017 
488 (green) anti-Rb Secondary Immunofluorescence, 1:500 Gt 
Alexa Fluor® 
Invitrogen, A11008 
594 (red) anti-Mo Secondary Immunofluorescence, 1:500 Gt 
Alexa Fluor® 
Invitrogen, A11020 
594 (red) anti-Rb Secondary Immunofluorescence, 1:500 Gt 
Alexa Fluor® 
Invitrogen, A11012 
HRP anti-Mo Secondary Western Blotting, 1:5,000 Gt BioRad, 170-6516 
HRP anti-Rb Secondary Western Blotting, 1:5,000 Gt Cell Signalling 7074S 
HRP anti-Gt Secondary Western Blotting, 1:5,000 Rb BioRad, 172-1034 
 
Table 2.12 – Antibodies used for various assays. Rb – rabbit. Mo – mouse. Hu – human. Gt 













Ubr2 in Oocyte Development and Chromosome 








Oocytes are particularly vulnerable to aneuploidy, as compared to the aneuploidy rates that 
arise as a result of spermatogenesis (Hunt and Hassold 2002). As discussed in Chapter 1, 
female meiosis is a much longer process than that of males, and this is thought to be a factor 
in the higher incidence of chromosome missegregation observed throughout oogenesis 
(Hassold and Hunt 2001; Herbert et al. 2015). Meiosis begins in the embryonic ovary, and 
chromosomes align for homologous recombination to occur. After genetic crossover, the link 
between homologous chromosomes matures and is only held together by interhomolog 
conformation and protein complexes, rather than a physical DNA linkage (Bascom-Slack, 
Ross, and Dawson 1997). This can be visualised cytologically as chiasmata, which hold each 
pair of homologs, each made up of a pair of sister chromatids, together in a bivalent structure. 
Cohesins are a particularly important group of protein complexes during this process, as they 
associate with the chromosome axis and hold sister chromatids together, so stabilising the 
chiasma structure downstream of the crossover event (MacLennan et al. 2015). Meiosis 
arrests at this point, in what is known as the dictyate arrest phase, and oocytes do not resume 
meiosis until the ovary is mature, at the onset of puberty. Chiasmata maintenance through 
dictyate arrest is key, as physical links allow the two homologous chromosomes to behave as 
a single unit (the bivalent) on the metaphase I spindle. Homologs are then able to attach to 
opposite spindle poles during the first meiotic division. Premature chromosome separation at 
this stage is one of the leading causes of oocyte aneuploidy, as homologous chromosomes 
lacking chiasmata (achiasmate chromosomes) will behave independently on the metaphase I 
spindle and therefore have a higher chance of segregating incorrectly to the same spindle pole 
(Lister et al. 2010). The length of the dictyate arrest in a mouse model can vary from around 2 
months, at female sexual maturity, to over a year or longer. There is evidence to suggest that, 
with age, there are less cohesin complexes present along the chromosome axis, and this is 
assumed to lead to a loss of chromosome cohesion during the dictyate arrest period 
(Cimadomo et al. 2018). This has also been observed in aged human oocytes (Tsutsumi et al. 
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2014), correlating with the increased incidence of aneuploidy with maternal age in humans. 
In order to study the cohesin complex in a meiotic context, with a view to preventing 
aneuploidy and related fertility disorders, we must first understand the mechanisms that 
undergo cohesin maintenance, particularly around MI and the dictyate arrest. The cohesin 
complex has been most widely studied in mitotic cells, and so we can use our knowledge of 
the mitotic maintenance mechanisms in order to infer conclusions about meiotic cells. The 
structure of the cohesin complex, and its dynamics within both mitotic and meiotic cell cycle, 
are discussed in detail in section 1.3. 
The cohesin subunit SMC3 is present in all cohesin complexes, in both mitotic and meiotic 
cells. During mitotic S phase, acetylation of SMC3 acts to recruit cohesin maintenance factors 
such as sororin, which antagonises the cohesin removal factor WAPL (Nishiyama et al. 2010; 
Losada 2014), so maintaining cohesion throughout G2. In mitotic prophase, sororin 
phosphorylation allows removal of chromosome arm cohesin, and chromosomes are held 
together by centromeric cohesin until segregation at the metaphase-anaphase transition 
(Brooker and Berkowitz 2014; Ladurner et al. 2016). Although there are many similarities 
between mitotic and meiotic cohesin complexes, arm cohesion must be maintained on the 
bivalent throughout prophase I and into metaphase I (MacLennan et al. 2015). Centromeric 
cohesion is maintained through the first metaphase-anaphase transition, only dissociating 
prior to the second meiotic division. SMC3 acetylation (formation of the AcSMC3 subunit) 
and sororin recruitment are active processes in the meiotic oocyte nucleus (Gómez et al. 2016; 
Huang et al. 2016), and so AcSMC3 may also be important for cohesin maintenance in the 
oocyte. Given the elevated importance for prevention of aneuploidy in the germline, the 
mammalian oocyte may have evolved mechanisms to maintain acetylated cohesin function 
during the later stages of female meiosis, and study of these will give insights into the 
molecular basis of aneuploidy and subsequent subfertility. 
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Ubr2 has been previously implicated in genomic stability and homologous recombination in a 
mitotic context (Ouyang et al. 2006), and our group have shown that Ubr2 acts to specifically 
regulate the AcSMC3 subunit of chromosome-associated cohesin, again in a mitotic context 
(J Reichmann et al. 2017). A major interactor of the UBR2 protein is TEX19.1, which is 
primarily expressed in hypomethylated tissues, including the ovaries, testes, and in 
embryonic stem cells (ESCs) in culture (Ollinger et al. 2008; Tarabay et al. 2013; Maclennan 
et al. 2017; J Reichmann et al. 2017). Our lab have outlined a role for Tex19.1 in protection of 
chromosome cohesion before the first meiotic metaphase: a Tex19.1-/- mouse has low levels of 
chromosome-associated AcSMC3, but not other cohesin subunits, and chromosome mis-
segregation at the first meiotic division, resulting in increased incidence of aneuploidy after 
meiotic completion and subfertility. TEX19.1 and UBR2 have a 1:1 stoichiometric interaction, 
and there is evidence to suggest that TEX19.1 acts to regulate the activity of UBR2, which is 
an E3 ubiquitin ligase that is active in the N-end Rule pathway (J Reichmann et al. 2017). 
Additionally, our lab have shown that, when ectopically expressed, TEX19.1 is able to regulate 
the Type II N-end Rule substrate binding activity of UBR2 – i.e. it regulates UBR2’s ability to 
target Type II substrates for N-end Rule ubiquitination (J Reichmann et al. 2017; T Tasaki et 
al. 2005). Therefore, I hypothesised that TEX19.1 acts to protect AcSMC3 by preventing UBR2 
from turning over either AcSMC3 itself or an indirect substrate that has downstream effects 
to regulate AcSMC3 and the cohesin complex as a whole (Fig. 1.4 and section 1.2.2). One 
prediction of this model is that, if UBR2 negatively regulates AcSMC3 in mouse oocytes, then 
loss of UBR2 may result in increased levels of AcSMC3. This molecular role could potentially 
have implications for meiotic chromosome segregation. 
In this chapter, I aimed to look at the role of Ubr2 in meiotic cohesin regulation using a          
Ubr2-/- mouse and investigate whether this is antagonistic to the known cohesin regulator 
Tex19.1. I showed that there is a reduction in chromosome cohesion in both Metaphase I and 
Metaphase II, although there is no detected chromosome missegregation in the first meiotic 
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division. This correlates with a specific decrease in the acetylated subpopulation of 
chromosome-associated cohesin complexes. Unexpectedly, rather than generating an 
opposite phenotype to Tex19.1-/- oocytes, loss of Ubr2 phenocopies aspects of the Tex19.1-/- 
oocyte phenotype, which indicates that there is a cell-type specific modulation of the role of 






3.2.1 AcSMC3 is specifically downregulated in Ubr2-/- metaphase I oocytes 
The Ubr2 and Tex19.1 genes are coexpressed in the murine ovary, and a stoichiometric 
interaction has been observed between these proteins in vitro (J Reichmann et al. 2017; Pan et 
al. 2008; Celebi et al. 2012). Lack of Tex19.1 shows a vital role for chromosome cohesion and 
segregation in the murine oocyte, and this is linked to a specific reduction in axis-associated 
acetylated SMC3, but not in total cohesin levels (J Reichmann et al. 2017). As Ubr2 is known 
to negatively regulate AcSMC3 in mitotic tissues, I hypothesised that Ubr2 and Tex19.1 work 
antagonistically in the oocyte to regulate cohesin complexes containing the AcSMC3 subunit. 
In order to investigate this, I first aimed to measure the level of chromosome axis associated 
AcSMC3 in the oocyte. As meiotic oocytes make up a very small proportion of the ovarian 
tissue and any direct protein quantification using Western blotting would be obscured by 
levels of the mitotic cohesin complex, I isolated oocytes during the germinal vesicle stage (GV) 
from the ovaries of Ubr2-/- and Ubr2+/+ females 42 hours after PMSG hormone treatment, 
cultured them to 3 hours post-GVBD (germinal vesicle breakdown) and carried out 
metaphase I chromosome spreads on glass slides in 1% PFA fixative. As female mice are 
reported to lose cohesin from the chromosomes of their oocytes with age, young (2-3 months 
old) age-matched mice were used for these experiments. I carried out immunofluorescence 
against AcSMC3 in these chromosome spreads (Fig. 3.1A). Cohesin complexes, represented 
here by AcSMC3, are present along the chromosome axes that hold each pair of sister 
chromatids together and can be distinctly observed in the condensed bivalent chromosome 
structure (Fig. 3.1A, inset). Centromeres are immunostained with ACA (anti-centromeric 
antibody), which is isolated from patients with CREST autoimmune disease and is specific 
to centromeric kinetochore complex proteins (Fritzler, Kinsella, and Garbutt 1980; Blengini 
and Schindler 2018). DAPI is used to stain DNA and observe gross chromosomal morphology 
at metaphase I, which appears generally normal with lack of Ubr2. All chromosome spreads 
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for quantification were thresholded at 18 bivalents per nucleus, allowing for loss of 2 bivalents 
per nucleus as an artefact of the chromosome spreading process. When the intensity of 
AcSMC3 immunofluorescent signal is quantified, normalised against intensity of the 
centromeric ACA signal per bivalent and calculated as a median intensity across all bivalents 
within each nucleus, Ubr2-/- oocytes have 61.6% (±4.2%) of wild type AcSMC3 intensity along 
the chromosome axes, which is a statistically significant decrease in the level of protein 
present (Fig. 3.1B, p≥0.001, Student’s T-test). Therefore, loss of Ubr2 results in a loss of 
chromosome axis-associated AcSMC3-containing cohesin complexes in the metaphase I 
oocyte. 
In order to assay whether this observed phenotype indicates a specific role for Ubr2 in 
AcSMC3 regulation, I also quantified total SMC3 protein in Metaphase I oocyte spreads (Fig. 
3.2A), again by immunofluorescence with normalisation against ACA signal. As SMC3 is 
present in all cohesin complexes, this gives an indication of the level of total cohesin present 
along the chromosome axis within each bivalent structure. The mean level of SMC3 protein 
in Ubr2-/- chromosome spreads is 88.1% (±20.2%) of the wild type mean protein, but this is not 
a statistically significant change in protein signal intensity (Fig. 3.2B, p=0.59, Student’s T-test). 
It should be noted that there is more variation in the quantification of total SMC3 as 
compared to the variation of AcSMC3 (Fig. 3.2A, B), due to the quality of antibody binding in 
these immunofluorescence experiments. ACA in particular was a variable signal in presence 
of the total SMC3 antibody, potentially due to interference between the two antibodies used 
in this experiment, and so SMC3 oocytes were quantified with a thresholded minimum of 
ACA signal present. 
Loss of Ubr2 results is a specific decrease in AcSMC3-containing cohesin complexes, which is 
not reflected in total SMC3 levels – i.e. there is no change in total axial cohesin at this stage 
of meiosis. Therefore, UBR2 appears to promote AcSMC3-containing cohesins along the 
metaphase I oocyte chromosome axis. Surprisingly, this decrease in AcSMC3 in absence of 
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Ubr2 is a phenocopy of the cohesin phenotype observed in the Tex19.1-/- oocyte, both showing 
a 40-50% reduction in AcSMC3 intensity (J Reichmann et al. 2017). However, my original 
hypothesis was that Ubr2 and Tex19.1 work antagonistically to regulate acetylated cohesin 
levels in the oocyte, and so I concluded that the TEX19.1-UBR2 interaction may instead be 
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Figure 3.1 (previous page) – AcSMC3 is reduced in the Ubr2-/- metaphase I oocyte 




 prometaphase I oocyte chromosome spreads, 
immunostained for AcSMC3 in red and anti-centromeric antibody (ACA, or CREST) in green, 
with DAPI shown in blue to mark DNA. Inset images show an individual bivalent in 3-colour (left) 
and the AcSMC3 alone (greyscale, right) along chromosome axes. B. Mean AcSMC3 
immunofluorescence signal over 14 Ubr2
+/+
 (grey) and 13 Ubr2
-/-
 (green) oocytes from 5 mice of 
each genotype. Median of signal within each chromosome normalised to ACA signal for each 
oocyte, and means calculated for each mouse, then normalised to the Ubr2
+/+ 
same day control mean 
to control for day-to-day variation. n is the number of nuclei analysed. 








Figure 3.2 (next page) – Total SMC3 is unaffected in the Ubr2
-/- 
metaphase I oocyte 




 prometaphase I oocyte chromosome spreads, 
immunostained for SMC3 in red and anti-centromeric antibody (ACA, or CREST) in green, with 
DAPI shown in blue to mark DNA. Inset images show an individual bivalent in 3-colour (left) and 
the SMC3 alone (greyscale, right) along chromosome axes. B. Mean SMC3 immunofluorescence 
signal over 14 Ubr2
+/+
 (grey) and 10 Ubr2
-/-
 (green) oocytes from 4 mice of each genotype. Median 
of signal within each bivalent normalised to ACA signal for each oocyte, and means calculated for 
each mouse, then normalised to the Ubr2
+/+ 
same day control mean to control for day-to-day 






































3.2.2 Loss of Ubr2 does not negatively affect cohesin functions in foetal prophase I 
While the cohesin complex is vital for chiasmata maintenance during metaphase I, this 
phenotype is not often observed in a genetic model of cohesin null or mutant oocytes, as there 
are also vital roles during prophase I, including homolog synapsis, genetic recombination and 
formation of the chromosome axis (Anderson et al. 1999; Agostinho et al. 2016; Rong et al. 
2016). In both male and female cohesin mutant meiocytes, it has been observed that the length 
of the synaptonemal complex at prophase I is altered with changes in cohesin levels, or the 
composition of different cohesin complexes present along the axis (Biswas, Stevense, and 
Jessberger 2018). As Ubr2 has many wide-reaching roles across different tissues, it is possible 
that the AcSMC3 phenotype observed in metaphase I could be a result of cohesin defects 
during establishment of chromosome cohesion during prophase I. 
Although no specific role for AcSMC3 has been identified in prophase I SC formation, and 
total cohesin levels are unaffected in a Ubr2-/- oocyte, it is prudent to ascertain that cohesin is 
functioning normally during prophase I in absence of Ubr2. In order to do this, I measured the 
lengths of chromosome axes, by immunofluorescence against SC lateral element protein 
SYCP3 (Syrjänen, Pellegrini, and Davies 2014; Enguita-Marruedo et al. 2018), in fully synapsed 
prophase I Ubr2+/+ and Ubr2-/- oocytes. In females, prophase I is approximately synchronous 
during foetal ovary development, and the fully synapsed stage of prophase I (pachytene) can 
be isolated from E18.5 foetal ovaries. I carried out chromosome spreads from this tissue onto 
glass slides with 1% PFA fixative, performed immunofluorescent staining and measured the 
length of each fully synapsed SYCP3 axis (Fig. 3.3A). As there is variation in the length of each 
of the 20 murine chromosomes, and there is no reliable way to identify each individual 
chromosome in these chromosome spreads, I ranked these 20 axis measurements within each 
nucleus by length. The shortest chromosome was designated 1, and so on until the longest 
chromosome was designated 20 (Fig. 3.3B). I then grouped these into sets of 5 chromosomes 
with similar lengths within each nucleus, and showed that there is no significant difference 
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in the lengths of each of these 4 groups between the Ubr2+/+ and Ubr2-/- genotypes (shortest 1-
5: p=0.50, 6-10: p=0.49, 11-15 p=0.17, and longest 16-20 p=0.40, Student’s T-tests). Therefore, 
cohesin complexes are functional during foetal prophase I, and the cohesin defects observed 
at metaphase I are a result of misregulation of the acetylated cohesin complex before 
commencement of metaphase I, potentially during the dictyate arrest. 
The cohesin complex also plays a role in regulation of genetic recombination rate 
(Bhattacharyya et al. 2019; Covo et al. 2010) during foetal prophase I, and so I performed 
immunofluorescence in foetal prophase I chromosome spreads against MLH1. This is a 
mismatch repair protein that marks genetic crossovers, which occur during pachytene as a 
result of homologous recombination (S. M. Baker et al. 1996; Anderson et al. 1999) (Fig. 3.4A). 
In order to assess the number of crossovers that occur in absence of Ubr2, I first counted MLH1 
foci per nucleus. Pachytene is the longest stage of prophase I, and MLH1 focus formation and 
resolution occurs continuously throughout this stage (Zickler and Kleckner 1999). Therefore, 
I thresholded these counts at a minimum of 15 MLH1 foci per nucleus in order to assess select 
nuclei at optimal stages of pachytene. The mean wild type number of MLH1 foci present in a 
pachytene oocyte is 20.35±0.67, and the mean number of foci present in a Ubr2-/- pachytene 
oocyte is 21.51±0.60; this is not a statistically significant difference, and the median number of 
foci for each genotype is 21 foci per nucleus (Fig. 3.4B, p=0.20, Student’s T-test). This indicates 
that recombination and genetic crossover rate are not perturbed in absence of Ubr2 at 































Figure 3.3 The synaptonemal complex has normal morphology in Ubr2
-/- 
prophase I oocytes 





immunostained for SYCP3 protein in grey. Scale bars are 5µm. B. Chromosome axis lengths during 
pachytene, ranked by increasing length, across 42 Ubr2
+/+
 (grey) and 52 Ubr2
-/-
 (green) nuclei 
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In order to assess the position of recombination and crossovers along the chromosome axis, I 
measured position of MLH1 foci relative to the centromeric end of each chromosome, as 
marked by higher DAPI intensity at centromeric heterochromatin (Fig. 3.4A). As crossover 
interference affects the position of neighbouring recombination points, I limited this analysis 
to chromosome axes containing only a single MLH1 focus (Foss et al., 1993; Hillers, 2004; 
Anderson et al., 1999). The length of each axis was measured and divided into three segments: 
distal, interstitial, and proximal to the centromere. MLH1 foci occur at the distal end of the 
chromosome in 35.0% of Ubr2+/+ pachytene oocyte chromosomes, and in 32.6% of Ubr2-/- 
pachytene oocyte chromosomes. They occur in the interstitial segment in 40.5% and 42.6% of 
each, and proximal to centromeres in 26.4% and 22.6% of each genotype. The position of 
MLH1 foci are not significantly changed between Ubr2+/+ and Ubr2-/- single-focus chromosomes 
during pachytene (Fig. 3.4C, p=0.87, χ2 test). 
Taken together with Fig. 3.3, in which Ubr2 is shown to not be vital for chromosome axis 
length or SC formation, I conclude that Ubr2 does not have a specific role in cohesin regulation 
in prophase I and Ubr2-/- oocytes progress through foetal prophase I normally. Similarly, there 
is no perturbation of prophase I progression, SC axis length or recombination rates in a  
Tex19.1-/- foetal prophase I oocyte (J Reichmann et al. 2017), indicating that the AcSMC3 
phenotype observed in both genotypes results from defects that arise postnatally, either 
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Figure 3.4 Crossover frequency and position is unaffected in the Ubr2
-/- 
pachytene oocyte 
A. Representative images of Prophase I oocytes in the fully synapsed pachytene stage, indicated 
by the synaptonemal complex component SYCP3, immunostained in red. MLH1 recombination 
marker is immunostained in green. DAPI is used to mark pericentromeric heterochromatin in 
blue. Scale bars are 5µm. B. Number of MLH1 foci identified per Ubr2
+/+
 (grey) or Ubr2
-/- 
(green) 
pachytene nucleus, with a lower threshold of 15 foci to select out very early or very late pachytene 
nuclei. n is number of nuclei analysed, from three mice of each genotype. C. Positions of single 
MLH1 foci along the chromosome axis in pachytene, relative to the telocentric centromere – 
proximal is within the third of the axis closest to the centromere, interstitial is in the centre of the 
axis, and distal is within the furthest third of the axis from the centromere. n is number of single-











3.2.3 Ubr2-/- metaphase I oocytes exhibit defects in sister chromatid cohesion 
The major function for cohesin when it binds to the chromosome axis during meiosis is in the 
cohesion of sister chromatids together throughout meiosis. Cohesion along sister chromatid 
arms holds the homologous bivalent together in MI, and sister chromatid cohesion is 
maintained until the second meiotic division by centromeric cohesion. Both centromeric and 
arm cohesion are intact throughout prophase I, and arm cohesion acts to stabilise chiasmata, 
holding the bivalent together through alignment of the spindle in metaphase I. At the first 
metaphase-anaphase transition, cohesin complexes are removed along the chromosome arms, 
but maintained at the pericentromeric region. Centromeric cohesion does not break down 
until the metaphase-anaphase transition of MII, so allowing sister chromatids to bi-orient 
and segregate in the second meiotic division. 
 
3.2.3.1 Ubr2 in chromosome arm cohesion 
In order to measure the extent of chromosome cohesion in the chromosome arms I 
used the number and position of chiasmata as a measure of how stably the 
chromosome arms are held together. One of the consequences of losing chromosome 
arm cohesion is a concentration of chiasmata towards the telomeric end of 
chromosome arms, and a subsequent reduction in chiasmata frequency, as chiasmata 
are lost off the telomeric end. A possible reason why loss of arm cohesion can affect 
the number and position of chiasmata is that arm cohesion on the telomeric side of 
chiasmata may act to prevent movement of chiasmata towards the telomere, where 
they could become terminal or potentially be lost (Fig. 3.5A). This is known as 
chiasmata terminalisation (Jagiello and Fang 1979; Jessberger 2012), which is 
associated with an increased risk of premature separation of the homologs before 
alignment on the spindle. This has been linked to a loss of cohesin molecules bound 
to the chromosome arms (E Revenkova et al. 2010; Garcia-Cruz et al. 2010). 
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To investigate this, I assessed the number and position of chiasmata in each 
chromosome bivalent, marked by DAPI staining, of metaphase I oocyte spreads at 3 
hours post-GVBD isolated from young (2-3 months old) Ubr2+/+ and Ubr2-/- females, as 
in section 3.2.2 (Fig. 3.5B). In order to first assess the absolute number of chiasmata, 
I counted the number of chiasmata per nucleus (Fig. 3.5C). The mean number of 
chiasmata present in a Ubr2+/+ metaphase I oocyte is 27.35, represented by a 
combination of single and multiple instances of chiasmata within each bivalent. 
There is no statistically significant change in the mean number of chiasmata in a   
Ubr2-/- oocyte, which have 28.24 chiasmata per nucleus (p=0.41, Student’s T-test), and 
so it does not appear that chiasmata are gained or lost in absence of Ubr2. However, a 
subtle movement or loss of chiasmata may not be detected this way, and so I also 
quantified the proportion of single to multiple (two or three, more than this is very 
uncommon) chiasmata within each bivalent (Fig. 3.5D). Of the 20 chromosomal 
bivalents within the Ubr2+/+ nucleus, 67.0% have a single chiasma, and 33.0% have two 
or more, whereas in the Ubr2-/- nucleus 58.3% of bivalent have a single chiasma and 
41.7% have multiple. This indicates that there is no significant change between Ubr2+/+ 
and Ubr2-/- oocytes at metaphase I (p=0.24, Fisher’s exact test). This is not a 
statistically significant deviation from the wild type proportions, and so there is not 
a detectable change in the number of chiasmata present in absence of Ubr2. 
However, when the position of these chiasmata are taken into account, there is a 
deviation from the wild type state. Mouse chromosomes are telocentric, meaning the 
centromere is at one end of the chromosome. I estimated the distance of chiasmata 
within each bivalent with a single chiasma from the centromeric end by dividing the 
length of the bivalent into approximately three sections: distal, interstitial or 
proximal to either pair of centromeres, and then judged the position of the chiasma 
by blind scoring. I restricted this analysis to chromosomes in which only one 
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recombination event has occurred, as crossover interference between multiple events 
on the same chromosome axis affects the position of neighbouring chiasmata (Foss et 
al. 1993; Broman et al. 2002; Hillers 2004). Chiasma in the centromeric-proximal third 
of the bivalent occur in 14.0% of Ubr2+/+, but in only 5.7% of Ubr2-/- bivalents. There is 
also a reduction in interstitial single chiasma this occurs in 48.1% of Ubr2+/+ bivalents 
and 38.2% of Ubr2-/- bivalents. Finally, there is an increase in the proportion of 
bivalents that have a single chiasma distal to the centromere, or at the telomeric of 
the chromosomes, which indicate a terminal association between homologs, rather 
than a true chiasma. This occurs in 37.9% of Ubr2+/+ bivalents and 56.1% of Ubr2-/- 
bivalents. Taken together, this is a significant deviation from the proximal-
interstitial-distal proportions observed in the Ubr2+/+ metaphase I oocyte (p=0.0004, 
χ2 test), indicating that there is a shift in chiasmata towards the telomeric end of each 
pair of homologous chromosomes in metaphase I, in absence of Ubr2. 
Chiasmata positions in wild type Ubr2+/+ metaphase I oocytes were estimated based 
on the conformation of the single-chiasma bivalents. The proportion of proximal-
interstitial-distal chiasma are not statistically different from the proportional 
position of single recombination events in prophase I cells, as more accurately 
measured by distance of MLH1 foci from the centromeric end of pachytene 
chromosomes in Fig. 3.4C (p=0.14, χ2 test), indicating that these methods are indeed 
comparable to measure crossover position across these different stages of meiosis. 
The shift in chiasmata position in metaphase I Ubr2-/- oocytes could potentially reflect 
either an altered distribution of crossover recombination during foetal meiotic stages, 
or functions of Ubr2 in maintaining chiasmata position in post-natal oocytes. When 
taken together with the normal crossover positions observed as MLH1 foci in Ubr2-/- 
foetal pachytene (Fig. 3.4C), the skew of chiasmata towards the distal or telomeric 
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end of the chromosome observed in Fig. 3.5 indicates a loss of post-natal chromosome 
cohesion in absence of Ubr2, resulting in chiasmata terminalisation. This is the first 
indication that Ubr2 has a role in meiotic chromosome cohesion regulation, 














Figure 3.5 (next page) – Ubr2
-/- 
results in chiasmata terminalisation in metaphase I 
A. Schematic representing the movement of chiasmata as a result of cohesin (red) loss along the 
chromosome axis in a Metaphase I bivalent with one chiasma. Recombined homologs are 





 females. Inset: representative bivalents with a single chiasma or 
multiple (two) chiasmata, indicated by white arrows. C. Number of chiasmata present within the 
20-chromosome nucleus of Ubr2
+/+
 (grey) and Ubr2
-/-
 (green) Metaphase I oocytes. Mean values 
represented by black bars. n is the number of nuclei analysed over 5 female mice of each genotype.  
D. Proportion of single to multiple chiasmata identified within each 20-chromosome nucleus. n is 
the number of bivalents analysed over 25 Ubr2
+/+
 and 21 Ubr2
-/-
 nuclei from 5 female mice per 
genotype. Standard error is indicated. E. Position of chiasma relative to the centromeric end of 
each bivalent. n is the number of single-chiasma bivalents analysed, from 10 Ubr2
+/+
 and 7 Ubr2
-/-
 
female mice. Standard error is indicated. 
Statistical significance calculated using Student’s T-test (3.5C), Fischer’s exact test (3.5D) or χ2 
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3.2.3.2 Ubr2 in pericentromeric cohesion 
The second type of chromosome cohesion observed in the oocyte is pericentromeric 
cohesin. This is distinctly regulated in a meiosis-specific manner, as it must be 
maintained through the first metaphase-anaphase transition, holding sister 
chromatids together until separation in anaphase II, in MII. This is occurs through 
centromeric localisation of shugoshin 1 (SGO1) and protein phosphatase 2A (PP2A), 
which act at least in part to prevent separase interaction with cohesin by  
dephosphorylation of the meiotic Rec8 kleisin subunit (Kitajima, Kawashima, and 
Watanabe 2004; Kitajima et al. 2006; Z. Xu et al. 2009). I measured the distance 
between the centromeres of each pair of sister chromatids in metaphase I, as indicated 
in Fig. 3.6A and B, using 3-dimensional z-stack images. The mean distance within 
each pair of sister chromatid centromeres at this stage of a Ubr2-/- oocyte is 
0.50±0.01µm, which is not significantly changed from the mean of 0.53±0.03µm in a 
Ubr2+/+ oocyte (Fig. 3.6C, p=0.17, Student’s T-test). This implies that centromeric 
cohesin protection mechanisms are intact at this stage of meiosis. 
I also measured the distance between sister chromatid centromeres at Metaphase II, 
in which sister chromatids depend on pericentromeric cohesion (Fig. 3.7A and B). At 
this stage of meiosis, Ubr2-/- centromeres are 0.54±0.06µm apart, which is significantly 
more than the mean wild type centromeric distance measured at this stage, 
0.19±0.02µm (Fig. 3.7C, p<0.001, Student’s T-test). 
It should be noted that the mean sister centromeric distance in Ubr2+/+ is significantly 
smaller in metaphase II than in metaphase I (mean distances 0.19µm and 0.53µm, 
respectively: p<0.00001, Student’s T-test, Fig. 3.6B and Fig. 3.7B), indicating that there 
may be some change in kinetochore or centromeric structure between these stages, 
bringing the sister centromeres closer together in metaphase II. Sister kinetochores 
are mono-oriented in metaphase I, whereas they change in structure and become bi-
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oriented in metaphase II, allowing for segregation of the two sisters to opposite poles 
of the oocyte in the second meiotic division (MacLennan et al. 2015). This structural 
change could attribute for the reduction in measurements between these stages, 
although the ACA/CREST (anti-centromeric antibody) signal used to mark 
centromeric foci is not specific for particular proteins within the kinetochore 
(Blengini and Schindler 2018; Fritzler, Kinsella, and Garbutt 1980) and so I cannot 
infer what structural changes may have taken place. There is no significant difference 
between centromeric distances in the Ubr2-/- metaphase I and metaphase II oocytes 
(mean distances 0.50µm and 0.54µm, respectively: p=0.52, Student’s T-test, Fig. 3.6B 
and Fig. 3.7B), indicating that perhaps the changes in kinetochore structure do not 
taken place in absence of Ubr2. Therefore, this could indicate a role for cohesin in 
kinetochore orientation between the two stages of meiosis. 
Taken together, these data indicate that Ubr2 has a role in maintaining 
pericentromeric sister chromatid cohesion in the murine oocyte, potentially through 
regulation of the AcSMC3-containing subpopulation of cohesin complexes. It may 
also play a secondary role in centromeric or kinetochore structure, which is 
















Figure 3.6 – Ubr2
 





 Metaphase I bivalents, white arrows indicate centromeres 
marked by anti-centromeric antibody (ACA, or CREST) in green; DAPI was used to mark 
condensed DNA, in blue. B. Schematic shows the pattern of cohesins along the chromosome axis 
in red, holding the recombined homologs together (yellow and blue). Pairs of sister chromatid 





 Metaphase I (Met I) oocytes, as measured across three dimensions in z-
stack images and calculated using the Pythagorean Theorem. Means are indicated as black bars. 
 
 





Figure 3.7 – Ubr2
 





 Metaphase II bivalents, white arrows indicate centromeres 
marked by anti-centromeric antibody (ACA, or CREST) in green; DAPI was used to mark 
condensed DNA, in blue. B. Schematic shows the pattern of cohesins along the chromosome axis 
in red, holding the sister chromatids together at the centromere (yellow and blue). Pairs of sister 
chromatid centromeres are indicated by black brackets. C. Distances between sister chromatid 




 Metaphase II (Met II) oocytes, as measured across three 
dimensions in z-stack images and calculated using the Pythagorean Theorem. Means indicated as 
black bars. 
Statistical testing carried out using Student’s T-test, *** p<0.001 
  
*** 
C Distance between sister centromeres at Met II 
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3.2.4 Ubr2-/- oocytes are not aneuploid 
Defects in chromosome cohesion and misregulation of the cohesin complex during oogenesis 
are associated with chromosome missegregation and aneuploidy (E Revenkova et al. 2010; L. 
Liu and Keefe 2008; Herbert et al. 2015). In order to ascertain whether the misregulation of 
cohesin and cohesion observed in absence of Ubr2 during metaphase I is sufficient for 
missegregation, I investigated a potential role for Ubr2 in ploidy. I isolated mouse oocytes at 
metaphase II from both Ubr2-/- and Ubr2+/+ females from the same colony 18 hours after 
treatment with hCG, which was administered 48 hours after PMSG for superovulation. As 
female mice are reported to lose cohesin and exhibit an increase in oocyte aneuploidy with 
age (L. Liu and Keefe 2008), I carried out these experiments on young (2-3 months old) age-
matched mice. Oocytes were dissected from the ampulla and spread on glass slides in a 1% 
PFA fixative, and then visualised with DAPI to stain DNA, and anti-centromeric antibody 
(ACA) (Fig. 3.8A). At this stage, pairs of sister chromatids can be observed, held together at 
their centromeric end by cohesin molecules. These are classified as either euploid (an 
expected 40 sister chromatids, in pairs of 2), hypoploid (less than 40) or hyperploid (more 
than 40) and calculated the proportion of oocytes observed with each (Fig. 3.8B). 23.5% of 
Ubr2+/+ oocytes are hypoploid, and this is likely a artefact of the nature of chromosome 
spreading, in which some chromosomes can be lost or not bind directly to the slide. I did not 
observe any hyperploid metaphase II oocytes isolated from Ubr2+/+, and so 76.5% of nuclei in 
this genotype were observed as being euploid, so having gone through no chromosomal 
missegregation during the first meiotic division. In the Ubr2-/- Metaphase II oocyte the 
incidence of hypoploidy is at a similar rate (21.4% of nuclei), and no hyperploidy indicative of 
bone fide chromosome missegregation was observed. There were no observed hyperploid cells; 
78.6% of Ubr2-/- were observed as euploid, and so there is no significant change in the 
proportion of ploidies observed between these and the wild type control cells (p=0.74, Fisher’s 
exact test). No incidences of premature separation of sister chromatids in the metaphase II 
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spreads were observed (Fig. 3.8A), and therefore analysis of metaphase II oocytes suggests 
that loss of Ubr2 does not have a detectable effect on the fidelity of chromosome segregation 





















Figure 3.8 (next page) Absence of Ubr2 does not affect ploidy in the metaphase II oocyte 
A. Representative Metaphase II oocyte chromosome spreads, immunostained for anti-centromeric 
antibody (ACA, or CREST) in green, and DAPI showing condensed DNA in blue. Scale bars are 
5µm. B. Proportional counts of hypoploid, hyperploid or euploid nuclei identified in Metaphase II 
oocytes. n is the number of nuclei analysed, over three Ubr2
+/+
 and three Ubr2
-/-
 female mice. 











In this chapter I showed that Ubr2 is important in regulation of AcSMC3-containing cohesin 
complexes, and a mouse model lacking Ubr2 has a specific loss of chromosome-associated 
AcSMC3, which is associated with cohesion defects in both metaphase I and metaphase II. 
However, this does not result in reduced numbers of chiasmata or chromosome 
missegregation during the first meiotic division. 
 
3.3.1 The TEX19.1-UBR2 complex in meiotic cohesin regulation 
Both the Ubr2-/- and Tex19.1-/- oocytes have a 40-50% reduction in chromosome-associated 
AcSMC3 at metaphase I, which is not observed in other cohesin subunits (J Reichmann et al. 
2017). In both genotypes, there are chromosome cohesion defects: terminalisation of 
chiasmata, and an increase in centromeric distance at metaphase II. My original hypothesis 
for the role of the TEX19.1-UBR2 complex in the oocyte was that Ubr2 acts to, either directly 
or indirectly, remove AcSMC3-containing cohesin from the chromosome axis and that Tex19.1 
antagonises this to protect the cohesin complex and prevent chromosome missegregation (Fig. 
3.9A). Instead, TEX19.1 and UBR2 may be working together in this tissue to protect AcSMC3 
from turnover (Fig. 3.9B). However, as UBR2 has been shown to negatively regulate AcSMC3 
in mitotic tissues, both in presence and absence of TEX19.1, it is not clear how it could have 
switched so starkly from downregulation to upregulation. This could be due to a role in a 
meiosis-specific pathway of cohesin regulation that is not found in mitotic cells, but there are 
no current candidates for this and it will be necessary to study UBR2’s role in meiosis further, 
as discussed in sections 3.3.2 and 3.3.3. Finally, another explanation could be that TEX19.1 is 
antagonistic of UBR2’s role to regulate a cohesin regulatory mechanism – as was previously 
hypothesised. However, if UBR2 is able to also negatively regulate a redundant protein, for 
example another member of the UBR family which acts as an E3 ubiquitin ligase in the N-end 
Rule pathway for ubiquitination and protein degradation, and if this is unable to be negatively 
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regulated by TEX19.1, the other UBR protein could act to negatively regulate AcSMC3, 
independently of TEX19.1. Further work will be required to ascertain whether there are any 


























Figure 3.9 – A model for activity of the TEX19.1-UBR2 complex in meiotic oocytes 
A. As discussed in Chapter 1, in presence of TEX19.1, in mitotic ESCs (embryonic stem cells) 
TEX19.1 binds to UBR2 and inhibits its turnover of AcSMC3, so protecting the cohesin complex 
and chromosome cohesion, potentially through inhibition of the Type II N-end Rule. B. In the 
oocyte, TEX19.1 and UBR appear to work together to promote AcSMC3, so acting as a cohesin-
protection mechanism during meiotic arrest and progression. C. Another hypothesis is that UBR2 
negatively regulates a protein redundant for its role in AcSMC3 removal in the oocyte, which is 
then upregulated in absence of UBR2. TEX19.1 is unable to inhibit the removal of AcSMC3 by this 
protein, which could be another component of the N-end Rule pathway, and so AcSMC3 is 







protects Type II 
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Although Ubr2-/- oocytes phenocopy the Tex19.1-/- loss of AcSMC3, there is a potential 
difference in the severity of chromosome cohesion defect between the oocytes of these 
genotypes, as there is aneuploidy detected in absence of Tex19.1 in both metaphase II oocytes 
and in the single-celled zygote after natural fertilisation, whereas I did not observe it at 
metaphase II in the Ubr2-/-. A Tex19.1-/- oocyte also has a more pronounced loss of cohesion 
during metaphase I, with loss of absolute chiasmata number per nucleus as well as the 
terminalisation also detected in Ubr2-/- cells (J Reichmann et al. 2017). The published data on 
Tex19.1-/- metaphase I oocytes were from chromosome spreads that were analysed at 5 hours 
post-GVBD, whereas in my experiments Ubr2-/- metaphase I spreads were carried out at 3 
hours post-GVBD. As discussed earlier, chiasma terminalisation is associated with loss of 
cohesin, which is assumed to occur during dictyate arrest, but chiasmata terminalisation may 
only occur once GVBD has taken place and the cell has exited quiescence (Jessberger 2012). 
While this experimental difference may affect number of chiasmata, which may have 
terminalised but not yet been lost at 3 hours post-GVBD, this does not explain the increased 
incidence of missegregation at both the first and second meiotic divisions observed in Tex19.1-
/- genotype. Therefore, we must proceed with caution when interpreting the loss of AcSMC3 
in absence of Ubr2. Although TEX19.1 and UBR2 interact in a 1:1 stoichiometric ratio in vitro (J 
Reichmann et al. 2017), this does not indicate that the TEX19.1-UBR2 complex is as such in 
vivo, and there may be as-yet unidentified components of this complex that are vital for 
AcSMC3 regulation and mediation of the TEX19.1-UBR2 interaction. In absence of one or the 
other protein, unidentified oocyte-specific interactors may act differently, so leading to 




3.3.2 Ubr2 in regulation of cohesin in the arrested oocyte 
This chapter shows that UBR2 has a role in regulation of the cohesin complex between foetal 
prophase I and ovulatory metaphase I, specifically through regulation of the AcSMC3 subunit. 
Between these stages of meiosis, the oocyte nucleus is in the dictyate arrest phase, in which 
chromosomes are quiescent and chromosome cohesion must be maintained for a long period 
of time (Herbert et al. 2015). Exit from dictyate arrest is modulated by steroidal hormone 
signalling (Sen and Caiazza 2013), and occurs in small groups of oocytes at ovulation. This 
stage of meiosis is very difficult to study as oocytes cannot be isolated from the ovary for 
chromosome spreads, and so the majority of work surrounding age-related cohesin loss 
focuses on either foetal prophase I, or immediately after dictyate arrest in metaphase I 
(Herbert et al. 2015; E Revenkova et al. 2010; J. Lee et al. 2003). 
Cohesin has been observed to be reduced at metaphase I after a longer dictyate arrest period, 
i.e. in oocytes isolated from older females, but the mechanism by which cohesin loss is 
mediated is unknown (Jessberger 2012). Selective pre-dictyate depletion of the cohesin 
kleisin subunit REC8 in mouse oocytes results in chromosome missegregation and 
aneuploidy (Burkhardt et al. 2016), indicating that chromosome-associated cohesin 
complexes are not turned over during the arrest. Genes encoding cohesin subunits are 
expressed during this time, although only at around 10% of the mRNA levels detected in 
prophase I (Hodges et al. 2005), and this is not sufficient to replace all chromosome-
associated cohesin complexes that are loaded during prophase I (Burkhardt et al. 2016; 
Tachibana-Konwalski et al. 2010). This low-level cohesin synthesis during dictyate arrest 
(Hodges et al. 2005) may be sufficient to supplement depletion of cohesin in young oocytes, 
but potentially not over time. Additionally, artificial expression of separase enzyme during 
metaphase I demonstrates an increased vulnerability to centromeric cohesin removal with age 
(Chiang, Schultz, and Lampson 2011), implying a decline in cohesin protection mechanisms 
over time. Separase is active in wild type oocytes during mitotic anaphase and acts to cleave 
the kleisin subunit of the cohesin complex (Brooker and Berkowitz 2014). It is negatively 
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regulated by both SGO1/PP2A and by the chaperon securin; upon satisfaction of the spindle 
assembly checkpoint (SAC), securin is phosphorylated and separase is able to cleave kleisin 
and remove the cohesin complex (Z. Xu et al. 2009; Clift, Bizzari, and Marston 2009; Holland 
et al. 2007; Luo and Tong 2018). Separase is thought to only be active during MII, prior to the 
second meiotic division, as sister centromere cohesion is important for sister chromatid 
cohesion during MI, preventing premature separation (Terret et al. 2003). 
Other cohesin regulatory mechanisms that are active during various stages of meiosis include 
the ESCO1/2 acetyltransferases (Whelan et al. 2012; Brooker and Berkowitz 2014), the 
WAPL/PDS5 complex (Nishiyama et al. 2010; Wolf et al. 2018), which is actively antagonised 
by SMC3 acetylation and recruitment of the cohesin maintenance factor sororin (Ladurner et 
al. 2016; Brieño-Enríquez et al. 2016), and HDAC8 deacetylase (Brooker and Berkowitz 2014). 
None of these mechanisms have been shown to be perturbed or enhanced in the ageing oocyte, 
and so it is unclear whether these play a role in oocyte ageing and loss of chromosome 
cohesion. However, they would be likely targets for an oocyte-specific cohesin maintenance 
mechanism that may have adapted for the extended dictyate arrest period. 
UBR2 is an E3 ubiquitin ligase, with demonstrated ability in protein degradation via the 
ubiquitin-proteasome system (UPS) (T Tasaki et al. 2005; Rageul et al. 2019; H. Xu et al. 2019). 
Proteolysis is a vital component of all cells, as it carries out homeostasis of the proteome as 
well as regulation of protein levels under specific conditions (Tanaka 2009). Loss of the Ubr2 
gene in the oocyte results in a specific decrease in the acetylated subpopulation of cohesin 
molecules (the AcSMC3 subunit), and so this implies that UBR2 acts to regulate a cohesin 
maintenance or removal mechanism, such as those described above, acting to control against 
cohesin depletion and protect AcSMC3 on chromosome axes. 
It would be interesting to observe if there is any change to Ubr2 mRNA or protein levels over 
time in the ageing oocyte, which could indicate an essential role for the enzyme in prevention 
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of oocyte aneuploidy with age. Tex19.1 mRNA can be observed in foetal, perinatal and 
postnatal mouse oocytes (Celebi et al. 2012), and interestingly this expression is reduced in 
germinal vesicle oocytes from older mice, indicating a potential decline in the TEX19.1-UBR2 
cohesin regulatory function over time (Pan et al. 2008). However, the only cohesin subunit 
thus far shown to decline with age is the kleisin REC8 (L. Liu and Keefe 2008; Chiang et al. 
2010), and so it must be noted there is no direct evidence to suggest that AcSMC3 is a 
regulator of cohesin maintenance in an aged oocyte. 
This is a different mechanism for the regulation of AcSMC3 as compared to mitotic tissues: 
chromatin-associated AcSMC3 is increased in both the Ubr2-/- mitotic spleen and in Ubr2-/- 
ESCs (Reichmann et al. 2017, and unpublished data, Karen Dobie, MRC HGU). This indicates 
both a TEX19.1-independent and TEX19.1-dependent role, respectively, for UBR2 in AcSMC3 
removal. The potentially different mechanism by which UBR2 acts in any of these three 
tissues is not understood. All known functions of UBR2 involve ubiquitination and protein 
turnover, and so identification of UBR2 ubiquitination substrates in these various tissues 
would indicate how UBR2 is able to impact cohesin levels, potentially indirectly through one 
of the cohesin regulatory mechanisms, and whether there is an oocyte-specific substrate or 
cofactor that acts to change its regulatory function in the meiotic cell. These hypotheses could 
be tested using single cell oocyte mass spectrometry, or protein interaction assays coupled 
with proteasomal inhibition. 
 
3.3.3 Ubr2 in regulation of MII kinetochore distance 
A secondary potential role for Ubr2 in the oocyte identified in this chapter is in the regulation 
of centromeric or kinetochore structure (section 3.2.3.2). The kinetochore is a large protein 
complex localised to the sister chromatid centromeres and, among other functions, acts as an 
attachment point for spindle microtubules during the two meiotic divisions. The meiotic 
kinetochore is specialised for meiotic spindle attachment and sister chromatid orientation, 
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which is functionally different from the mitotic kinetochore. In the first meiotic division, the 
kinetochore mono-orients, allowing sister chromatids to segregation to the same spindle pole. 
Metaphase II involves kinetochore remodelling to bi-orient sister chromatids, so allowing 
segregation in opposite directions at the second meiotic division to generate a haploid oocyte 
pronucleus (MacLennan et al. 2015). Interestingly, the distance between sister chromatid 
centromeres, as marked by ACA, is reduced between metaphase I and metaphase II (Fig. 3.6B 
and Fig. 3.7B), implying that this remodelling for sister chromatid orientation can be observed 
by immunofluorescence. Lack of Ubr2 results in an increase in distance between kinetochores 
at metaphase II, as compared to metaphase II in presence of Ubr2, which appears to be 
maintained from the distances measured at metaphase I in the Ubr2-/- oocyte. 
Cohesin regulatory mechanisms involving separase and the SGO2/PP2A complex have been 
implicated in regulating kinetochore structure and attachment to microtubule spindle fibres, 
in both mouse and D. melanogaster oocyte meiosis (L. I. Wang, Das, and McKim 2019; Rattani 
et al. 2013; Tang et al. 2016). This could indicate that either cohesin regulation is essential for 
kinetochore function, or that these complexes have a secondary role in regulation of 
kinetochore proteins directly. The kinetochore structure has been implicated in maintenance 
of pericentromeric cohesin complexes (Weber et al. 2004; Schalch and Steiner 2017; Miller et 
al. 2012), so I would hypothesise that SGO2/PP2A are essential for this cohesin-kinetochore 
function. Furthermore, the effect of Ubr2 loss on kinetochore distance at metaphase II implies 
that UBR2 protein acts to promote kinetochore remodelling and reorientation, potentially 
through regulation of cohesin or a cohesin-regulatory mechanism such as SGO2/PP2A. One 
flaw in this hypothesis is that there is not currently any identified role for AcSMC3 
specifically in meiotic centromeric cohesin, and it is not linked to SGO2 or PP2A. However, 
AcSMC3 has been shown to recruit sororin in mitotic cells (K Nasmyth and Haering 2009) 
and, although sororin appears to have some AcSMC3-independent roles in meiotic arm 
cohesin, it also has a potential function in centromeric cohesin, which requires PP2A 
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phosphorylation activity (Gómez et al. 2016), although this is SGO2-independent. Therefore, 
this role could involve AcSMC3 regulation, which I have shown here requires UBR2. 
No aneuploidy at metaphase II was identified in the Ubr2-/- oocyte – i.e. in the first meiotic 
division. However, if UBR2 is able to regulate centromeric cohesin or kinetochore structure, 
this could result in defects in spindle microtubule attachment during MII, and potentially 
missegregation during the second meiotic division, which was not tested in this study. 
Further work to assess the ploidy of single-celled zygotes, after the second division, could 
lead to insights into UBR2’s role in oocyte meiosis and kinetochore-spindle attachment. This 
could explain the subfertility previously identified in Ubr2-/- female mice (Y T Kwon et al. 
2003), which does not correlate with the lack of MII aneuploidy identified thus far. This could 
also be studied in a more indirect sense by assessing fertility with a Ubr2-/- breeding strategy. 
SGO2 and PP2A are required for centromeric cohesion and, as null mutants result in infertility 
in both males and females (Faridi et al. 2017; Tang et al. 2016), it would be difficult to separate 
out a kinetochore-regulatory function in MII from that of pericentromeric sister chromatid 
cohesion throughout MI. For example, oocytes isolated from mice null for Pp2a do not 
progress beyond the first meiotic division (Tang et al. 2016). Instead, the hypothesis that 
UBR2 acts to regulate SGO2/PP2A could be approached from a Ubr2 angle, by identifying if 
these, or other related proteins, are candidate substrates for UBR2 binding and, potentially, 
degradation via the proteasome. 
 
3.3.4 Summary 
In summary, in this chapter I have shown that Ubr2 is required for maintenance of AcSMC3 
between foetal prophase I and metaphase I, similarly to Tex19.1. This is associated with defects 
in chromosome cohesion – although Ubr2-/- oocytes do not exhibit MII aneuploidy, which has 
been observed in the Tex19.1-/- oocyte. As the proteins expressed by these genes have a 
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stoichiometric interaction and function together in a variety of tissues, this overlapping 
phenotype, although not a full phenocopy, implies that the TEX19.1-UBR2 complex acts to 
promote AcSMC3-containing cohesin complexes along the meiotic chromosome axis, 
perhaps through regulation of a cohesin regulatory mechanism. Another potential role for 
Ubr2 also exists in kinetochore orientation, possibly through direct regulation of the cohesin 
complex – although this could simply act through a similar mechanism to that which has 
already been identified. Further work into the role of UBR2 in meiotic sister chromosome 
cohesion will require identification of UBR2’s N-end Rule ubiquitination substrates in the 










The Tex19.1-associated Role of Ubr2 in Embryonic 








In addition to the identified meiotic phenotypes in both male (Y T Kwon et al. 2003; Crichton 
et al. 2017) and female (see Chapter 3) Ubr2-/- mice, there is a reported female-specific perinatal 
lethality (Y T Kwon et al. 2003), which varies in penetrance depending on genetic strain 
background, but the cause of this lethality is not yet clear. Interestingly, a similar sex-specific 
lethality was observed in Tex19.1-/- mice (Yang et al. 2010; J Reichmann et al. 2013), which is 
potentially related to defects in placenta function during foetal development having more 
pronounced consequences for females (J Reichmann et al. 2013). TEX19.1 protein 
stoichiometrically interacts with UBR2 in a 1:1 ratio (J Reichmann et al. 2017), and in the testis 
UBR2 has been shown to stabilize TEX19.1, indicating a functional interaction (Yang et al. 
2010). Therefore, it is possible that the female-specific lethality in Ubr2-/- embryos is caused 
by loss of function of the TEX19.1-UBR2 complex in the placenta and that there may be some 
overlap between the Tex19.1-/- and Ubr2-/- phenotypes. In order to test this hypothesis, in this 
chapter I aimed to investigate whether the female-specific lethality reported for Ubr2-/- 
embryos is associated with defects in placenta development and function, and whether any 
defects in Ubr2-/- placentas phenocopy those present in Tex19.1-/- mice. 
In absence of Tex19.1, embryos exhibit a growth restriction that arises between E12.5 and E14.5. 
This is associated with a reduction in placental size, particularly in the trophoectoderm-
derived junctional zone (Jz) (Reichmann et al., 2013; Tarabay et al., 2013, and Playfoot et al. 2019, 
manuscript submitted, MRC HGU). The placenta is a naturally hypomethylated tissue (Oda 
et al. 2013; Schroeder et al. 2015); global DNA methylation dynamics vary in both embryonic 
and extraembryonic tissues throughout development. There is a global hypomethylation 
event in the first few days post-conception, and by E2.5, the majority of DNA methylation is 
lost, only being maintained at DMRs (differentially methylated regions of the genome), 
including IAP and L1 retrotransposons, and imprinted loci (Fig 4.1A, and Playfoot et al. 2019, 
manuscript submitted, MRC HGU). Tex19.1 is highly expressed in the placenta (Celebi et al. 
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2012), and across hypomethylated stages of early development (Fig. 4.1B), before the placental 
structure itself forms. These include the E2.5 8-cell stage, the E3.5 blastocyst inner cell mass 
(ICM) and trophectoderm (TE), and the E6.5 extraembryonic ectoderm (ExE). The TE and 
ExE will go on to form components of the junctional zone and placental labyrinth (Rossant 
and Cross 2001), and remain globally hypomethylated (Oda et al. 2013; Schroeder et al. 2015), 
whereas the epiblast (Epi) will go on to form the major three layers of early embryonic tissue 
(mesoderm, endoderm and ectoderm, Rossant and Cross, 2001) and so regains DNA 
methylation after implantation (Z. D. Smith et al. 2014; Schroeder et al. 2015) (Fig. 4.1A). The 
Epi does not have high expression levels of Tex19.1, as compared to that detected in the other 
early embryonic tissues in Fig. 4.1B, which correlates with the need for Tex19.1 expression only 
in a hypomethylated context. Ubr2 is a ubiquitously expressed gene, and early developmental 
stages are no exception. Ubr2-encoding mRNA can be detected across all cell types in Fig. 4.1B, 
in both hypomethylated and methylated contexts, and it is most highly expressed alongside 
the highest expression of Tex19.1 detected, in ExE tissues that will go on to form the 
trophectoderm-derived placental tissues. Expression data presented here is in RPKM (reads 
per kilobase million), calculated from mapped raw RNAseq data to the mm10 genome 
assembly (GRCm38) and corrected for gene length in kb, kilobases (Z. D. Smith et al. 2017) 
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Figure 4.1 (previous page) Ubr2 and Tex19.1 are coexpressed in hypomethylated 
developmental contexts 
A. Schematic representation of global DNA hypomethylation throughout early post-fertilisation 
development. Both paternal and maternal alleles are globally hypomethylated following 
fertilisation, and all cells in the 8-cell stage (E2.5) and in the blastocyst (E3.5), including the ICM 
and TE, are hypomethylated. Exceptions to this include DMRs (differentially methylated regions) 
such as IAP and L1 retrotransposons and imprinted loci. DNA methylation is restored in 
embryonic lineages that are derived from the E6.5 Epi post-implantation, but the TE-derived 
placenta tissues including the ExE remain hypomethylated. B. RNAseq expression data from (Z. 
D. Smith et al. 2017) for the mouse genes Tex19.1 and Ubr2 in five stages of early embryonic 
development. RPKM (reads per kilobase million) calculated as described, by Ian Adams, MRC 
HGU. ICM: inner cell mass. TE: trophectoderm. Epi: epiblast. ExE: extraembryonic ectoderm. 
Schematic in A adapted from Playfoot et al. 2019, manuscript submitted, MRC HGU. 
 
Tex19.1 has a variety of known roles in the placental trophectoderm-derived tissues, including 
retrotransposon repression and transcriptional repression of imprinted genes. These are 
thought to act through TEX19.1 protein’s interaction with the transcriptional corepressor 
KAP1, which together recruit SETDB1 (Leung et al. 2014; Jang et al. 2018), a histone 
methyltransferase that lays down H3K9 trimethylation marks at specific genomic loci, so 
acting as a genome defence mechanism in a globally hypomethylated context (Oda et al., 2013; 
Cheng, Kuo and Ann, 2014, and Playfoot et al. 2019, manuscript submitted, MRC HGU). 
The placenta is one of the first organs to develop during embryogenesis, and it is vital that it 
is able to grow quickly and support development, acting as the conduit for nutrient and 
oxygen delivery from the maternal blood stream (Rossant and Cross 2001). Intrauterine 
growth restriction (IUGR) is defined as the smallest 10% of human births, and this has been 
associated with defects in placental size and limited nutrient transfer (Scifres and Nelson 
2009; Woods, Perez-Garcia, and Hemberger 2018). Small placental size can arise as a result of 
a variety of different disorders in chromatin or genomic stability, including misregulation of 
imprinted genes (Tunster, Jensen, and John 2013). DNA hypomethylation at DMRs and 
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altered expression of imprinted genes observed in Tex19.1-/- mouse placentas bear some 
resemblance to those seen in the placentas of human pregnancies that exhibit IUGR 
(Takahashi, Kobayashi, and Kanayama 2000; Lefebvre et al. 1998; McMinn et al. 2006; 
Koukoura et al. 2011). For example, perturbation of the paternally expressed mouse gene Mest, 
associated with angiogenesis in placental layers (Mayer et al. 2000), leads to both pre- and 
post-natal growth restriction (Lefebvre et al. 1998), and this is significantly upregulated in 
absence of Tex19.1 in the mouse placenta (Playfoot et al. 2019, manuscript submitted, MRC 
HGU). The human homolog MEST has also been identified in placental growth defects 
associated with IUGR, such as Silver Russell Syndrome, or SRS (Hannula et al. 2001). 
The human paralog of mouse Tex19.1, TEX19, is not expressed in the human placenta – but the 
human gene UBR2 is (Fagerberg et al. 2014). Although functionally convergent, there are many 
key differences in the tissue structure between the human and murine placenta. However, 
much of the trophectodermal cell lineage is key to nutrient transport and invasion of maternal 
tissue in both layers, and many of the molecular pathways in this lineage are conserved 
(Woods, Perez-Garcia, and Hemberger 2018). Therefore, if the mouse TEX19.1-UBR2 
complex is vital for murine placental development and embryonic growth, this could 
potentially reflect a conserved role for human UBR2 in this tissue. 
This chapter aims to investigate a potential role for the gene Ubr2 in murine placental 
development using a Ubr2-/- mouse, and look for any overlap with the placental phenotype of 
the Tex19.1-/- mouse (J Reichmann et al. 2013, 2017), which is a null mutant for the known UBR2 
interacting protein TEX19.1. I demonstrate a novel role for UBR2 in the placenta, which 
associates with intrauterine growth restriction (IUGR), and begin to separate the functions 







4.2.1 Ubr2-/- females on a C57BL/6J background are small and under-represented at 
weaning 
Ubr2-/- mice have been previously reported to exhibit a female-specific embryonic lethality (Y 
T Kwon et al. 2003). However, in that study, there was variable severity of the null mutation 
depending on strain background. Very few male or female Ubr2-/- pups survived in an inbred 
129SvJxSvImJ background (1.58% and 1.64% each of all males and females on this background, 
respectively). Differing strain backgrounds can result in varying survival rates of 
developmentally challenged pups (Cranston and Fishel 1999; Aihara et al. 2007; J.-Z. Jin and 
Ding 2015) and so, interestingly, the Ubr2-/- lethality was reported as female-specific when 
using either 129SvJxC57BL/6J or 129SvJxCD1 mixed backgrounds, and Kwon et al. were able 
to obtain male Ubr2-/- mice at an expected rate (23.7% and 24.5% of all males in each 
background, respectively). The Ubr2-/- mouse generated in our group is on a C57BL/6J inbred 
background, and so it cannot be assumed that the published embryonic lethality is present in 
our hands (Crichton et al. 2017). In our group, a premature stop codon was introduced at Cys-
121, which is within the UBR2 UBR box (Uniprot Q6WKZ8-1) and is encoded in exon 3 of 
the Ubr2 gene; the majority of the UBR box domain is encoded by exons 3 and 4 (T Tasaki et 
al. 2009). A silent XbaI restriction site was also introduced as a means to genotype the Ubr2-/- 
allele (Crichton et al. 2017). In contrast, Kwon et al. generated a truncated UBR2 protein in 
embryonic stem cells (ESCs) by deletion of exons 4 and 5, and partial deletion of exons 3 and 
6, by introduction of a lacZ marker gene between the 7th codon of exon 3 and the 16th codon of 
exon 6. They did not detect any β-galactosidase activity, and UBR2 protein could not be 
detected in either ESCs, or in the liver or testis of mice produced by chimaeric introduction 
of these ESCs and backcrossing to produce a Ubr2-/- line (Y T Kwon et al. 2003). 
Although the mutations introduced into the Ubr2 gene in these two mouse lines are different, 
both involve truncation of exon 3, which is known to encode part of the UBR box domain (T 
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Tasaki et al. 2009), and neither Ubr2-/- mouse lines produce any detectable UBR2 protein in 
the testis (Y T Kwon et al. 2003; Crichton et al. 2017). Therefore, it does not appear that there 
are any allele-specific differences in how the two mutant proteins are expressed, and I 
assumed any major differences noted between the two strains was a result of genetic 
background. 
To test if female-biased embryonic lethality is present in the Ubr2-/- mice used here, I examined 
the breeding data obtained from heterozygous Ubr2+/- x Ubr2+/- crosses used during breeding 
to generate Ubr2-/- mice for the meiotic phenotypic analyses described in the previous chapter. 
These animals were genotyped at 3 weeks post-partum (pp) by PCR against exon 3 (Fig. 4.2A) 
and the 310bp PCR product digested with the introduced XbaI restriction site, which 
produces 2 bands at 205bp and 100bp for a Ubr2-/- genotype, or both these and the wild type 
310bp band for Ubr2+/- animals (Fig. 4.2B). Crosses between Ubr2+/- mice are expected to 
generate 25% Ubr2+/+, 50% Ubr2+/- and 25% Ubr2-/- animals, with half of the pups expected to 
be male and half expected to be female (Fig. 4.2C). However, at weaning, around 3 weeks 
post-partum, only 15% of pups are Ubr2-/- (53 of 344 mice born from heterozygous Ubr2+/- x 
Ubr2+/- crosses); this is a statistically significant deviation from expected Mendelian ratios 
(Fig. 4.2D, p=0.004, χ2 test), indicating that there is a lethality in our Ubr2-/- line. As the 
previously observed lethality is female-specific on some strain backgrounds, I separated the 
genotypes of the mice produced from heterozygous Ubr2+/- x Ubr2+/- crosses at 3 weeks post-
partum by gender. Male Ubr2-/- mice make up 21% of males from heterozygous crosses at 
weaning. Wild type and heterozygote males make up 23% and 56% of all males. These 
proportions are not statistically significantly different from expected Mendelian ratios (Fig. 
4.2D, p=0.4762, χ2 test). Interestingly, only 9.8% of female mice are Ubr2-/-. Wild type and 
heterozygote genotypes represent 26.0% and 64.0% of the female pups, respectively. 
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Therefore, female Ubr2-/- mice are present at a statistically significant sub-Mendelian ratio at 
weaning (Fig. 4.2D, p=0.0008, χ2 test). 
Of the 173 females genotyped in our colony, a Mendelian ratio of heterozygote crosses would 
predict 43 Ubr2-/- females but only 17 are present, which is 9.8% of all females born – this is 
39.5% of the expected number, which suggests that any lethality affects 60.5% of Ubr2-/- 
females. In the previous study on either 129SvJxC57BL/6J or 129SvJxCD1 mixed backgrounds, 
only 8.2%and 15.2% of expected Ubr2-/- females were weaned, respectively. The first is 
significantly more penetrant than the Ubr2-/- female penetrance observed from our 
heterozygous crosses (p=0.0049, χ2 test), and the second is not significantly more penetrant 






Figure 4.2 (next page) Ubr2
-/-
 female mice do not survive to adulthood at a Mendelian ratio. 
A. The Ubr2
-/-
 allele has a premature STOP codon introduced into exon 3 at Cys-121, which is 
within the UBR box domain and will give a truncated protein product. A silent XbaI restriction 
site was introduced into exon 3 upstream of the STOP codon for genotyping. B. Representative gel 
electrophoresis of genotyping in the Ubr2
-/-
 colony. The PCR product (primers indicated in blue in 
A) produced by Ubr2
-/-
 mice have two bands after XbaI cleavage: 210bp and 100bp. * non-specific 









 and 25% Ubr2
-/-





) crosses. Absolute numbers shown (total mice: 344, 171 males and 
173 females), and as a percentage of the total number of mice. All mice were genotyped at weaning 
(3 weeks post-partum). Also separated by gender. 
All statistical differences calculated using χ
2
 tests: ** p≤0.01. 
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Therefore, the lethality in Ubr2-/- mice on a C57BL/6J inbred background is female-biased. This 
is an incompletely penetrant phenotype in all strain backgrounds covered here, and the strain 
appears to affect the level of penetrance; in our C57BL/6J inbred mice, the penetrance of female 
lethality is significantly reduced as compared to one of the previously published lethalities. 
This could reflect either an embryonic or perinatal lethality, which is prevalent before 3 weeks 
pp, i.e. age of weaning. 
In the previous study, surviving adult Ubr2-/- females in the 129SvJxC57BL/6J background 
exhibited a 20% growth retardation (Y T Kwon et al. 2003). Adult growth retardation of 
around 8% has also been observed in Tex19.1-/- females (J Reichmann et al. 2013). Adult males 
do not have a growth retardation in either published phenotype. In order to investigate 
whether this growth retardation is present on our C57BL/6J inbred Ubr2-/- mice, I weighed 
surviving adult mice at 8-10 weeks of age. As growth rates differ by gender in the C57BL/6J 
background (Gall and Kyle 1968), I separated the weights to reflect this. Male Ubr2-/- adult 
mice are not significantly reduced in size, as compared to age-matched littermate Ubr2+/+ males 
(Fig. 4.3A, p=0.58, Student’s T-test), suggesting that males have normal postnatal growth, as 
has been previously reported. Heterozygote males also do not deviate in size from their Ubr2+/+ 
littermates (p=0.74, Student’s T-test).  However, surviving females are significantly reduced 
in size by 18% (Fig. 4.3B) compared to both age-matched wild type and heterozygous females 
(p=0.006 and p=0.026, Student’s T-Test), which is similar to the previously observed 20% 
magnitude of growth retardation in Ubr2-/- females (Y T Kwon et al. 2003). Lack of Ubr2 during 



















Figure 4.3 Surviving female Ubr2
-/- 
mice have a growth retardation 





 heterozygote crosses. B. Beeswarm plots of female mouse body weights (g) 




 heterozygote crosses.  




4.2.2 Ubr2-/- embryos exhibit intrauterine growth restriction and a placental size defect 
Placental growth is important to support the growth of the embryo in utero and placental 
defects hinder this growth – this is known as intrauterine growth restriction (IUGR), which 
is associated with murine embryonic lethality, smaller size at parturition and poor health 
(Beauchamp et al. 2015; G. Li et al. 2017). In human IUGR cases, there is an increase in 
neonatal or perinatal morbidity, and this may also be a factor in mouse models of IUGR 
(Malhotra et al. 2019) – which could explain the perinatal lethality observed in our Ubr2-/- 
females. 
A                    Male Weights at 8-10 weeks pp            B                  Female Weights at 8-10 weeks pp 
** 
* 
























Figure 4.4 – E18.5 Ubr2
-/-
 mice have an embryonic growth defect associated with a placental 
defect. 
A. Beeswarm plots of E18.5 embryo weights (mg) over 5 litters from Ubr2
+/- 
mating pairs. 
Littermate wild type (+/+, n=13, grey), heterozygote (+/-, n=21, light grey) and homozygote null (-
/-, n=11, green). Means shown as black bars. Due to Home Office regulations, these are combined 
head and body weights of decapitated embryos. B. Data from A separated into male and female 
E18.5 embryo weights (mg), means shown as black bars. C. Beeswarm plots of placenta weights 
(mg) of E18.5 embryos, as in A. Means shown as black bars. D. Data from C separated into male 
and female placenta weights (mg), means shown as black bars. All statistical differences 
calculated used Student’s T-Test: * p≤0.05, ** p≤0.01, *** p ≤0.001.  
A                  E18.5 Embryo Weights 
C                 E18.5 Placenta Weights 
B                           E18.5 Embryo Weights by Gender 














Female                                               Male 
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As the Ubr2-/- female embryos in (Y T Kwon et al. 2003) were smaller than their Ubr2+/+ 
littermates at early (E9.5) embryonic stages, an embryonic growth restriction appears be 
associated with the observed female-specific lethality in absence of UBR2. Female embryonic 
growth restriction could also potentially be linked to the observed female adult growth 
restriction phenotype. Around 50% of female E9.5 embryos were deemed to be 
developmentally arrested at around E7.5-like stages (Y T Kwon et al. 2003). However, the 
lesser affected E12.5 embryos were histologically analysed and no overt defects were observed 
in major organs during development. This indicates that UBR2 has a role in embryonic growth, 
potentially being so severe as to prevent developmental progression, but it is not required for 
major developmental processes. It should be noted that this variance in penetrance of the 
Ubr2-/- phenotype has been observed across differing genetic backgrounds (129SvJxC57BL/6J 
or 129SvJxCD1 mixed backgrounds, Kwon et al. 2003) and in this study all mice were 
generated on a C57BL/6J inbred background. 
Considering these data, I hypothesised that UBR2 has a role in placental development, and 
that this is linked to IUGR, which would present as an embryonic growth restriction. To 
assess this, I first measured the weights of dissected E18.5 embryos. Ubr2-/- embryos are 
significantly reduced in size; the mean weight of 11 individuals was 794.3±40.1mg (± standard 
error), 16.50% less than wild type littermate control weights (mean 951.2±46.2mg) and 20.50% 
less than heterozygous littermates (mean 999.1±33.6mg) (Fig. 4.4A, p=0.0197, p=0.0008 
respectively, Student’s T-test). Additionally, there is no significant difference in embryo size 
between wild type and heterozygote littermates (p=0.3992, Student’s T-test). When 
separated by gender, this growth restriction can still be observed; female and male Ubr2-/- 
embryos have mean weights of 774.6±52.6mg and 774.3±42.2mg, respectively, and are 
significantly smaller than heterozygote littermates (Fig. 4.4B, p=0.0199, p=0.0032 respectively, 
Student’s T-test), reduced by 21.1% and 21.7%, respectively. Although Ubr2-/- females weigh 
17.0% less than the weights of wild type female littermates (mean weight 933.1±80.3mg), the 
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reduction in embryonic size is not significantly changed between these two groups (p=0.1210, 
Student’s T-test). However, males are significantly smaller than wild type littermate males, 
which have a mean weight of 1035.2±32.4mg (p=0.0002, Student’s T-test), i.e. a 25.2% 
reduction in size; the scale of reduction in embryonic weight is slightly higher for male         
Ubr2-/- embryos than female Ubr2-/- embryos. 
Therefore, loss of Ubr2 results in a growth restriction in both male and female embryos at E18.5. 
As female adult Ubr2-/- mean weight is 82.1% of mean female wild type weight (Fig. 4.3B), and 
at E18.5 the mean female Ubr2-/- embryos are 83.0% of wild type littermate weight (Fig. 4.4B), 
intrauterine growth defect persists into adulthood in Ubr2-/- females. Although they have not 
caught up with littermates, there is no proportional loss of size and so females do not have a 
substantial lack of postnatal growth. Males, however, are able to catch up to their Ubr2+/+ 
littermates (Fig. 4.3A). 
As discussed previously, embryonic growth restriction can be associated with placental 
defects, and a restriction of nutrient flow to the developing placenta. As the Tex19.1-/- 
embryonic growth restriction is associated with a reduction in placental size, I hypothesised 
that this may also be the case in the Ubr2-/- embryonic phenotype. In order to ascertain if the 
embryonic growth restriction is associated with defects in placental function, I measured the 
weights of placentas dissected from E18.5 placentas. Ubr2-/- placentas have a mean weight of 
60.5±2.6mg, and are significantly smaller than the placentas of both wild type (88.9±2.6mg, 
smaller by 32.03%) and heterozygote (80.9±1.4mg, smaller by 25.30%) littermates (Fig. 4.4C, 
p=0.0000005, p=0.000001 respectively, Student’s T-test). Interestingly, although there is no 
difference between the wild type and heterozygote embryo sizes reported above, the 
heterozygote placentas weigh 9.0% less than their wild type counterparts, which is a 
statistically significant reduction in weight (p=0.0136, Student’s T-Test) and implies a 
potentially dose-dependent phenotype. 
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As both female and male embryos are affected at E18.5, I hypothesised that, when separated 
by gender, this placental defect is also not sex biased (Fig. 4.4D). Firstly, female placentas 
have a mean weight of 54.4±3.8mg, and are significantly reduced in size by 37.3% compared 
to the placentas of wild type littermates (mean weight 86.7±2.5mg), and reduced by 25.3% in 
comparison to the placentas of heterozygote littermates, mean weight 72.8±5.9mg 
(p=0.000006, p=0.025 respectively, Student’s T-test). Male Ubr2-/- placentas are also affected; 
they have a mean weight of 62.6±4.5mg, which is significantly smaller than wild type 
littermates’ placentas by 29.3% (mean weight 88.6±3.4mg), and heterozygote littermates’ 
placentas by 20.5%, mean weight 78.8±3.5mg (p=0.0005, p=0.016 respectively, Student’s T-
Test). The dose-dependent effect of partial loss of UBR2 in a Ubr2+/- placenta appears to only 
affect female heterozygotes, which are significantly smaller than wild type female placentas 
by 16.0% (p=0.048, Student’s T-Test). These are, however, still significantly larger than Ubr2-
/- female placentas, suggesting that, if placental size is causative of the embryonic growth 
defect, there is a threshold at which the reduced placental size begins to affect the embryo. 
Therefore, there appears to be both a placental and an embryonic growth defect in a Ubr2-/- 
mouse. Although only Ubr2-/- females are affected by perinatal lethality and post-natal growth 
restriction, there is no sex bias in placental or embryonic size at E18.5. There also appears to 
be a female-specific dose-dependent role of Ubr2 in the placenta, as Ubr2+/- female placentas 
are reduced in size. As female Ubr2+/- embryos are unaffected, this could point to a causative 












Figure 4.5 (next page) Ubr2
-/-
 mice exhibit embryonic growth defects earlier in 
development 
A. Beeswarm plots of E12.5 embryo weights (mg) over 12 litters from Ubr2
+/- 
mating pairs. 
Littermate wild type (+/+, n=33, grey) and heterozygote (+/-, n=40, light grey) and homozygote null 
(-/-, n=22, green) embryos. Means shown as black bars. B. Beeswarm plots of E12.5 embryo weights 
(mg) of placentas from, as in A. Means shown as black bars. C. Representative paired E12.5 
embryos and placentas. Scale bars are 1mm. D and E. Beeswarm plots of littermate wild type (+/+, 
n=11, grey) and heterozygote (+/-, n=14, light grey) and homozygote null (-/-, n=9, green) E10.5 
embryo and placenta weights (mg), over 4 litters from Ubr2
+/- 
mating pairs, as in A and B. Means 
shown as black bars. 
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4.2.3 The Ubr2-/- and Tex19.1-/-placental defects arise at a similar developmental 
timepoint  
The embryonic growth defect associated with a placental size defect indicates potential 
IUGR and, if this is the case, the placental size defect should precede the embryonic growth 
defect. Kwon et al. (2003) detected a growth restriction at E9.5 in absence of Ubr2, however 
due to the differences in penetrance of the Ubr2-/- lethality across different strain backgrounds, 
I surmised that this may result in a difference in the timing of growth restriction as well. To 
investigate at what stage the placental defect first appears, I dissected embryos at E12.5, i.e. 
12.5 days into embryonic development, and weighed both embryo and placenta. Kwon et al.’s 
study was limited to embryonic development only, and so measurement of placental weights 
at E12.5 will also give an insight into the staging of Ubr2-/- placental defects and how this 
relates to embryonic growth. There is no difference in the embryonic or placental weights 
between males and females at E18.5, and the phenotype only becomes sexually dimorphic in 
adulthood, exhibiting a female-specific lethality and growth restriction, and so for these 
earlier stages I grouped genders together. 
Ubr2-/- E12.5 embryos have a mean weight of 78.9±2.5mg, which is subtly but significantly 
smaller than wild type littermates, which have a mean weight of 86.3±1.6mg (Fig. 4.5A, 
p=0.0118, Student’s T-test), which is a difference of 7.4mg, or an 8.5% reduction. The placentas 
of Ubr2-/- E12.5 animals have a mean weight of 69.4±3.4mg, and are significantly smaller than 
wild type littermates, mean weight 84.1±2.6mg (Fig. 4.5B, p=0.00009, Student’s T-test); this 
is a 17.5% decrease in placental size. Interestingly, at E18.5 the difference in placental weight 
was a 37.3% reduction between Ubr2+/+ and Ubr2-/- animals, which is a larger magnitude of size 
defect and implies a potentially progressive size restriction over time, between E12.5 and E18.5. 
Ubr2+/- E12.5 embryos have a mean weight of 84.9±2.1mg, and this is not significantly different 
from wild type littermate embryos (Fig. 4.5A), which is similar to the observed E18.5 embryos. 
Their placentas have a mean weight of 75.7±2.7mg, significantly smaller than wild type 
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littermates (10.1% reduction, Fig. 4.5B, p=0.0284, Student’s T-Test). Again, this is similar to 
the heterozygous placenta size difference that can be observed in E18.5 Ubr2+/- placentas (Fig. 
4.4C), and implies a dose-dependent role of Ubr2 in the placenta, which could indicate a 
causative role for placental size in the embryonic growth restriction. 
In the Tex19.1-/- phenotype, there is no clear embryonic size defect at E12.5, and the placental 
growth defect does not begin until after E10.5 (Chris Playfoot, unpublished data, MRC HGU). 
To ascertain if the Ubr2-/- placental defect has similar timing, I also dissected and weighed 
placentas and embryos at this earlier stage of development. There is no significant reduction 
in E10.5 Ubr2-/- embryonic weights (mean 13.5±1.3mg) compared to wild type (mean 13.0±1.1mg) 
or heterozygote (mean 13.7±1.3mg) littermates (Fig. 4.5D, p=0.762 and p=0.916 respectively, 
Student’s T-test). This indicates that the embryonic growth defect begins to present between 
E10.5 and E12.5, which is slightly earlier than the size defect recorded in the Tex19.1-/- embryo 
(Chris Playfoot, unpublished data, MRC HGU). E10.5 Ubr2-/- mean placental weight is 
33.3±2.6mg, which is not a detectable change from either wild type (mean 34.5±1.7mg) or 
heterozygote (mean 32.0±1.5mg) littermates’ placentas (Fig. 4.5E, p=0.8725 and p=0.2565 
respectively, Student’s T-test), implying that the defect in placental growth also presents 
between E10.5 and E12.5 – this is the same stage as the Tex19.1-/- placental defect (Chris 
Playfoot, unpublished data, MRC HGU). 
Heterozygote placentas are also not significantly smaller than wild types (p=0.2515, Student’s 
T-test), and so the potential dose-dependent phenotype in these placentas presents at the 
same developmental stage as the null phenotype. 
Although around 50% of E9.5 female embryos have been previously reported as 
developmentally arrested at an E7.5-like stage (Y T Kwon et al. 2003), I did not observe this 
in any of the E10.5 or E12.5 (Fig. 4.5C) embryos isolated on this strain background, which are 
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also grossly morphologically normal (Fig. 4.5C). This indicates that there may be molecular 
phenotypes at this stage that are not penetrant in our Ubr2-/- mouse. 
Again, this published phenotype is variable and so ack of an observable phenotype here could 
be a result of changes in penetrance. Taken together, the data presented in this section (Fig. 
4.5) indicate that both Ubr2-/- males and females have an embryonic growth defect that 
presents between E10.5 and E12.5. This growth defect is associated with a smaller placenta, 
indicating a potential intrauterine growth restriction caused by lack of nutrients during 
embryogenesis. The Ubr2-/- placental size defect also presents between E10.5 and E12.5, which 
is similar to the Tex19.1-/-placental phenotype, a related gene whose protein product directly 
interacts with UBR2. The Tex19.1-/- placental phenotype has many superficial similarities to the 
timing and IUGR of the Ubr2-/- placental phenotype. 
For all further experiments I assumed E10.5 to be prior to the placental phenotype, as there is 
no detectable size defect, and used E12.5 placentas to study the Ubr2-/- placenta in more detail. 
 
4.2.5 Ubr2 has a role in trophoblast-derived layers of the placenta 
The placenta is made up of three tissue layers: the embryonic labyrinth, the central junctional 
zone and the maternal decidua (Rossant and Cross 2001); see Chapter 1 for more detail on 
placental structure and development. Tex19.1 is expressed in trophectoderm-derived cell types, 
which are most abundant in the junctional zone (Jz) and labyrinth (Lb). In a Tex19.1-/- placenta, 
there is a specific reduction in the trophectoderm-derived cell types of the Jz, leading to a 
reduction in the size of this tissue layer (J Reichmann et al. 2013). Although the size of the Lb 
is unaffected in the Tex19.1-/- placenta, there is also a loss of specific cell-type markers in this 
tissue layer, indicating a role for the gene in both trophectoderm (TE)-derived layers (Chris 
Playfoot, unpublished data, MRC HGU). As TEX19.1 and UBR2 interact and have overlapping 
phenotypes in the testis (Yang et al. 2010; Crichton et al. 2017), I hypothesized that defects in 
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a Ubr2-/- placenta would also overlap the Tex19.1-/- phenotype, i.e. defects in TE-derived tissue 
layers, primarily the junctional zone (Jz). This is characterised by glycogen-rich cell types and 
so to distinguish the three layers in histological sections of whole Ubr2-/- E12.5 placenta tissue, 
I stained these cell types with PAS-H (periodic acid Schiff-Haematoxylin), which stains 
glycogen-rich cells that are abundant in the Jz, such as spongiotrophoblast glycogen cells 
(SGCs) (P. M. M. Coan et al. 2006). 
Despite the smaller size of homozygote null placentas, the tissue sections have grossly normal 
morphology (Fig. 4.6A). To assess this in more detail, I measured the size of each tissue layer 
and calculated the proportional contribution of these to the overall placenta size (Fig. 4.6B). 
Due to the small size of the placenta and the nature of histological sections, the absolute size 
of the whole placental tissue measured was variable depending on the section taken for 
measurement, and so this was carried out as a proportion of whole tissue section size. In the 
Ubr2-/- placenta, the Lb is only 29% of the total placenta size, which is a statistically significant 
1.27-fold decrease (p=0.042, Student’s T-test) when compared to the wild type E12.5 labyrinth, 
which makes up 37% of total placenta size. The Jz and the maternal decidua (Md) make up 
28% and 43% of the total Ubr2-/- placenta, respectively, which is not a statistically significant 
change in contribution of either layer (p=0.37 and p=0.57, respectively, Student’s T-test). In 
the wild type E12.5 placenta, Md is 39% of the total placental size and the Jz makes up 24%. 
These are similar to previously reported proportions of placental tissue layers at this stage (P. 
M. Coan, Ferguson-Smith, and Burton 2004). The growth defect in E12.5 Ubr2-/- placentas 
therefore appears to be accompanied by defects in the size of the trophectoderm-derived Lb. 
The  Tex19.1-/- phenotype has a specific junctional zone reduction and has no change in 
labyrinth contribution to the total placental cross-sectional area, and so this seems to be a 















Figure 4.6 (next page) Ubr2
-/- 
placentas are specifically reduced in size in the 
trophectoderm-derived labyrinth layer. 
A. Representative 5µm transverse tissue sections of whole fixed E12.5 placentas, stained with PAS 
to mark glycogen-rich cells of the junctional zone. Md: maternal decidua, Jz: junctional zone, Lb: 
labyrinth. Scale bars are 1mm. B. Proportional contribution of placental layers to the total tissue 
size, as measured in histological sections such as A, across 3 biological repeats. 
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Although the Jz is the only layer whose size is specifically affected in absence of Tex19.1, there 
are differences in the expression of trophectoderm-specific genes in both the Jz and the Lb. In 
order to assess whether similar defects are present in Ubr2-/- placentas, I isolated whole 
placenta RNA at E12.5, generated cDNA and performed qRT-PCR (quantitative real time 
PCR) to investigate the expression level of placental cell-type specific marker genes that are 
known to be perturbed in the Tex19.1-/- placenta (Fig. 4.7). Cdx2 is a homeobox transcription 
factor that is expressed across the trophectoderm lineage, in cells in both the Lb and Jz 
(Sferruzzi-Perri et al. 2009), and so I used this as a general trophectoderm marker gene to look 
at the cell composition in both tissue layers. Expression is slightly decreased, but not 
significantly in the absence of Ubr2 across the whole placenta (p=0.06, paired Student’s T-
test). As the RNA for these qRT-PCR experiments is isolated from whole placenta at E12.5, 
the larger junctional zone may obscure any compositional changes in the smaller labyrinth 
layer, which could explain why there is no detectable decrease in Cdx2 in these placentas. 
Pregnancy-specific glycoproteins Psg21 and Psg23, are both highly expressed in both the 
spongiotrophoblast and in trophoblast giant cells in the junctional zone (Wynne et al. 2006) , 
and are significantly downregulated in the Tex19.1-/- placenta (J Reichmann et al. 2013). The 
expression of both of these genes is significantly decreased in the Ubr2-/- placenta (Fig. 4.7, 
p=0.039, p=0.005 respectively, paired Student’s T-tests). S-TGC (sinusoidal trophoblast giant 
cell) specific gene Ctsq (Simmons et al. 2008) and trophectoderm-specific gene Prl8a8 are both 
specifically expressed in these trophectoderm-derived cell types of the junctional zone, and 
are also both downregulated to varying degrees in the Tex19.1-/- phenotype at E14.5 (Reichmann 
et al., 2013 and Playfoot et al. 2019, manuscript submitted, MRC HGU). In the E12.5 Ubr2-/- 
placenta, expression of both of these genes is also significantly decreased (Fig. 4.7, p=0.033 
and p=0.045 respectively, paired Student’s T-tests). Therefore, Ubr2 is required for expression 
of a subset of TE-derived cell-type specific genes that also require Tex19.1 for their normal 
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expression levels in the developing placenta, and these genes are characteristic of both the Lb 
and Jz, indicating a role for Ubr2 in both tissue layers. 














Figure 4.7 The Ubr2
-/- 
placental defect can be characterised by cell-specific compositional 
differences in both the labyrinth and junctional zone tissue layers. 
Relative gene expression levels measured by qRT-PCR in the whole E12.5 Ubr2
-/-
 placenta over 5 
repeats, corrected against expression of housekeeping gene β-Actin and relative to gender-matched 
and paired littermate wild type controls. Black bar is the mean, relative to wild type mean. 




Taken together, these data suggest that UBR2 has a role in development of the placental 
labyrinth and, although the junctional zone does not contribute any less to the total placental 
size than that in Ubr2+/+ placenta (Fig. 4.6B), the expression of some trophectoderm-specific 
genes expressed in the junctional zone is perturbed and so UBR2 appears to have a role in 
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regulating the development of trophectoderm-derived cells in the placenta. Although TEX19.1 
does not have a specific role in labyrinth growth, the compositional differences in the 
junctional zone that arise in the Ubr2-/- phenotype overlap those observed in the Tex19.1-/- 
placenta at E14.5, indicating that Ubr2 may have both Tex19.1-dependent and Tex19.1-
independent roles in the development of the placenta. 
 
4.2.6 Placental Tex19.1-/- retrotransposon derepression does not act through UBR2 
Tex19.1 has previously been shown to regulate expression of retrotransposon RNAs LINE1 and 
MMERVK10C in the testes (Ollinger et al. 2008; Judith Reichmann et al. 2012) and in the 
placenta (J Reichmann et al. 2013; Tarabay et al. 2013). Ubr2-/- testes de-repress the same 
MMERVK10C retrotransposon RNAs that are de-repressed in the Tex19.1-/- placenta, and 
contain no detectable TEX19.1 protein, suggesting that Ubr2 is required for Tex19.1-dependent 
regulation of MMERVK10C retrotransposon RNA in this tissue. MMERVK10C is unchanged 
in the Tex19.1-/- placenta, but UBR2 may be required for TEX19.1-dependent regulation of 
retrotransposons in this tissue, i.e. LINE-1 and VL30. Although the compositional differences 
identified in both the Jz and Lb (Fig. 4.7) may affect the proportion of hypomethylated cells 
present in the Ubr2-/- placenta, so potentially obscuring a role in derepression of 
retrotransposons, these compositional differences can also be observed in the Tex19.1-/- 
placenta, which do exhibit an upregulation of LINE-1 and VL30. Therefore, I hypothesised 
that any changes in retrotransposon expression levels detected here, reflecting those that are 
regulated by Tex19.1 in the placenta, would also be dependent on Ubr2 for their repression in 
this tissue. 
I performed qRT-PCR to quantify the level of RNA present in the tissue for three 
retrotransposons (LINE-1 Orf2, VL30 and MMERVK10C – Fig. 4.8A). In absence of Ubr2, 
there is no change in level of either LINE-1 Orf2 or VL30 RNA (p=0.982 and p=0.976 
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respectively, paired Student’s T-tests). The abundance of the control retrotransposon 
MMERVK10C does not change in Ubr2-/- placentas either (p=0.26, paired Student’s T-test). 
Thus, TEX19.1’s role in regulating retrotransposon RNA levels is independent of UBR2 in the 
placenta. 
Interestingly, E12.5 Tex19.1-/- placentas also exhibit a modest increase in expression of 
interferon-stimulated genes and activation of innate immune response signaling 
(unpublished data, Chris Playfoot, MRC HGU). The activation of this innate immune 
response is partly dependent on the cytosolic DNA sensor STING (unpublished data, Chris 
Playfoot, MRC HGU), but it is not clear whether the increased innate immune signaling in 
Tex19.1-/- placentas is triggered by retrotransposon de-repression or through other mechanisms. 
Increased expression of retrotransposons has been linked to an elevated interferon (IFN) 
response in a variety of tissue contexts, including a specific link between LINE-1 derepression 
and an IFNβ response in the testes (Yu et al. 2015). As Ubr2-/- placentas appear to phenocopy 
some aspects of the Tex19.1-/- placenta phenotype, but do not de-repress retrotransposons, I 
tested whether innate immune responses were activated in Ubr2-/- placentas independently of 
derepression of these retrotransposons. The interferon-stimulated genes activated in Tex19.1-/- 
placentas are Tmem173, Ifitm2, Ifitm3, Oasl1, Oasl2, Irf7 and Ifi44. However, most of these genes 
are not detectably upregulated in Ubr2-/- placentas (Fig. 4.8B). These data suggest that, in 
contrast to the Tex19.1-/- placenta, an innate immune response is not activated in Ubr2-/- 
placentas. Irf7 is modestly downregulated in the absence of Ubr2 (Fig. 4.8B, p=0.025, paired 
Student’s T-Test). This specific effect on only one gene within this group could be attributed 
to the changes in cell composition across the placenta at this stage of development. 
Additionally, the absence of both an immune response and retrotransposon derepression in 
Ubr2-/- placentas indicates that both these aspects of the Tex19.1-/- placenta phenotype are 
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independent of Ubr2, and that these may be linked, although there is no direct evidence that 











Figure 4.8 (next page) The Ubr2
-/- 




A. Relative retrotransposon expression levels measured by qRT-PCR in the whole E12.5 Ubr2
-/-
 
placenta (green), relative to gender-matched and paired littermate wild type controls (grey), over 
five gender-matched and littermate paired repeats. B. Relative interferon response gene expression 
levels measured by qRT-PCR in the whole E12.5 Ubr2
-/-
 placenta (green), relative to gender-
matched and paired littermate wild type controls (grey), over five gender and littermate paired 
repeats. 
All expression levels normalised to actin expression and relative to wild type means. * Paired 
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4.2.7 Tex19.1-mediated repression of imprinted loci is independent of Ubr2 
Our group has recently shown that some of the molecular defects present in Tex19.1-/- placentas 
are related to the physical interaction of TEX19.1 with an E3 ubiquitin ligase KAP1, which acts 
as a transcriptional co-repressor to recruit the histone methyltransferase SETDB1 and 
H3K9me3 chromatin modifications to specific genomic locations including imprinted genes 
(Playfoot et al. 2019, manuscript submitted, MRC HGU). As a result, Tex19.1-/- placentas 
exhibit reduced amounts of H3K9me3 at specific imprinted genes (Mest, Mcts2 and Impact) and 
transcriptionally de-repress Mest and Mcts2 around 2-fold in the labyrinth (Playfoot et al. 2019, 
manuscript submitted, MRC HGU). Impact is not de-repressed in the Tex19.1-/- labyrinth 
despite depletion of H3K9me3 from this locus, which could potentially reflect an absence of 
relevant transcription factors for this gene in this tissue. However, we have not been able to 
determine if the TEX19.1-KAP1 complex also contains UBR2, or whether TEX19.1 exists in 
separate TEX19.1-KAP1 and TEX19.1-UBR2 complexes, which would confer two separate 
roles for TEX19.1. In order to address whether Tex19.1-dependent regulation of KAP1 genomic 
targets depends on UBR2 in the placenta, I therefore investigated whether Tex19.1-dependent 
KAP1 genomic targets are dysregulated in Ubr2-/- placentas. 
To carry this out I dissected the junctional zone and labyrinth layers from E12.5 placentas, 
removing the maternal decidua tissue layer and carried out cDNA generation and qRT-PCR 
as above. In addition to Mest, Mcts2 and Impact, I also analysed Peg3 as a negative control in 
these layers of the Ubr2-/- placenta, as SETDB1-mediated H3K9me3 histone marks have been 
implicated in its repression (Skiles et al. 2018), which can be regulated by the TEX19.1-KAP1 
complex similarly to Mest, Mcts2 and Impact, but there is no transcriptional upregulation 
detected in the Tex19.1-/- placenta (unpublished data, Chris Playfoot, MRC HGU) and so its 
repression appears to be Tex19.1-independent. In absence of Ubr2 there is no gross 
upregulation of Mest, Mcts2 or Impact in either the placental junctional zone (Fig. 4.9A) or the 
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labyrinth (Fig. 4.9B). Rather, there is a significant decrease in expression of some genes: Mest 
and Impact in the junctional zone (p=0.0003 and p=0.0242 respectively, paired Student’s T-
tests), and Peg3 in the labyrinth (p=0.0212, paired Student’s T-test). These changes could be 
attributed to the cell-compositional changes observed previously (Fig. 4.6) in the E12.5       
Ubr2-/- placenta, as the reduction in proportion of hypomethylated trophectoderm-derived cell 
types in these layers may result in a proportional change of cells in which these genes are 
imprinted. Regardless, there is no gross upregulation, whereas the Tex19.1-/- placenta has 
similar trophectodermal compositional changes and a clear 2x upregulation of Mest and other 
imprinted gene expression. Therefore, these data indicate that, in contrast to Tex19.1, Ubr2 is 
not required to maintain repression of imprinted genes in the placenta; this aspect of 
TEX19.1’s interaction with KAP1 and the complex’s role in imprinted gene regulation does not 




Figure 4.9 (next page) Ubr2 does not have a role in maintaining placental imprinting 
A. Imprinted gene expression levels measured by qRT-PCR in the E12.5 Ubr2
-/-
 placenta junctional 
zone (green), over 4 repeats, normalised against expression of housekeeping gene Actin and 
relative to littermate and gender-matched wild type controls (grey). Mean values shown as a black 
bar. B. Imprinted gene expression levels measured by qRT-PCR in the E12.5 Ubr2
-/-
 placenta 
labyrinth layer (green), over 4 repeats, normalised against expression of housekeeping gene Actin 
and relative to littermate and gender-matched wild type controls (grey). Mean values shown as a 
black bar. 
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In this chapter, I aimed to investigate a potential role for Ubr2 in development of the murine 
placenta, and examine a potential link between the functions of Ubr2 and Tex19.1 in this tissue, 
and in its support of embryonic growth. I identified a Ubr2-/- female-specific lethality that is 
linked to an embryonic growth restriction and a placental defect primarily affecting 
trophectoderm-derived cell types. This placental defect also affects males, but there is no 
discernable lethality, and they recover from the growth defect in adulthood. 
Although there are similarities between the Ubr2-/- and Tex19.1-/- placental insufficiencies, 
including defects in trophectoderm-derived tissues, I showed that many of the currently 
understood roles for Tex19.1 in the placenta are Ubr2-independent. The Ubr2-/- placenta at E12.5 
is grossly normal, but the labyrinth layer is small and there are compositional differences in 
both trophoblast-derived tissue layers: the junctional zone and the labyrinth. This has 
similarities to the phenotype of a Tex19.1-/- placenta, which also has an embryonic growth 
restriction and defects in the trophectoderm-derived layers, although primarily in the 
junctional zone (Reichmann et al., 2013 and unpublished work by Chris Playfoot, MRC HGU). 
Although UBR2 and TEX19.1 have a strong interaction in vitro and in other tissues (Yang et al. 
2010; J Reichmann et al. 2017), the previously observed phenotypes in both the Tex19.1-/- 
junctional zone and labyrinth do not appear to involve UBR2. Therefore, UBR2 and TEX19.1 
may be acting independently to regulate placental development in different ways. Conversely, 
there may be an as-yet undescribed role for TEX19.1 in the placenta that regulates 
development of the trophoblast lineage, cell composition and, as a result, tissue size – and this 




4.3.1 Strain- and sex-dependent penetrance of the Ubr2-/- phenotype 
The previously identified female-specific lethality is also prevalent in our Ubr2-/- mouse, 
although with variable penetrance over three published strain backgrounds (Y T Kwon et al. 
2003), and the C57BL/6J background used in our group. This appears to be least severe on the 
C57BL/6J background, in which 39.5% of expected Ubr2-/- females survived to weaning at 3 
weeks pp (post-partum). Kwon et al. (2003) found that, on either 129SvJxC57BL/6J or 
129SvJxCD1 mixed backgrounds, only 21.7% and 20.0% of expected Ubr2-/- females survived 
to 3 weeks old. In all three of these strain backgrounds, males survived at expected Mendelian 
ratios. However, the most severe of these lethalities (129SvJ/SvImJ strain background) 
affected both male and female Ubr2-/-, and only 1 male and 1 female (6.6% and 6.3%, respectively, 
of expected Ubr2-/- mice) survived to 3 weeks. A strain-dependent phenotype such as this 
could be a result of differentially expressed genetic modifiers across different genetic 
backgrounds. There is evidence to suggest that, even in wild type animals across different 
strain backgrounds, the size of the placenta and ability of it to support embryonic growth is 
highly variable, which is linked to growth factor response (Dackor, Caron, and Threadgill 
2009). Dackor et al. identified differences between wild type trophectoderm-derived tissues 
on different strain backgrounds that have some similarity to the trophectoderm-specific 
defects I identified in our Ubr2-/- placenta: number of spongiotrophoblasts and intensity of 
glycogen-rich PAS staining was reduced, alongside highly variable expression of trophoblast-
derived cell-specific genes such as Ctsq. This appears to indicate a particular vulnerability in 
placental development to changes in strain background, especially in the trophoblast lineage. 
When this is challenged by null mutations such as Ubr2-/-, I would hypothesise that these 
subtle molecular changes in strain background could exacerbate placental insufficiencies, 
particularly in the trophoblast lineage. 
Another variability in the Ubr2-/- lethalities identified here is sexual dimorphism. Both male 
and female embryos have a growth restriction at E12.5 and E18.5, associated with placental 
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growth defects and trophectoderm-derived compositional differences in both genders. 
However, only female embryos exhibit lethality or growth restriction post-partum in the 
majority of strain backgrounds, except for the 129SvJ/SvImJ strain background, in which 
neither males nor females survive to weaning. There is considerable sexual dimorphism in the 
epigenetic programming of placental tissue (Gabory et al. 2013, 2012; Gong et al. 2018), and 
these differences in chromatin structure and methylation marks could lead to a difference in 
vulnerability to mutations that act to regulate epigenetic or hypomethylated genome defence 
states between the male and female placenta. 
The UBR2-interactor TEX19.1 is important for genome defence, acting in complex with KAP1 
to lay down H2K9me3 histone methylation via SETDB1 (Playfoot et al. 2019, manuscript 
submitted, MRC HGU). Aside from genomic imprinting and repression of retrotransposons, 
which are perturbed in absence of Tex19.1 but I have shown in this chapter do not require 
UBR2, one of the key epigenetic functions in a hypomethylated tissue such as the placenta is 
X-inactivation. This is a phenomenon only present in female XX cells, which must silence the 
genes encoded on one X chromosome in order to carry out dosage compensation (Ercan 2014). 
Inactivation of this chromosome is mediated by the Xist (X inactive-specific transcript) gene, 
which encodes cis-acting RNA molecules, specifically expressed from an inactive X, which 
bind and induce chromatin modifications along their own chromosome (Migeon, Axelman, 
and Jeppesen 2005). Long-term inactivation depends on CpG dinucleotide DNA methylation 
(McGraw et al. 2013); this occurs during early embryonic development (A. Wutz and Jaenisch 
2000) and all resulting tissues depend on successful X-inactivation at this specific timepoint. 
It has been suggested that X-inactivation can be reversed in specific tissues – for example in 
the  germline, where reprogramming of methylation marks is crucial for epigenetic diversity 
(Reik, Dean, and Walter 2001), and in the placenta, the role of which is much less understood. 
Cells of the trophoblast lineage undergo de- and remethylation of the X chromosome 
(Prudhomme et al. 2015), resulting in highly heterogenous X-inactivation and epigenetic 
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mosaicism across the trophectoderm-derived cell types (Looijenga et al. 1999; Moreira de 
Mello et al. 2010; Prudhomme et al. 2015). In addition, various mice exhibiting X-inactivation 
defects in the placental are deficient in trophectodermal layers (B. Jiang et al. 2012). 
Hypomorphic expression of Xist leading to defects in X-inactivation in the trophectodermal 
lineage have been shown to result in biallelic X-linked gene expression and is associated with 
placental defects. These include small placentas and an embryonic growth restriction, 
particularly characterised by trophectodermal tissue reduction such as a significant loss of 
trophoblast giant cells (TGCs, which are also reduced in the Tex19.1-/- placenta) at E13.5 (Hoki 
et al. 2011). Although these embryos bear some distinct similarities to both Ubr2-/- and Tex19.1-
/- embryos (Reichmann et al., 2013 and Playfoot et al. 2019, manuscript submitted, MRC HGU), 
it must be noted that all males progressed through development normally, and did not exhibit 
any growth or placental defects. 
X-inactivation has been associated with regulatory monoubiquitination of histone H2A, 
leading to repressive chromatin structure and transcriptional silencing (D. E. Cohen and Lee 
2002). The canonical E3 ubiquitin ligase associated with this in somatic cells is RING1B (D. 
E. Cohen and Lee 2002) but UBR2 has been implicated in mediation of H2A. This appears to 
be essential for meiotic transcriptional silencing at the XY body of spermatocytes (J Y An et 
al. 2010; J. M. A. Turner 2007) in presence of TEX19.1, as well as for chromosome stability in 
somatic cultured fibroblasts (Jee Young An et al. 2012) in absence of TEX19.1, and so could 
also be important for genomic stability through histone ubiquitination in the X-chromosomes 
of placental cell types. 
Therefore, the trophectodermal defects in absence of Ubr2 indicate a potential role for the 
protein in X-inactivation in females. This may act through its interaction with TEX19.1, as 
this protein has been shown to be important for genomic defence and epigenetic silencing 
(Playfoot et al. 2019, manuscript submitted, MRC HGU). Investigation of this by study of 
global methylation marks or expression levels of X-encoded genes such as Xist would give 
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insights into how UBR2 is acting in this tissue. However, it must be noted that although X-
inactivation defects may give rise to female-specific lethalities, they do not necessarily explain 
the male phenotype observed in Ubr2-/- and Tex19.1-/- embryonic stages. 
 
4.3.2 Ubr2’s role in cohesin regulation 
Ubr2 has been implicated in cohesin regulation, both alongside and in absence of Tex19.1 
(Reichmann et al. 2017, and Chapter 3), and so it is possible that this is the mechanism by 
which placental growth restriction is taking place in the null phenotype. Study of cohesin 
protein levels in this tissue is confounded by chromatin preps from E10.5 tissue, preceding the 
growth restriction phenotype, which have highly variable and inconclusive cohesin levels 
(data not shown). 
One of the best studied roles for cohesin is in sister chromatid cohesion during the mitotic 
cell cycle, allowing even division of chromosomes and preventing aneuploidy, which can lead 
to cell death. Both Ubr2 and Tex19.1 have particularly been implicated in regulation of the 
acetylated cohesin subpopulation (the AcSMC3 subunit), which is well-studied in mitosis 
and is required for recruitment of cohesin-maintenance factors such as sororin throughout S 
and G2 phases of the cell cycle and into mitosis (Nishiyama et al. 2010; Ladurner et al. 2016). 
Efficient and timely loading and removal of the cohesin complex during the cell cycle is vital 
for correct chromosome segregation during cell division, and maintenance of the acetylated 
cohesin complex during mitosis itself is important. In the placenta, one of the key 
trophoblast-derived cell types are the trophoblast giant cells (TGCs). These are large 
polyploid cells located in various tissue layers that are important for remodeling and 
vascularization of maternal and embryonic tissue to allow highly efficient nutrient transfer 
(D. Hu and Cross 2010). They develop from the trophoblast lineage via endoreduplication, in 
which cells skip mitosis and undergo multiple rounds of DNA synthesis. Not much work has 
been done to look at the role of the cohesin complex in this specialized cell cycle, but I would 
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hypothesise that cohesin regulation is highly important in these cell types. The cohesinopathy 
WABS is associated with defects in the DNA helicase DDX11/ChIR1, which is required for 
establishment of chromosome cohesion during DNA replication in S phase. This helicase 
stabilises replication fork structures by interaction with replication fork protectors (Pisani et 
al. 2018), and it has an in vitro interaction with cohesin complexes (Cortone et al. 2018). 
Therefore, cohesin appears to play a role in replication fork stability and loss of chromosome 
cohesion during a specialised S phase such as in placental TGCs could be a cause of 
chromosome instability or cell death. 
In order to specifically study this cell type in the Ubr2-/- placenta it would first be important 
to count the number of TGCs and other individual cell types and conduct a more thorough 
histological examination of the Ubr2-/- placenta. For example, TUNEL stains could be used for 
quantification of apoptotic cells that may not survive a perturbed cell cycle, leading to the 
smaller tissue size. In vitro migratory assays could also be used to assess the competency of 
TGCs for their normal placental ability to invade the maternal decidua  (James, Tun, and 
Clark 2016). Finally, there are also some studies into the culture and differentiation of 
trophoblast stem cells (TSCs) into cell types such as syncytiotrophoblasts (SynTs) which 
could be a tool to study placental requirements for Ubr2 in cohesins in cell culture in an in vitro 
setting (Latos and Hemberger 2016; Zhu et al. 2017). 
Finally, recent work shows that cohesin is required for much more than simply sister 
chromatid cohesin and mitotic stability, and the cohesin complex is important for chromatin 
structure in a broader sense, potentially regulating the structure of TADs and loops within 
chromatin (G. Wutz et al. 2017; Nuebler et al. 2018; Skibbens 2019). Defects in cohesin 
complex regulation as a result of either Ubr2-/- or Tex19.1-/- could therefore have wide-reaching 
implications within placental tissue, affecting interphase chromatin structure or genomic 
stability, so leading to transcriptional or regulatory changes within individual cell types in 
the trophoblast lineage. This could be tested by chromosome conformational capture assays 
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such as HiC, in which closely localised regions of the genome are cross-linked and deep 
sequenced, leading to construction of a spatial chromatin ‘map’. 
 
4.3.3 Roles for UBR proteins in embryonic and placental development 
In addition to further investigation of the placental phenotype itself, the molecular 
mechanism by which Ubr2 is important for placental development is unclear. UBR proteins 
are a small family of E3 ubiquitin ligases that act to provide substrate specificity in the N-end 
Rule pathway of ubiquitination. They have a high level of structural conservation, particularly 
in their substrate binding domain, and so there is a large potential for redundancy and overlap 
of function between these proteins (T Tasaki et al. 2009). Tex19.1 has been implicated in the 
regulation of UBR2’s substrate binding ability in the N-end Rule pathway (J Reichmann et al. 
2017) and so it could be that the placental phenotype is a result of the loss of this molecular 
function. 
Some, potentially redundant, roles for UBR1 and UBR2 during development include 
embryonic neurogenesis and cardiovascular development (Jee Young An et al. 2006). There is 
also evidence to suggest that UBR4 (also known as p600) has key roles in both embryonic 
and placental development, presenting a growth restriction phenotype similar to that seen in 
Ubr2-/- females (Nakaya et al. 2013). Therefore, whether the role of UBR2 in the placenta is 
TEX19.1-dependent or independent, further work into potential N-end Rule functions of the 
UBR2 protein in the placenta will be required in order to ascertain the mechanism by which 
UBR2 is important for placental development. This could be achieved through selective 
inactivation of N-end Rule functions of UBR proteins, which is discussed in further detail 





In summary, in this chapter I was able to identify a placental defect in absence of Ubr2 that 
associates with embryonic growth restriction. This is not gender-specific, affecting both 
males and females during embryonic stages to a similar level. However, it only persists in 
females, as a female-specific growth restriction can be observed at 3 weeks post-partum, and 
a female-specific lethality in  60.5% of expected Ubr2-/- females born from heterozygous 
matings. UBR2’s major interactor, TEX19.1, has been implicated in genome defence in the 
hypomethylated trophectoderm lineage, particularly in repression of retrotransposons and 
imprinted gene expression. However, UBR2 is not required for either function in the 
developing placenta, and so it is unclear how these placental defects arise in absence of Ubr2. 
Further work will be required to elucidate the role of UBR2 in placental development, 
potentially through other genome defence roles such as X-inactivation or through cohesin 

















As discussed in Chapter 1, UBR2 is one of seven UBR proteins that contain the UBR box; four 
of which, including UBR2, have been shown to have activity as E3 ubiquitin ligases in the N-
end Rule protein recognition system of the UPS (T Tasaki et al. 2009). These proteins are 
coexpressed in a wide variety of tissues and there is evidence for redundancy between them 
(Jee Young An et al. 2006). However, the Ubr2-/- mouse has a specific subset of phenotypes, 
suggesting that UBR2 has essential molecular functions in specific tissues, whether through 
the N-end Rule, or through other potential functions of the protein that cannot be 
compensated by UBR protein redundancy for N-end Rule substrate binding. 
UBR2 has a 1:1 stoichiometric interaction with TEX19.1, which is a protein expressed 
primarily in hypomethylated contexts: the ovary, testis, placenta, and in ES cells (Yang et al. 
2010; J Reichmann et al. 2017; Crichton et al. 2017). Data previously published by our lab 
shows that TEX19.1 is able to regulate turnover of Type II reporters by UBR2 (J Reichmann 
et al. 2017). The phenotypes of Tex19.1-/- and Ubr2-/- mice have some overlap, appearing to work 
both agonistically and antagonistically depending on the context of their co-expression, 
although there are key differences indicating that both genes have roles independent of each 
other as well (see Chapters 3 and 4 for more details). 
One of the best characterised of the Ubr2-/- phenotypes is in male meiosis and spermatogenesis, 
in the testes. This includes gross spermatocyte apoptosis and male infertility, which can be 
characterised by gross morphological changes in the seminiferous tubules of the testis, low 
testis weight and a lack of mature sperm (Y T Kwon et al. 2003), seeming to result from 
chromosome asynapsis and a zygotene-like arrest (Crichton et al. 2017).       The infertile 
Tex19.1-/- male also has a zygotene-like asynaptic arrest and reduction in recombination rates 
(Crichton et al. 2017). Indeed, TEX19.1 protein is destabilised in the Ubr2-/- testis (Yang et al. 
2010), indicating that their interaction is vital for normal spermatogenesis. However, it 
remains unclear whether the phenotype is a result of lack a functional TEX19.1-UBR2 
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complex, perhaps through TEX19.1’s regulation of Type II N-end Rule activity, or if UBR2 is 
simply required for TEX19.1 stabilisation in this tissue, producing such a stark phenocopy 
between these male mice. Aside from UBR2, the UBR protein with the highest Type II N-end 
Rule affinity is UBR1 (T Tasaki et al. 2005), and these are both expressed in the testes (T 
Tasaki et al. 2005; Y T Kwon et al. 2003). However, there is a difference in localisation of UBR1 
and UBR2 in this tissue; UBR1 is highly expressed in spermatogonia, whereas UBR2 is 
specifically localised to spermatocytes (Y T Kwon et al. 2003). This implies that the Ubr2-/- 
testis may have lost a specific Type II N-end Rule function in spermatocytes that cannot be 
covered by protein redundancy, resulting in the observed phenotypes. 
Our group have also identified a novel role for UBR2 in regulation of the cohesin complex 
(Reichmann et al. 2017 and Chapter 1) – specifically, in the regulation of the chromatin-bound 
acetylated subpopulation of cohesin, linked to the role of TEX19.1 in acetylated cohesin 
regulation in the murine oocyte. Both Ubr2 and Tex19.1 are expressed in embryonic stem cells 
(ESCs), and presence of TEX19.1 protein is important for repressive chromatin modifications 
and genomic stability in these contexts (Hackett et al., 2012; Maclennan et al., 2017 and 
Playfoot et al. 2019, manuscript submitted, MRC HGU). Another role for both Tex19.1 and Ubr2 
in ESCs is in the regulation of the AcSMC3-containing cohesin complex. Tex19.1-/- ES cells have 
a specific loss of the chromatin-associated acetylated cohesin subunit AcSMC3, as observed 
in the meiotic oocyte (J Reichmann et al. 2017), but in a Ubr2-/- ES cell line, there is a significant 
increase in this acetylated subpopulation. This indicates an antagonistic relationship 
between these proteins in the regulation of acetylated cohesin in this cell type (unpublished 
data, Karen Dobie, MRC HGU). Ubr2 also has Tex19.1-independent roles in AcSMC3 
regulation in mitotic tissues such as the spleen, in which there is again an increase of the 
acetylated subpopulation of cohesin in absence of Ubr2. As the N-end Rule is the most well 
characterised molecular function of UBR2, I hypothesised that its role in cohesin regulation 
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across various tissues acts, either directly or indirectly, through this substrate binding 
pathway. 
UBR2’s role in the N-end Rule is as an E3 ubiquitin ligase, which confers substrate specificity 
for a ubiquitination cascade (Takafumi Tasaki and Kwon 2007). This is regulated by two 
protein domains (Fig. 5.1A, Tasaki et al., 2009): the UBR box, a highly conserved 70-residue 
zinc-finger-like structure which is shared across all UBR proteins, and the N-domain, which 
has high homology with the bacterial ClpS domain and is common to both mouse proteins 
UBR1 and UBR2. Alanine-scanning mutagenesis of these domains of mouse UBR1 identified 
two point mutations: D118A and D233A, which specifically interfere with the ability of UBR1 
to bind either Type I or Type II substrates, respectively (T Tasaki et al. 2009). 
The Ubr1D118A point mutation lies within the UBR box of UBR1 protein (Fig. 5.1B), which 
directly binds both Type I and Type II substrates (E Matta-Camacho et al. 2010), although 
the N-domain is also required to accommodate Type II peptide binding (T Tasaki et al. 2009). 
Within the UBR box, the residue D118 specifically conjugates a water molecule with the N-
terminal Arginine of Type I peptides (E Matta-Camacho et al. 2010; J Muñoz-Escobar et al. 
2017), (Fig. 5.1C) and so mutation of this is expected to leave the whole UBR box intact, 
maintaining the binding ability towards Type II peptides as normal (T Tasaki et al. 2009). 
Alanine screening of other amino acid residues in the UBR box (Fig. 5.1B) resulted in either 
partial perturbation of the Type I interaction, or perturbation of both Type I and Type II 
(Tasaki et al. 2009), presumably destabilising the UBR box structure altogether, and so I 
surmised that Ubr1D118A would be the best candidate for a Type I mutation in Ubr2. 
The Ubr1D233A point mutation lies within the N-domain and is conserved in UBR2, and in the 
homologous bacterial ClpS protein (Fig. 5.1D). ClpS is a small (12kDa) adaptor protein that 
acts to provide substrate specificity in the E. coli proteolytic ClpAP machinery, the bacterial 
equivalent of an N-end Rule (Gottesman et al. 1998) by binding the ClpA catalytic subunit 
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(Zeth et al. 2002). The D233 residue is also essential for ClpS substrate binding (Tan et al. 
2016). 
To assess the importance of the N-end Rule in UBR2’s major functions and investigate the 
molecular basis of the null phenotypes, I aimed in this chapter to generate separation-of-
function mutations in these two substrate-binding domains: the UBR box and the N-domain, 
with a view to understand the molecular functions of UBR2 more closely. I generated a 
Ubr2D233A mouse model using CRISPR to assess the hypothesis that UBR2 primarily acts 
through the Type II N-end Rule substrate binding pathway. However, Type II is less 
important for the essential functions identified in a Ubr2-/- phenotype than has been previously 
hypothesised. This, paired with introduction of the Ubr2D118A point mutation into ESCs, shows 
that neither Type I or Type II pathways are apparently important for the recently uncovered 
novel role of Ubr2 in cohesin regulation, so indicating potential non-canonical roles for Ubr2, 




















Figure 5.1 – The conserved UBR1 and UBR2 UBR box and N-domain. 
A. Schematic representation of the UBR2 gene, with key domains highlighted. Taken from Tasaki 
et al. 2009. B. Protein sequence alignment of the UBR box of four UBR proteins, showing 
homology. Green: cysteine and histidine residues conserved throughout, required for zinc ion 
binding. Blue: D118 residue, the location of the D118A Asp->Ala point mutation, which is conserved 
between UBR1 and UBR2. C. Structural representation of chemical interactions within the UBR1 
UBR box. Green: a typical bound Type I peptide, in which two N-terminal residues are shown. 
Negatively charged D118 (marked by blue box) specifically conjugates an H2O molecule with the 
N-terminal Arginine (Arg1). Adapted from Matta Camacho et al. 2010. D. Protein sequence 
alignment of mouse UBR1 and UBR2 N-domains and bacterial ClpS domain. Blue: conserved D233 
residue, the location of the D233A Asp->Ala point mutation.  
>m-UBR1   CGKVF----KSGETTYSCRDCAIDPTCVLCMDCFQSSVHKNHRYKMHTSTGGGFCDCGDTEAWKTGPFC 
>m-UBR2   CGRVF----KVGEPTYSCRDCAVDPTCVLCMECFLGSIHRDHRYRMTTSGGGGFCDCGDTEAWKEGPYC 
>m-UBR4   CTFTITQKEFMNQHWYHCHTCKMVDGVGVCTVCAK-VCHKDHEIS-YAKYGSFFCDCGAKEDG----SC 
























































5.2.1 In vitro validation of the Ubr2D118A and Ubr2D233A point mutations  
In order to specifically interfere with the N-end Rule functions of UBR2, I sought to generate 
point mutations that interfere with the binding of UBR2 to its N-end Rule substrates. 
Analogous mutations D118A and D233A have previously been generated in the Ubr1 gene (T 
Tasaki et al. 2009). However, although UBR1 and UBR2 are highly conserved family members 
(E Matta-Camacho et al. 2010), and both residues D118 and D233 are conserved in the UBR 
box and N-domain, there is no direct evidence that these residues will be directly important 
for UBR2 N-end Rule function. Our lab previously cloned the UBR2 CDS (coding sequence, 
exons only) into the plasmid p3xFLAG-CMV-10, which encodes an N-terminal triple FLAG 
tag immediately upstream of a multiple cloning site into which the UBR2 CDS was cloned 
(Fig. 5.2A). 
In order to introduce either D118A or D233A point mutations into this UBR2 CDS, I used site-
directed mutagenesis, in which I designed primers that would introduce the point mutation 
during a PCR, so generating a linear version of the mutant plasmid that I then circularised. I 
used Sanger sequencing to verify the introduction of these mutations (Fig. 5.1B and C). This 
gave me a tool to overexpress the mutant UBR2 proteins and so assess the binding capacity 
of either Ubr2-T1 (D118A) or Ubr2-T2 (D233A) mutants in an in vitro setting, examining the 




























Figure 5.2 – Site-directed mutagenesis of the Ubr2 CDS. 
A. Schematic representation of the pCMV10-FLAG plasmid, with the Ubr2 CDS (coding sequence, 
5268bp) inserted into the multiple cloning site downstream of the N-terminal 3xFLAG tag 
sequence. Locations of either the D118 or D233 residues are shown, which are mutated using site-
directed mutagenesis in this screen.                B. Sanger sequencing data for the UBR2-D118A mutant 
CDS, the D118A mutation is underlined, GAC->GCC. C. Sanger sequencing data for the UBR2-









































Firstly, I aimed to investigate the ability of these mutant UBR2 proteins to bind substrates 
within the N-end Rule. To do so, I transfected HEK293T cells with each of these plasmids, so 
overexpressing either wild type FLAG-UBR2, FLAG-UBR2-T1D118A or FLAG-UBR2-T2D233A 
protein and performed a peptide pulldown assay on the cell lysate. To do this I chemically 
conjugated peptides to resin beads via a C-terminal Cysteine residue, allowing 
immobilisation of the peptide via a thioether bond. These have a specific amino acid at their 
N-terminal end: Type I (arginine, TI), Type II (phenylalanine, TII) or a stabilising negative 
control (glycine, -ve) (Fig. 5.3A). This will specifically identify proteins able to bind either 
Type I, Type II, or both N-end Rule peptides, which I then assayed by Western blotting 
against the N-terminal FLAG-tag of the overexpressed UBR2 protein. 
Wild type UBR2 has very low Type I (TI) binding, as has been shown in previous studies (T 
Tasaki et al. 2005) and a very strong Type II (TII) binding ability (Fig. 5.3B and C). The –ve 
(stabilising, glycine) peptide negative control pulls down a very low level of FLAG-tagged 
UBR2 protein, and so I attributed this to low level non-specific binding of the protein to resin 
beads. In both the FLAG-UBR2-T1D118A and FLAG-UBR2-T2D233A assays, the –ve control pulls 
down a very low, or no, detectable level of FLAG-tagged UBR2 protein over all three 
independent repeats, as observed with the wild type UBR2 protein. 
The FLAG-UBR2-T1D118A protein is able to bind TII peptides to a similar level as that observed 
with wild type UBR2, but there is very minimal detectable interaction with TI peptides over 
three independent repeats (Fig. 5.3B). Therefore, the D118 residue is important to the ability 
of the UBR2 UBR box to bind Type I peptides, as has been previously observed in UBR1 (T 
Tasaki et al. 2009), but the UBR box itself is intact and able to recognise a Type II substrate. 
Finally, the FLAG-UBR2-T2D233A mutant protein has no detectable interaction with TII 
peptides over three independent repeats, although this is a highly detectable interaction when 
using the wild type protein (Fig. 5.3C). As discussed above, the TI peptide recognition is low 
and difficult to detect in in vitro UBR2 studies and so it is difficult to assess whether the 
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FLAG-UBR2-T2D233A mutation affects TI binding. However, as loss of the N-domain in UBR1 
has been shown to maintain UBR box functionality in binding to TI substrates (T Tasaki et 
al. 2009), and the sequences of the UBR box, N domain and surrounding regions of UBR1 and 
UBR2 are highly conserved (T Tasaki et al. 2005), I assumed that the D233A mutation does 
not affect UBR box structure and any potential Type I ability of UBR2 is unaffected. 
In vitro peptide pulldown studies for these point mutations in UBR1 show similar results; 
Ubr1D118A prevents detectable binding to Type I peptides, and Ubr1D233A prevents Type II 
binding (T Tasaki et al. 2009). Therefore, the conserved structure between the two proteins 
appears to translate to conserved functional residues between the two proteins in the UBR 
box and N-domain, and these residues are important for N-end Rule function as I 
hypothesised. In contrast to UBR1, UBR2 has a particular affinity, at least in in vitro pulldown 
assays for Type II peptide recognition, although there are known Type I substrates of UBR2 




Figure 5.3 – The UBR2-T1 and UBR2-T2 mutations prevent detectable substrate binding. 
A. Sequences of peptides chemically conjugated to resin beads used in a peptide pulldown assay. 
N-terminal residues R, F or G are Type I, Type II or negative control peptide sequences, 
respectively. B. Western blots showing 3 independent repeats of a peptide pulldown after 
overexpression of UBR2-T1 (D118A) in Hek293T cells. I, input protein. TI, Type I (arginine). TII, 
Type II (phenylalanine). –ve, negative (glycine, stabilising) control. Probed using anti-FLAG M2 
antibody for the N-terminally FLAG tagged UBR2 protein. * indicates a possible isoform of the 
UBR2 protein. C. Western blots showing 3 independent repeats of a peptide pulldown after 





Type I (TI) RIFSTDTGPGGC Arginine (R) 
Type II (TII) FIFSTDTGPGGC Phenylalanine (F) 
-ve control GIFSTDTGPGGC Glycine (G) 
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Although there are detectable changes in protein binding ability when the Ubr2-CDS FLAG 
point mutant constructs are overexpressed in HEK293T cells, there is no evidence that these 
mutant proteins are still functional in any pathway aside from their targeted substrate 
binding. Therefore, I next aimed to validate that, although they have impaired N-end Rule 
activity, the FLAG-UBR2-T1D118A and FLAG-UBR2-T2D233A mutant proteins are still 
functional outside their N-end Rule substrate binding. One of the only other validated 
molecular functions of UBR2 is its stoichiometric interaction with TEX19.1 (J Reichmann et 
al. 2017), and so I overexpressed the FLAG-tagged plasmid constructs alongside a GFP-tagged 
TEX19.1 plasmid (pCAAGS-Tex19.1-GFP), which was previously generated in our lab, in 
HEK293T cells and performed co-immunoprecipitation with FLAG-M2 beads to pull down 
the UBR2 protein, and any interacting proteins. 
Wild type UBR2 (Fig. 5.4A and B, FLAG coIP, lane 1) pulls down GFP-TEX19.1, as has been 
previously observed, but not to GFP alone (Fig. 5.4A and B, FLAG coIP, lane 2). Both FLAG-
UBR2-T1D118A (Fig. 5.4A, FLAG coIP, lane 3) and FLAG-UBR2-T2D233A (Fig. 5.4B, FLAG coIP, 
lane 3) also co-immunoprecipitate with GFP-TEX19.1. As in the wild type UBR2, GFP 
expressed alone does not pull down with either T1 or T2 versions of UBR2 (Fig. 5.4A, FLAG 
coIP, lanes 2 and 4). As a final control, coexpression of the pCMV10 FLAG construct alone 
with GFP-TEX19.1 (pCAAGS) does not pull GFP-TEX19.1 down (Fig. 5.4A, FLAG coIP, lane 
5) and so I was able to conclude that the interactions observed between both wild type and 
either T1 or T2 mutant UBR2 and TEX19.1 are due to a specific interaction of the proteins 
themselves. 
In this section, using both peptide pulldown assays and coimmunoprecipitation with known 
interactor TEX19.1, I was able to show that that these specific point mutations within UBR2 
are functionally conserved from UBR1 and are successfully able to perturb its canonical 
substrate binding abilities, via either Type I (Arg) or Type II (Phe) N-end Rule binding. These 
do not deter UBR2 from other functions, such as its interaction with TEX19.1, which is 
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thought to be important for regulation of UBR2’s Type II N-end Rule binding ability (J 
Reichmann et al. 2017). Therefore, these point mutations are ideal tools to separate out the 





















 proteins are functional outside the 
N-end Rule 
A. Representative Western blot of co-immunoprecipitation with FLAG-M2 beads, after 
coexpression of either wild type FLAG-UBR2 or FLAG-UBR2-T1
D118A
 (pCMV10-Ubr2-FLAG or 
pCMV10-Ubr2-T1-FLAG) with GFP-TEX19.1 (pCAAGS-Tex19.1-GFP). Controls: FLAG and GFP 
are the pCMV10-FLAG and pCAAGS-GFP transfected to ensure no crossreaction of the tags with 
proteins of interest. Probed using anti-FLAG M2 antibody for the N-terminally FLAG tagged 
UBR2 protein and anti-GFP antibody for the GFP-tagged TEX19.1 protein. * Indicates other 
isoforms of the UBR2 protein. B. Representative western blot of co-immunoprecipitation of either 
wild type FLAG-UBR2 or FLAG-UBR2-T1
D118A






Input  FLAG coIP  
UBR2-FLAG + + – – – –  + + – – – – UBR2-FLAG 
UBR2-T1-FLAG – – + + – –  – – + + – – UBR2-T1-FLAG 
FLAG – – – – + –  – – – – + – FLAG 
TEX19.1-GFP + – + – + –  + – + – + – Tex19.1-GFP 









Input  FLAG coIP  
UBR2-FLAG + + – – – –  + + – – – – UBR2-FLAG 
UBR2-T2-FLAG – – + + – –  – – + + – – UBR2-T2-FLAG 
FLAG – – – – + –  – – – – + – FLAG 
TEX19.1-GFP + – + – + –  + – + – + – Tex19.1-GFP 









































5.2.2 Generation and validation of a Ubr2-T2D233A mouse line using CRISPR-Cas9 
As discussed in section 5.1, the major detectable role for UBR2 in the N-end Rule is in the 
recognition and binding of Type II N-terminal degrons. The protein has a very low detectable 
binding to Type I degrons, and this is generally assumed to be the role of other coexpressed 
UBR proteins. The essential functions of UBR2 are hypothesised to act through the Type II 
pathway, and so I surmised that the best way to begin investigation of the molecular basis of 
these phenotypes would be to prevent function of UBR2 in the Type II N-end Rule, by 
introduction of the D233A point mutation. 
In order to generate a Ubr2-T2D233A mouse line, I utilised CRISPR-Cas9 technology. In order to 
introduce a specific point mutation into this locus, I used wild type Cas9 for generation of 
double-strand breaks (Cong et al. 2013) and a homology directed repair (HDR) template, 
which can be introduced into the break site by recombination (Fig. 5.5A). The repair 
templates were designed as such that either the wild type sequence or the D233A point 
mutation could be integrated, with a mutant PAM site in both to prevent re-editing after 
repair template integration (Fig. 5.5B). Ubr2-/- males are infertile and therefore I used both a 
wild type and mutant repair template to reduce the efficiency of editing with the mutant 
repair and ensure that heterozygote mice are generated for further breeding and colony 
establishment. These were injected into the cytoplasm of single-celled mouse zygotes 
alongside an RNA guide sequence specific to a region within 20bp of the target residue, with 
a PAM sequence on the 3’ end – this is an NGG motif that aids in binding of the Cas9 
machinery. (Fig. 5.5C). 
After injection, zygotes were transferred into a surrogate mother in the CD1 background (Fig. 
5.5C), and the pups born were screened at weaning (3 weeks pp) for successful integration of 
the repair templates. 9 individuals were successfully born following one round of zygote 
injections and genotyped as in Fig. 5.6. Of these individuals, 5 had undergone active genomic 
editing, but only 3 of these mice were identified as being heterozygote for the mutant allele 
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(30% successful editing). However, these were all heterozygote against mosaic or offtarget 
mutant alleles, and not wild type Ubr2, and so one round of breeding with wild type C57BL/6J 
mice was carried out in order to generate 50% true heterozygote offspring, which were then 
bred together to give a stable heterozygous mouse colony (Fig. 5.5C), expected to produce 25% 













Figure 5.5 – Generation of a Ubr2
D233A
 mouse line using CRISPR-Cas9. 
A. Schematic of CRISPR-wtCas9 homology directed repair. Adapted from 
www.addgene.org/crispr/guide/. B. CRISPR-HDR guide and repair sequences for the UBR2-T2 
CRISPR experiment. PAM sequence is shown in bold and cut site of wtCas9 enzyme marked by 
^. Introduced point mutations are marked in repair templates in green. Homology arms are 
underlined. C. Schematic representation of zygotic injection of CRISPR components and breeding 
strategy for Ubr2
D233A 
mouse colony establishment. Components were introduced by injection into 
the cytoplasm of the single-celled zygote, then cultured and transferred into a CD1 host mother. 
Pups born were on the C57BL/6J background and were genotyped as being heterozygote for the 
D233A mutation against indel or mosaic Ubr2 alleles. These were bred with C57BL/6J wild type 
mice and the 50% heterozygote Ubr2
+/T2
 offspring were then crossed together to produce an 
expected 25% Ubr2
T2/T2
 experimental mice, with 25% Ubr2
+/+
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All subsequent colony genotyping was carried out using tetra-primer ARMS-PCR, which 
depends on the binding ability of a pair of inner primers that overlap at their 3’ end over the 
point mutant (Fig. 5.6A). The forward and reverse outer primers act to amplify with either 
one or both inner primers, and also generate a control PCR product that encompasses the 
mutated region and controls for a successful PCR and any unintentional indels in the 
CRISPR-Cas9 site. (S. Ye et al. 2001; Medrano and De Oliveira 2014). Mice generated from 
heterozygote (Ubr2+/T2 X Ubr2+/T2) crosses were genotyped in this way and then assayed by gel 
electrophoresis (Fig. 5.6B). The outer control fragment gives a PCR product at 476bp, present 
in all mice genotyped here. Wild type mice (Ubr2+/+) 2899 and 2900 also have a PCR product 
at 242bp, and D233A mutants 2895, 2896 and 2899 (Ubr2T2/T2) have a PCR product at 292bp. 
Heterozygote mice 2897 and 2901 (Ubr2+/T2) have both smaller bands, as both C and A alleles 
are present. 
These genotypes can be confirmed using Sanger sequencing of the 476bp outer fragment (Fig. 
5.6C). Wild type Ubr2+/+ mouse 2899 has the Asp-encoding (D) GAT codon, and a wild type 
PAM site (AGG), as the heterozygotes generated from zygotic CRISPR injection were crossed 
to unedited wild type C57BL/6J mice. Ubr2T2/T2 mouse 2895 has the Ala-encoding (A) GCT 
codon and a silently mutated PAM site (AAG). 
Using these genotyping tools, I was able to generate and maintain a stable mouse line with 
the Ubr2-T2D233A mutation. For all further experiments in this chapter, Ubr2T2/T2 experimental 
mice were generated from heterozygote (Ubr2+/T2 X Ubr2+/T2) crosses, and all control animals 

























Figure 5.6 Genotyping of Ubr2
D233A
 mouse colony using tetra ARMS-PCR 
A. Schematic of tetraARMS-PCR, used for screening and genotyping of mice. Green are outer 
primer pair, which amplify the outer control band. Blue are inner primers, which bind specifically 




heterozygous cross, showing tetraARMS-PCR products for T2 genotyping. 100kb ladder shown 
on left. Control  (outer primer) band is 476bp. Wild type A allele band is 242bp and UBR2-T2 C 
allele band is 292bp. 4-digit labels indicate mouse codes. C. Representative Sanger sequencing 
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My previous work to validate the D233A point mutant in UBR2 (Fig. 5.3C and 5.4B) showed 
that this is a key residue in the UBR2 N-domain, and the protein is unable to carry out 
detectable binding to Type II substrates, although the whole protein, particularly the UBR 
box, appears to be intact and functional, and able to interact with the protein TEX19.1. 
However, in an in vivo context, the D233 residue may not be as vital for Type II substrate 
binding as appears in vitro. Therefore, in order to validate the functional capabilities of the 
UBR2-T2 protein, I carried out in vitro peptide pulldown assays as in section 5.2.1 using whole 
testis in vivo-expressed protein extract to ascertain that the D233A point mutation is also vital 
for Type II N-end Rule binding in the endogenous UBR2 protein. 
For this peptide pulldown, I incubated whole testis protein extract from male mice at 8-10 
weeks pp with resin conjugated to either Type I, Type II or negative control peptides as in 
section 5.2.1 (Fig. 5.3). I then probed this for endogenous UBR2 protein in a Western blot 
assay (Fig. 5.7). UBR2 protein can be detected in input lanes and in the Type II pulldown 
lanes for Ubr2+/T2 controls. Importantly, although UBR2-T2 protein is readily detectable in the 
input samples, and appears to be stable at around 210kDa, similar to the wild type UBR2 
protein, there is no detectable UBR2-T2 pulled down by Type II (phenylalanine-containing) 
peptides from Ubr2T2/T2 testis protein extract. Either UBR2 or UBR2-T2 protein cannot be 
detected in either Type I pulldown lanes or negative control lanes for either genotype. This 
demonstrates that endogenous UBR2D233A is a stably expressed protein, as it is readily 
detectable in input samples, but has lost Type II binding ability and so will not be able to 
carry out UBR2 Type II N-end Rule functions. 
In this section I showed the design and implementation of a CRISPR-Cas9 HDR experiment 
to generate a successful Ubr2-T2D233A mouse line. Introduction of the point mutation D233A in 
vivo results in a loss of detectable Type II substrate peptide binding ability, as I observed in 
section 5.2.1 in vitro (Fig. 5.3C), and so this mouse line can be used to study the Type II N-end 
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Figure 5.7 – The Ubr2
D233A
 mutation prevents detectable Type II N-end Rule substrate 
binding in vivo. 
Peptide pulldowns with Ubr2
T2/T2
 testis protein extract, as compared to Ubr2
+/T2 
control testis, 
probed with an antibody against endogenous UBR2 protein. Peptides have N-terminal residues R 
(TI), F (TII) or G (-ve), which confer specificity for the Type I and Type II N-end Rule pathways, 
or act as a stabilising negative control, respectively. 
 
 
5.2.3 Phenotyping of the Ubr2-T2D233A mouse line 
5.2.3.1 Ubr2’s role in trophoblast-derived placental development is not a Type II 
function 
One of the most initially obvious phenotypes of the Ubr2-/- mouse is an 
underrepresentation of female Ubr2-/- animals born from heterozygote (Ubr2+/- X 
Ubr2+/-) crosses, which is described in detail in Chapter 4. In addition to this 
observation in our own Ubr2 null colony, which is on a C57BL/6J inbred background, 
this female-specific lethality has been documented to varying penetrance, depending 
on the genetic background, by Kwon et al. 2003. This lethality is associated with a 
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size defects in both males and females (Chapter 4). Ubr2-/- embryos are around 80% 
of Ubr2+/+ littermate size at E18.5, which is 1-2 days before parturition, and the 
placenta at this stage is around 70% of Ubr2+/+ littermates’ placental weight (Chapter 
4). 
In order to assess whether Ubr2’s role in female survival acts through the Type II 
substrate binding ability of UBR2 protein, I assessed the proportions of mice born in 
the Ubr2-T2D233A mouse colony as a result of heterozygote (Ubr2+/T2 X Ubr2+/T2) crosses, 
genotyping as described in section 5.2.2, Fig. 5.5C and Fig. 5.6. Crosses between 
Ubr2+/T2 mice are expected to generate 25% Ubr2+/+, 50% Ubr2+/T2 and 25% Ubr2T2/T2 
animals, with half of the pups expected to be male and half expected to be female (Fig. 
5.8A). At weaning (3 weeks post-partum, pp), Ubr2T2/T2 mice represent 22% of pups 
born (65 of 295 total mice genotyped) over 35 litters, and heterozygote and wild type 
littermates make up 53% and 25% of pups, respectively (Fig. 5.8B). This does not 
significantly deviate from the expected Mendelian ratio of pups from these crosses 
(p=0.6318, χ2 test). There is no immediately obvious lethality in the Ubr2T2/T2 mice, as 
was observed in Ubr2-/- mice at 3 weeks pp on the same genetic background 
(C57BL6/J), Chapter 4. 
The Ubr2-/- lethality has been observed to be female-specific in the majority of genetic 
backgrounds that a Ubr2-/- has been generated on (Y T Kwon et al. 2003), but of the 
295 mice genotypes, there are 152 females and 143 males, which does not deviate from 
the expected 1:1 ratio of female:male pups (p=0.6810, χ2 test). Female Ubr2T2/T2 mice 
represent 23% of all female mice genotyped over these 35 litters (34 of 152 females), 
and heterozygote and wild type females make up 53% and 24%, respectively (Fig. 
5.8B). This is, again, not significantly different from the proportion of female mice that 
were expected (p=0.8209, χ2 test). Finally, male Ubr2T2/T2 mice represent 22% of all 
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male mice in these 35 litters (31 of 143 males genotyped), and heterozygote and wild 
type males make up 53% and 25%, respectively (Fig. 5.8B) – this is also not a 
significant change in proportion of genotypes as was expected from Ubr2+/T2 X Ubr2+/T2 
crosses (p=0.7622, χ2 test). 
Therefore, there is no lethality in Ubr2T2/T2 females, as has been observed in the Ubr2-/- 
genotype, and so I concluded that UBR2 Type II N-end Rule ability is not required 




























 crosses produce offspring in Mendelian ratios 
















) crosses in the T2 colony; all mice, and split into males and females. 
Statistical testing carried out using χ
2 


































As there is no definite causal relationship between embryonic growth restriction and 
lethality detected post-partum, the placental defects or embryonic growth restriction 
observed in the Ubr2-/- E18.5 embryo (Chapter 4) may still act through UBR2’s Type 
II binding ability. It should be noted that the Ubr2-/- phenotype is variably penetrant 
and so a partial placental defect may not be reflected in a breeding assay alone. 
In order to assess the molecular basis of UBR2’s role in placental development, I 
dissected embryos at E18.5 from heterozygote Ubr2+/T2 X Ubr2+/T2 crosses and weighed 
the embryos and placentas, as in Chapter 4. The Ubr2-/- phenotype at this stage can be 
observed by eye; both male and female Ubr2-/- embryos are morphologically normal 
but are noticeably smaller than littermates. However, Ubr2T2/T2 embryos, while also 
grossly normal in morphology, do not have an obvious size defect when compared to 
both littermate Ubr2+/+ and Ubr2+/T2 controls (Fig. 5.9A). The embryo weights reflect 
this observation (Fig. 5.9B); the mean combined head and body weight of Ubr2T2/T2 
embryos is 1082.13±29.9mg (± standard error), and that of Ubr2+/+ littermates is 
1096.42±30.1mg, measured over 4 litters of E18.5 animals – this is not a statistically 
significant change (p=0.7394, Student’s T-test). Ubr2+/T2 embryos have a mean 
combined weight of 1114.99±38.7mg, which is again not significantly different from 
either wild type or Ubr2T2/T2 littermates (p=0.7058 and p=0.5083 respectively, Student’s 
T-test). Thus, there is no detectable growth restriction in Ubr2T2/T2 embryos at this 
stage of development. 
The mean placental weight of a Ubr2T2/T2 E18.5 embryo is 92.49±4.7mg (± standard 
error), and that of Ubr2+/+ littermates over 4 litters is 86.38±3.8mg – this is not a 
significant change in weight (p=0.3196, Student’s T-Test). The placenta of Ubr2+/T2 
embryos have a mean weight of 90.13±2.3mg, which is again not significantly different 
from either wild type or Ubr2T2/T2 littermates’ placental weight (p=0.4181 and p=0.6558 
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respectively, Student’s T-test). This led me to the conclusion that placental 
development is not regulated by Ubr2’s role in the Type II N-end Rule pathway, but 
instead through a different molecular function of UBR2. 
Taken together, the 3 week pp breeding ratios and E18.5 embryonic and placental 
weights indicate that neither the female-specific lethality or the placental defect and 
embryonic growth restriction that I, and others (Y T Kwon et al. 2003), have observed 



























 E18.5 embryos do not exhibit a growth or placental defect 
A. Representative images of littermate embryos from heterozygote pairs before decapitation, 
showing no gross morphological defects. Scale bar is 500µm B. Weights (mg) of E18.5 embryos 
over 4 litters from Ubr2
+/T2 
mating pairs. Littermate wild type (+/+, n=13), heterozygote (+/T2, n=12) 
and homozygotes (T2/T2, n=12). Due to Home Office regulations, these are combined head and 
body weights of decapitated embryos. Black bar is mean weight. C. Weights (mg) of placentas 
from E18.5 embryos, as in B. Black bar is mean weight.  











B                       E18.5 Embryo Weights                 C             E18.5 Placenta Weights 
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5.2.3.2 There are no gross infertility phenotypes observed in a Ubr2T2/T2 male mouse 
One of the most well characterised phenotypes of a Ubr2-/- mouse, both in our group 
(Crichton et al. 2017) and by others (Y T Kwon et al. 2003; Yang et al. 2010; J Y An et 
al. 2010), is the role of Ubr2 during spermatogenesis. UBR2 stabilises TEX19.1 protein, 
resulting in undetectable TEX19.1 in the Ubr2-/- testes (Yang et al. 2010) and at least a 
partial phenocopy of the Tex19.1-/- males, which have a partial meiotic arrest at 
prophase I, resulting in infertility (Crichton et al. 2017). This regulation of meiotic 
recombination is hypothesised to be a function of the Type II N-end Rule pathway (Y 
T Kwon et al. 2003; Yang et al. 2010), and TEX19.1 is thought to act as a cofactor in 














Figure 5.10 TEX19.1 protein is stable in the Ubr2
T2/T2
 testis 
Western blotting assay for TEX19.1 (~40kDa) and loading control Lamin B1 (~80kDa) in testis 




control animals. * are non-specific bands. 
 
The UBR2-T2 protein is still able to bind ectopically expressed TEX19.1 in an 
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investigate the stability of endogenous TEX19.1 in the Ubr2T2/T2 testis, I isolated whole 
testis protein extract and carried out Western blotting to assess the level of TEX19.1 
protein present in the testis of Ubr2T2/T2 and age matched Ubr2+/+ males (Fig. 5.10). The 
TEX19.1 protein is expected to be around 40kDa (Uniprot Q99MV2) and is observed 
in both Ubr2T2/T2 and Ubr2+/+ testis protein extracts, alongside Lamin B1 as a loading 
control protein. Therefore, endogenous TEX19.1 protein is stable in presence of 
UBR2-T2 protein, and this will be a useful mouse model to test whether the UBR2-
TEX19.1 interaction itself is essential for spermatogenesis, or if UBR2 is acting 
through its Type II ability in prophase I progression. 
In order to investigate the role of UBR2 Type II N-end Rule function in male fertility, 
I dissected mouse testes from Ubr2+/+ and Ubr2T2/T2 males between 8 and 10 weeks old 
and assessed the weight. We have previously reported a 67.6% reduction in testis 
weight between Ubr2+/+ and Ubr2-/- males, and an undetectable level of sperm isolated 
from the epididymis of Ubr2-/- testes (Crichton et al. 2017). In this study, the average 
weight of each testis in a Ubr2+/+ male is 85.0±2.8mg (± standard error), and Ubr2T2/T2 
testes are 83.7±4.7mg; these are not significantly different in size (Fig. 5.11A, p=0.83, 
Student’s T-test). The average testis weight of heterozygous Ubr2+/T2 males is 
76.6±2.7mg, which is not significantly smaller than either wild type or T2 testes 
(p=0.08 and p=0.39 respectively, Student’s T-tests). This indicates a lack of gross 
fertility phenotypes in the Ubr2T2/T2 male. 
To investigate the Ubr2T2/T2 testes in more detail, I dissected the epididymis of each 
testis from these mice and performed sperm counts using a haemocytometer. I 
calculated an estimated mean of 11.9x106±1.1x106 cells/ml mature sperm produced by 
a Ubr2+/+ testis, and an estimated mean of 10.3x106±1.4x106 cells/ml produced by a 
Ubr2T2/T2 testis. The difference between these counts are not statistically significant 
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(Fig. 5.11B, p=0.46, Student’s T-test). Mean sperm counts in the Ubr2+/T2 testis were 
9.7x106±2.3x106cells/ml, which again are not statistically significantly deviated from 
either Ubr2+/+ or Ubr2T2/T2 sperm counts (p=0.40 and p=0.83 respectively, Student’s T-
tests). The sperm counted in this assay were generally motile and had a normal 
morphology, and so the Ubr2T2/T2 males do not have any overt defects in 
spermatogenesis, which are clearly detectable in the Ubr2-/- testis. 
Finally, to assess the Ubr2T2/T2 testis morphology in more detail, I performed tissue 
sections and stained with H&E to look at the seminiferous tubules (Fig. 5.11C). 
Spermatogenesis occurs within each seminiferous tubule and as spermatocytes 
develop and go through meiosis, they advance towards the lumen, which is the centre 
of the tubules in these sections. This is therefore a useful assay to look at the different 
stages of meiosis and ascertain an estimated stage of meiosis in which any cell death 
or morphological changes may occur. Ubr2-/-seminiferous tubules have an 
accumulation of zygotene-like arrested cells and absence of round and elongated 
mature spermatids, indicating a meiotic arrest and cell death, observed as large spaces 
in the seminiferous tubule lumen (Crichton et al. 2017). There are no clear 
morphological defects in the Ubr2T2/T2 sections as compared to Ubr2+/+ testes, and both 
round and elongated spermatids exist in the seminiferous tubules examined here. 
Therefore, there is no grossly overt male meiotic arrest in the Ubr2T2/T2 testis. 
Taken together, the data presented in this section shows that Ubr2T2/T2 males do not 
grossly phenocopy the overt spermatogenesis defects seen in Ubr2-/- males, and so the 
major functions of UBR2 in this tissue do not appear to act through Type II N-end 
Rule substrate binding. TEX19.1 protein is stable, indicating that perhaps the 































 males have no overt defects in spermatogenesis 





) and homozygote D233A mutant (Ubr2
T2/T2
) males at 8 weeks pp. Black bars are means. 
B. Counts of mature sperm from the same males as in (A), isolated from the epididymis. Black bars 





 males. Scale bar is 100µm. ST: seminiferous tubule, L: lumen, arrow 
indicates direction of meiotic progression, black arrowhead: elongated spermatids, white 
arrowheads: round spermatids.  

















C       Ubr2
+/+      
            Ubr2
T2/T2
 







5.2.3.3 The novel role of Ubr2 in cohesin regulation does not act through Type II N-
end Rule 
We have previously shown that Ubr2 has a role in splenocytes (J Reichmann et al. 
2017) and oocytes (Chapter 3) in the regulation of the AcSMC3-containing 
subpopulation of cohesin complexes, which is thought to mediate sister chromatid 
cohesin. In     Ubr2-/- splenocytes, chromatin-associated AcSMC3 increases, whereas 
in Ubr2-/- oocytes it decreases. Importantly, Ubr2 specifically regulates AcSMC3-
containing cohesin complexes, which is a relatively minor population of cohesin in 
cells, and specific effects on this population typically do not cause detectable changes 
in the abundance of other cohesin subunits, such as total SMC3. 
In order to investigate if this role of Ubr2 is perturbed in the Ubr2T2/T2 mutant mouse, 
I first looked at the level of chromatin-associated cohesin levels from splenocytes 
isolated from the Ubr2T2/T2 spleen. Chromatin preparation from the Ubr2-/- spleen 
exhibits a ~2-fold increase in AcSMC3, and no detectable change in SMC3 or other 
cohesin subunits (J Reichmann et al. 2017). I assayed the level of total chromatin-
associated cohesin in the Ubr2T2/T2 spleen using the SMC3 subunit, which is present 
in all cohesin complexes, and the AcSMC3 subpopulation, by Western blotting of 
chromatin prepared from the spleens of 3 independent mice (Fig. 5.12A). Upon 
quantification of the intensity of Western blot protein bands, normalised to the 
intensity of chromatin-associated histone H3 protein detected in these samples, I was 
unable to detect a significant change in either SMC3 or AcSMC3 protein levels (Fig. 
5.12B, p=0.7172 and p=0.6515 respectively, Student’s T-Test). This implies that UBR2 
acts to regulate mitotic AcSMC3 cohesins through a molecular pathway other than 



























Figure 5.12 Mitotic cohesin regulation is not perturbed in the Ubr2T2/T2 mouse 
A. Representative western blots of chromatin-associated proteins SMC3 and AcSMC3 
isolated from spleens of wild type (+/+) and homozygous D233A mutant (T2/T2) mice, and 
chromatin-associated histone H3 protein as a loading control. B. Quantified mean protein 
levels of SMC3 and AcSMC3 from western blotting in A, corrected against histone H3 protein 
level, and relative to the wild type mean. Standard error over three pairs of wild type and 
homozygous mutant mice shown. Differences between wild type and T2/T2 are not 
significant; SMC3: p=0.72, AcSMC3: p=0.65 (Student’s T-test).  









































































As well as a mitotic role for UBR2 in cohesin regulation, in Chapter 3 I outlined a role 
for UBR2 in regulation of the AcSMC3 cohesin subunit during female meiosis; in the 
Ubr2-/- prometaphase I oocyte, AcSMC3 is significantly decreased by around 40% (Fig. 
3.1, Chapter 3), implying a protective role of UBR2 for cohesin in this cell type. This 
contrasts with the decrease in chromatin-associated AcSMC3 in the mitotic spleen 
or in embryonic stem cells (ESCs) and so it appears to be an oocyte-specific role of 
UBR2. 
In order to assess whether the meiotic cohesin regulatory function of Ubr2 is 
perturbed by the Ubr2T2/T2 mutation, I isolated metaphase I oocytes from Ubr2T2/T2 and 
Ubr2+/+ age-matched females by superovulation and carried out AcSMC3 and SMC3 
immunofluorescence and quantification against ACA (anti-centromeric antibody) 
signal, as described in Chapter 3. Both AcSMC3 and SMC3 are detectable along the 
chromosome axis of metaphase I bivalents which are visualised using a DAPI DNA 
stain, in Ubr2T2/T2 and Ubr2+/+ controls (Fig. 5.13A, 5.14A). 
In the Ubr2T2/T2 oocyte, the mean corrected AcSMC3 protein level is 105% of wild type 
protein level, which is not a significant change in protein level (Fig. 5.13B, p=0.89, 
Student’s T-test). Ubr2T2/T2 SMC3 intensity, as an indicator of total chromatin-bound 
cohesin, is 111% of wild type level, which again is not a significant change (Fig. 5.14B, 
p=0.51, Student’s T-test). This implies that the AcSMC3-specific cohesin regulatory 



































Figure 5.13 (previous page) 
UBR2’s role in meiotic AcSMC3 regulation is not perturbed in Ubr2T2/T2 oocytes 
A. Representative prometaphase I oocyte chromosome spreads from wild type (+/+) and 
homozygous D233A mutant (T2/T2) female mice, aged 9-14 weeks, with immunofluorescent 
staining for centromeric proteins (ACA/CREST antibody) in green and AcSMC3 in red, and 
DAPI in blue to mark DNA. Scale bars are 10µm. Inset images show an individual bivalent in 3-
colour (left) and the AcSMC3 alone (greyscale, right) along chromosome axes.  B. Median nuclear 
intensity of chromosome axial AcSMC3 protein, relative within each bivalent to ACA signal 
and each nucleus corrected to the wild type mean nuclear intensity within each biological 










Figure 5.14 (next page) 
UBR2’s role in total meiotic cohesin regulation is not perturbed in Ubr2T2/T2 oocytes 
A. Representative prometaphase I oocyte chromosome spreads from wild type (+/+) and 
homozygous D233A mutant (T2/T2) female mice, aged 9-14 weeks, with immunofluorescent 
staining for centromeric proteins (ACA/CREST antibody) in green and SMC3 in red, and 
DAPI in blue to mark DNA. Scale bars are 10µm. Inset images show an individual bivalent in 3-
colour (left) and the SMC3 alone (greyscale, right) along chromosome axes.   B. Median nuclear 
intensity of chromosome axial SMC3 protein, relative within each bivalent to ACA signal and 
each nucleus corrected to the wild type mean nuclear intensity within each biological repeat. 






























As AcSMC3 protein intensity is not directly linked to chromosome cohesion, in order 
to confirm that the Ubr2T2/T2 allele does not perturb this in post-natal oocytes, I next 
assessed cohesion along the chromosome arms of metaphase I oocytes by quantifying 
the number, proportion and position of chiasmata in Ubr2T2/T2 metaphase I oocytes 
(Fig. 5.15A), as in Chapter 3. 
As quantified in Chapter 3, a mean of 28.2 chiasmata were observed in a Ubr2-/- 
metaphase I nucleus, as compared to a mean of 27.4 in a control Ubr2+/+ nucleus. In a 
Ubr2T2/T2 metaphase I nucleus, the mean number of chiasmata is 26.6±0.6 (± standard 
error), which is not a significant deviation from the mean of 27.9±1.1 observed in 
Ubr2+/+ oocytes isolated from control females from the same colony (Fig. 5.15B, p=0.36, 
Student’s T-test). Proportionally, in Chapter 3, a Ubr2-/- metaphase I nucleus contains 
a mean of 41.7% of bivalents with a single chiasma, and 58.3% with multiple (usually 
two or three). The Ubr2T2/T2 metaphase I oocytes contained 30.5% single-chiasma and 
69.4% multiple-chiasmata bivalents, which is not significantly changed from the wild 
type proportions observed in oocytes isolated from littermate Ubr2+/+ females. 35.4% 
of Ubr2+/+ bivalents assessed contained only a single chiasma, and 64.6% contained 
multiple (Fig. 5.15C, p=0.92, χ2 test). Finally, the Ubr2-/- metaphase I oocyte exhibits a 
positional terminalisation of single chiasmata towards the telomeric end of the 
bivalent; 56.1% of Ubr2-/- single-chiasma bivalents are distal to the centromere, with 
only 5.7% detected in the centromere-proximal third of the chromosome (Chapter 3). 
However, 9.8% of single-chiasma Ubr2+/+ bivalents and 14.4% of Ubr2T2/T2 bivalents 
were observed in the centromeric proximal third of the chromosome. 46.0% and 
42.4%, respectively, were observed in the interstitial third, and 44.2% and 43.3% 
respectively, were observed in the distal, or telomeric, third of the chromosome’s 
length. This is not a significantly altered proportion of chiasma positions between the 
271 
 
Ubr2+/+ and Ubr2T2/T2 oocytes (Fig. 5.15D, p=0.4135, χ2 test). Therefore, the chiasmata 
terminalisation observed in the Ubr2-/- metaphase I oocyte is not detectable with the 
Ubr2T2/T2 allele, and so UBR2’s role in chromosome arm cohesion between sister 












Figure 5.15 (next page) Ubr2
T2/T2 
oocytes do not exhibit defects in chromosome arm 
cohesion 





 females. Inset: representative bivalents with a single or multiple chiasmata, indicated by 





 (blue) Metaphase I oocytes. Mean values shown by black bar. C. Proportion of 
bivalents containing single or multiple chiasmata within each 20-chromosome nucleus. D. 










































































n=257                 n=219 
 








n=166                  n=152 
Single Chiasma Multiple Chiasmata 
+/+           -/- 





Taken together, the data in this section indicates that UBR2’s role in AcSMC3-
containing cohesin regulation, and meiotic chromosome arm cohesin, does not 
depend on its ability to bind Type II N-end Rule substrates. Neither mitotic nor 
meiotic AcSMC3, although affected in opposite directions in the Ubr2-/- mouse, are 
misregulated in the Ubr2T2/T2 mouse. 
 
5.2.3.4 Summary of the Ubr2T2/T2 mouse phenotype 
Generation of the Ubr2D233A mouse line was a tool in which I could begin to separate 
out the functional capacity of UBR2, in its most well characterised molecular 
function: binding to Type II ubiquitination substrates in the N-end Rule pathway. 
However, the three major phenotypes that I and others have identified in a Ubr2-/- 
mouse were are not present in this mouse model, and so my act through another 
molecular function of UBR2. 
 
5.2.4 A stable Ubr2-T1D118A ESC line using CRISPR Cas9 
5.2.4.1 Generation of Ubr2-T1D118A ESCs 
Of the Ubr2T2/T2 mouse phenotypes, the most interesting to my own research is the 
lack of cohesin phenotype in either the spleen or the oocyte. In addition, while 
phenotyping the Ubr2T2/T2 mice, it became apparent that the role of UBR2 in regulating 
cohesin could be modelled in ESCs in culture, which exhibit a specific upregulation 
of AcSMC3 in the Ubr2-/- genotype. Therefore, to further investigate which activities 
of UBR2 might be important for cohesin regulation, I designed a CRISPR-Cas9 
experiment with homology-directed repair (HDR), with the aim to generate a stable 
Ubr2-T1D118A mutant ES cell line, so perturbing the binding of UBR2 to Type I N-end 
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Rule peptides. The D118A point mutation was first identified in an Alanine-scanning 
mutagenesis screen of Ubr1 (T Tasaki et al. 2009), and acts to specifically perturb 
detectable binding of UBR2 to Type I N-end Rule peptides. Earlier in this chapter I 
confirmed that it is both sequence and functionally conserved in the Ubr2 gene, using 
ectopic expression of a FLAG-UBR2 construct in HEK293T cells (Fig. 5.3B and Fig. 
5.4A).  In order to carry out HDR, a dsDNA repair oligo with 50bp homology arms 
encoding the mutant repair template containing both the point mutation and the 
mutant PAM sequence was cotransfected into E14 ESCs alongside a Cas9 expressing 
plasmid and pX330 plasmid with the specific guide sequence cloned into it (Fig. 
5.16A). These cells were transfected and clonal colonies picked by Fiona Kilanowski 
(MRC HGU), and I carried out genetic screening to identify successfully edited 
clones. 
For screening of successfully edited stable Ubr2-T1D118A clones, I designed tetra-ARMS 
(amplification-refractory mutation system) PCR genotyping assays, as utilised for 
genotyping of Ubr2D233A mice and described in section 5.2.2 (Fig. 5.16B). I screened the 
PCR reactions by gel electrophoresis (Fig. 5.16C). The control band is at 363bp; the 
F10 clone was identified as a heterozygote, and the H10 clone was one of three 
successfully edited homozygous D118A clones identified from a 96-clone screen (3% 
success rate); the other two successful clones were designated H5 and E11. I then 
validated these clones by Sanger sequencing of the 363bp outer primer control 
fragment (Fig. 5.16D), which shows the GCC alanine-encoding codon in position 118. 
In order to confirm that Ubr2-T1D118A is still expressed at a wild type level and the 
protein is stable, I carried out Western blotting to detect endogenously expressed 
UBR2 levels (Fig. 5.16D). The three ESC clones H5, H10 and E11 were probed for 
UBR2 protein and Lamin B1 as a loading control, alongside E14 wild type ESCs (+/+). 
UBR2 protein is detectable in wild type E14 (+/+) cells, and in the two clones H5 and 
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H10. However, the E11 clone has no detectable UBR2 protein, although Sanger 
sequencing data of the 363bp outer tetraARMS fragment shows a normal sequence 
immediately around the CRISPR targeted region and successful introduction of the 
GAC->GCC point mutation and silent PAM site mutation. I took this to mean that 
there is an off-target mutation that destabilises the UBR2 protein, and therefore the 
E11 clone was unusable as a Type I N-end Rule mutant cell line. 
The H10 clone has a successfully incorporated GCC point mutation at position D118A, 
and there is near-wild type levels of UBR2 protein detected and so, for the remainder 
of this section, I use this as a stable Ubr2-T1D118A ES cell line to assess the role of UBR2’s 






Figure 5.16 (next page) Ubr2-T1
D118A 
mutant ES cell line screening 
A. DNA guide and repair template sequences for CRISPR. Green: point mutations introduced, 
both for D118A mutation and mutant PAM site. Bold: antisense PAM site used B. Schematic of 
tetraARMS-PCR, used for screening and genotyping of ESC clones during UBR2-T1 cell line 
generation. Outer primer and inner primer pairs. C. Representative gel electrophoresis showing 
tetraARMS-PCR products for T1 clone genotyping. 100kb ladder shown on left. Control (outer 
primer) band is 363bp. Wild type A allele band is 235bp and UBR2-T1 C allele band is 180bp. 
Successful clone H10 shown by *. D. Sanger sequencing data for the successful Ubr2-T1
D118A
 (H10) 
ESC clone (GAC->GCC). E. Protein levels of UBR2 using Western blotting in 3 Ubr2-T1
D118A 
clones, 
wild type E14 and Ubr2
-/-
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5.2.4.2 Ubr2-T1D118A ESCs exhibit no cohesin misregulation 
In order to investigate whether the D118A mutation, which is predicted to affect 
binding to Type I substrates, perturbs the ability of UBR2 to regulate cohesin, I 
measured the level of chromatin-bound cohesin protein present in a G2/M-enriched 
cell population. I carried out synchronisation of wild type E14 and Ubr2-T1D118A cells 
to enrich a minimum of 60% of cells into G2/M. To do so, I used a double thymidine 
block (Fig. 5.17A) – in which the two cell lines were treated with 1.25mM thymidine, 
a drug that arrests the cell cycle at S phase. A FACS (fluorescence-associated cell 
sorting) plot of PI-stained (propidium iodide) cycling ES cells has two peaks, one at 
G1 and one at G2/M, and a trough that I designated as S-phase. I carried out two 
rounds of thymidine blocking, resulting an a G1/S-boundary arrest (designated DT+0) 
before harvesting cells at DT+4, 4 hours after release from the second thymidine block, 
where cells were enriched in G2/M (Fig. 5.17B). I thresholded this enrichment at a 






























Figure 5.17 ES cell synchronisation to a G2/M-enriched population 
A. Cell treatment timeline for double thymidine block of ES cells. Cells were transferred into 
GMEM+serum/LIF with 1.25mM thymidine at 26h and 48h after treatment, with a release at 43h 
and 65h respectively. B. FACS profiles for cycling ES cells, and at timepoints DT+0 and DT+4 for 
wild type (E14, +/+) and H10 (Ubr2-T1
D118A
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In order to isolate chromatin-bound cohesin molecules, I carried out chromatin 
preparation on harvested DT+4 cells. Using Western blotting, I looked at the protein 
levels of total SMC3 (Fig. 5.18A) and AcSMC3 (Fig. 5.18B). I quantified the level of 
each of these proteins, relative to the level of histone H3 present in each sample over 
3 independent repeats, and showed that there is a no significant change in the level of 
AcSMC3 in the Ubr2-T1D118A mutant cell line (Fig. 5.18C, p=0.23, Student’s T-test). This 
contrasts with the 2.27-fold increase in AcSMC3 observed in the Ubr2-/- ES cells 
(unpublished data, Karen Dobie, MRC HGU), and the ~2-fold increase observed in 
the spleen of Ubr2-/- mice (J Reichmann et al. 2017). Quantification of total SMC3 also 
shows no significant change in the level of total cohesin bound to chromatin in these 
cells (Fig. 5.18C, p=0.50, Student’s T-test). As cohesin is loaded and unloaded from 
chromatin dynamically throughout the cell cycle, although the mESCs were 
synchronised to a minimum of 60% G2/M enriched cells, there is still a high level of 
variation (standard error) in the cohesin quantified, as has been observed before in 
the Ubr2-/- ESCs (unpublished data, Karen Dobie, MRC HGU).  
The misregulation of AcSMC3 observed in Ubr2-/- ESCs is not reflected in the 
AcSMC3 level in the Ubr2-T1D118A ES cell line. I conclude that UBR2’s role in regulation 
of the acetylated subpopulation of cohesin does not act through the Type I N-end 
Rule pathway. 
Taken together with the data presented in section 5.2.3.3, I have determined that the novel 
role of Ubr2 in cohesin regulation that our group have recently described (J Reichmann et al. 
2017) does not appear to act through either Type I or Type II UBR2 N-end Rule substrate 
binding, as predicted by the N-end Rule binding abilities of the Ubr2D118A and Ubr2D233A alleles 






























Figure 5.18 Chromatin-bound cohesin levels at G2/M are unaffected in Ubr2D118A ESCs 
A. Representative western blotting for chromatin-associated SMC3 and histone H3 protein as a 
loading control, isolated from wild type (WT) E14 and Ubr2-T1
D118A
 synchronised by a double 
thymidine block into G2/M. B. Representative western blotting for chromatin-associated 
AcSMC3 and histone H3 protein, as in A. C. Quantification ± standard error of chromatin-
associated SMC3 and AcSMC3 in Ubr2-T1
D118A 
at G2/M over 3 independent repeats, normalised 
against H3 protein levels and relative to protein levels in wild type (WT) E14 cells. 
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 5.3 Discussion 
In this chapter, I carried out validation and implementation of genetic point mutations in the 
Ubr2 gene in order to investigate the molecular basis of known essential functions of the E3 
ubiquitin ligase. The point mutations D118A and D233A are predicted using in vitro binding 
assays to perturb UBR2’s ability to bind Type I and Type II N-end Rule substrates, 
respectively. As has been previously described, both in our group and by others (Kwon et al. 
2003; Yang et al. 2010; Crichton et al. 2017; Reichmann et al. 2017 and Chapters 3 and 4), Ubr2 
is a vital gene for a subset of specific functions in the mouse, which may be a result of UBR2’s 
most highly detectable function, the Type II N-end Rule (T Tasaki et al. 2005). These include 
regulation of trophectoderm-derived placental tissue development associated with perinatal 
survival, regulation of spermatogenesis during male meiosis, and regulation of the chromatin-
associated AcSMC3 component of the cohesin complex across both mitotic and meiotic 
tissues. By stable introduction of D233A into the Ubr2 gene in a mouse line by CRISPR-Cas9 
homology directed repair, I was able to investigate these three major phenotypes of a Ubr2-/- 
mouse, and showed that none are perturbed in a Ubr2D233A mouse, indicating that they do not 
act through the Type II N-end Rule ability of UBR2. This indicates a need for further 
investigation into these phenotypes in order to investigate how UBR2, and potentially other 
UBR proteins, factor into these processes. 
 
5.3.1 Lack of redundancy within the UBR family 
Within the mouse testis, ovaries and placenta, the genes encoding all four UBR proteins 
shown to have N-end Rule binding activities (Ubr1, Ubr2, Ubr4 and Ubr5) are highly expressed. 
This can be observed by analysis of mapped raw long-RNAseq data from the ENCODE long 
transcriptome project to the mm9 genome assembly (NCBI 37) and calculation of RPKM 
(reads per kilobase million) corrected for gene length in kb, kilobases (Fig. 5.19, analysis by 
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Ian Adams, MRC HGU. Accession number GSE36025, Davis et al., 2018). Ubr2 is particularly 
highly expressed in the placenta and the ovaries, and the former has a similarly high 
expression level of Ubr5. In the testis, Ubr2 does not have particularly high expression, 
compared to the other N-end Rule UBR proteins and, indeed, Ubr5 is the most abundant of 
the four UBRs in this tissue. The D. melanogaster homolog of UBR5, Hyd, has been implicated 
in spermatogenesis in the fly (Pertceva et al. 2010), and our lab recently identified a TEX19.1-
independent role for UBR5 in mouse spermatogenesis, although the molecular function of this 
is as yet unknown (unpublished data, Chris Playfoot, MRC HGU). 
There is evidence for redundancy between the UBR proteins, particularly the highly 
homologous family members UBR1 and UBR2. Embryos lacking both proteins have impaired 
neurogenesis and cardiovascular development leading to embryonic death (Jee Young An et 
al. 2006), phenotypes which are not present in either single knockout (see Chapter 1, and 
Kwon et al. 2001; Yang et al. 2010). Indeed, disturbance of the N-End Rule through single 
knockouts of UBR proteins only result in a few key phenotypes, which can be attributed to 
unique functions of each protein. In humans, either full or partial loss of UBR1 protein activity 
is associated with developmental disorder Johanson-Blizzard Syndrome (JBS), and UBR2 has 
vital roles in a subset of functions, as characterised in the Ubr2-/- mouse studied in Chapters 3 
and 4, and in the following publications (Kwon et al. 2003, Yang et al., 2010; Crichton et al., 
2017). These independent functions could be attributed to differences in cell-specific 
expression of UBR proteins within a tissue, giving a specific dependence on one UBR protein 
for N-end Rule functions in certain cell types. For example, Ubr1 and Ubr2 are specifically 
expressed in spermatogonia and spermatocytes, respectively, in the mouse testis (Y T Kwon 
et al. 2003). However, in this chapter I showed that perturbation of the UBR2 Type II N-end 
Rule in the testis does not result in spermatogenesis defects. Although the role for UBR2 in 
spermatogenesis may be a Type I N-end Rule function, it may also act through an as-yet 
uncharacterised molecular role of UBR2. Yeast paralog of the mouse UBR family, Ubr1, has 
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been shown to bind ubiquitination targets such as the CUP9 transcriptional repressor 
through an internal degron (Xia et al. 2008), and so UBR2 could be acting in a non-N-end 
Rule ubiquitination function. Examples of these functions have been identified in mouse 
UBR2, such as LINE-1 or histone H2A (Maclennan et al. 2017; Jee Young An et al. 2012). The 
functional domain through which UBR2 is able to bind and ubiquitinate these substrates is 
unknown, and so it would be interesting to look at any potential additional binding domains 
of the UBR2 protein, which is largely unstudied. 
As a RING-class E3 ubiquitin ligase, UBR2 depends on binding to E2 ligases such as UBE2A/B 
and USE1 for ubiquitin transfer to target proteins through its RING domain (Deshaies and 
Joazeiro 2009). The point mutation W1170A has been previously identified in the UBR2 
RING domain as essential for binding of USE1 and UBE2A/B (C. W. P. Lee et al. 2011). 
Therefore, generation of a Ubr2W1170A mutant mouse line would show whether any of the 
previously identified roles of UBR2 that do not present in an N-end Rule mutant act through 
a non-N-end Rule ubiquitination pathway, or potentially outside of ubiquitination altogether. 
Although this is a highly conserved domain, UBR2 has been confirmed to act through a variety 
of other E2 ubiquitin conjugating enzymes, including UBE2O and HR6B (H. Xu et al. 2019; J 
Y An et al. 2010), and so this point mutation may not necessarily prevent binding of all 
potential E2 ubiquitin ligases and not generate a fully penetrant catalytic dead mutation. 
Coimmunoprecipitation assays could be carried out in order to test the extent of the mutation, 
as well as the conservation of the UBR2 RING domain structure between different potential 
E2 interactors. 
 
Figure 5.19 (next page) Ubiquitous coexpression of UBR proteins across mouse tissues 
Expression levels of Ubr2 and related UBR protein encoding genes Ubr1, Ubr4 and Ubr5, as 
measured by long RNAseq, ENCODE GEO (GSE36025, Davis et al., 2018), in RPKM (reads per 
kilobase per million mapped) across a variety of mouse tissues in the C57BL/6J genetic 
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5.3.2 Limitations of this study 
It should be noted that the study conducted in this chapter does not have the depth or scope 
to fully assess the variety of N-end Rule functions of UBR2. Initial investigation into the 
functions of the UBR N-end Rule E3 ubiquitin ligases led to the general assumption that 
UBR2 has a very limited ability within the Type I N-end Rule pathway, instead acting to turn 
over Type II substrates (T Tasaki et al. 2005). However, recent studies have identified 
canonical Type I substrates, e.g. encoding an N-terminal arginine, that depend on the presence 
of one or both of UBR1 and UBR2, the most highly conserved members of the UBR family 
(Rageul et al. 2019). 
UBR1 is the best studied of the mammalian N-end Rule E3 ubiquitin ligases, and its UBR box 
has 47% sequence similarity and 68% structural similarity to UBR2. However, UBR1 is able 
to bind both Type I and Type II peptides to a similar level (T Tasaki et al. 2005). The point 
mutations utilised in this chapter were first identified in the Ubr1 gene using an alanine screen 
of the N-end Rule substrate-binding domains. D118 lies within the active site of the UBR box, 
and specifically conjugates a water molecule to the sidechain of N-terminal amino acid 
arginine, so giving the UBR box a highly specific binding to Type I substrates (E Matta-
Camacho et al. 2010; J Muñoz-Escobar et al. 2017; T Tasaki et al. 2009). 
Regardless, the low detectable in vitro peptide affinity poses issues for the investigation of 
Type I functions of UBR2 using a genetic approach, such as in this chapter. As noted in section 
5.2.1 (Fig. 5.3), a TI peptide pulldown with wild type UBR2-FLAG protein shows only a low 
detectable binding affinity to Type I substrates. The UBR2-T1-FLAG construct protein, 
which contains the D118A mutation, appears to perturb this binding, but the variability of 
this assay, which is difficult to standardise against loading controls, means that this does not 
necessarily fully ablate Type I binding ability of the UBR box. Instead, the Ubr2D118A allele, 
when introduced into an ES cell line as in section 5.2.4 (Fig. 5.15), could be assayed in vivo for 
Type I abilities. Ubr2-/- MEFs (mouse embryonic fibroblasts) exhibit a vulnerability to UV 
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irradiation as a result of a lack of Type I N-end Rule degradation of genomic stress regulator 
SDE2 (Rageul et al. 2019). If this activity is also required in mESCs, tested by irradiation of 
the Ubr2-/- ESC line, the Ubr2D118A mESCs could also be used to test the ability of Ubr2D118A to 
process the SDE2 C-terminal fragment Type I substrate under stress by UV irradiation. This 
interaction could also be studied in vitro by ectopic expression of the mutant proteins in a cell 
line such as HEK293T and co-immunoprecipitation for transient protein interactions, 
although this would require proteasomal inhibition by a treatment such as MG132 to preserve 
protein substrates destined for ubiquitin-associated proteasomal degradation. 
Additionally, although the peptide pulldowns for D233A show a clear reduction in Type II 
binding ability of UBR2 using both an ectopically overexpressed FLAG construct in 
HEK293T cells (section 5.2.1, Fig. 5.3A) and endogenously expressed in the testis (section 
5.2.2, Fig. 5.7), this does not necessarily demonstrate a fully ablation of Type II binding ability. 
In particular, UBR2-T2 may still be able to bind Type II substrates that do not contain an N-
terminal phenylalanine, which is the most common Type II sequence and was used as the TII 
peptide in this experiment (Fig. 5.3A), or with Type II-like substrates such as non-acetylated 
Met-Φ proteins. Further examination of the mutant UBR2 proteins by peptide pulldown 
with different peptide sequences such as Met-Φ could be used to predict the extent of their 
binding ability. However, there may be no phenotypes to study, as the UBR proteins are 
predicted to be redundant in this capacity and UBR1 is able to recognise the Met-Φ N-
terminus of known substrate proteins in the Ac/N-end pathway (H. K. Kim et al. 2014; 
Nguyen et al. 2018). 
 
5.3.3 Further study of the N-domain and UBR box structures 
Interestingly, given the similarities between UBR1 and UBR2, the difference in Type I in vitro 
binding affinity between the proteins suggests that there is a very subtle change in sequence 
287 
 
or structure of the domains within these proteins. The isolated structure of the UBR box of 
UBR2 alone is able to bind Type I peptides with a similar affinity to UBR1 in vitro (E Matta-
Camacho et al. 2010), and so there is always potential for Type I substrates, and perhaps 
another feature of the UBR2 protein structure favours binding to Type II substrates instead. 
Type II N-end Rule binding occurs directly at the active site of the UBR box, but requires the 
N-domain portion of the protein for Type II binding to occur. The N-domain shares structural 
similarity with the bacterial ClpS domain, which is a small 12kDa adaptor protein that carries 
out substrate specificity for the bacterial proteolytic ClpAP machinery (Gottesman et al. 
1998). This domain does directly and specifically bind substrates, and so this could indicate a 
direct interaction between the N-domain and Type II substrates, stabilising the interaction 
between the UBR box and the N-terminus of the substrate and so favouring Type II 
degradation in UBR2. The UBR2 residue D233, which was mutated in this study, is conserved 
in ClpS as D35 and is thought to be important for broad substrate binding and stability of 
interaction; other residues in this domain are more important for specificity of binding (Tan 
et al. 2016). Therefore, the D233A mutation introduced could act to simply destabilise Type II 
interactions and reduce UBR2’s UBR box affinity towards them. As there is no apparent 
increase in Type I interactions, this implies that the relationship between these two functions 
of the UBR2 protein cannot be simplified this much, and there may be multiple physical 
contact points in protein-substrate interactions, as well as possible additional cofactor 
proteins or domains that may form a larger complex. 
 
5.3.4 Summary 
In this chapter, I have demonstrated that the two amino acids D118 and D233 are vital for N-
end Rule functioning of the UBR2 protein, and that these canonical functions of UBR2 are 
not required for some of the major essential roles of the protein in the mouse. 
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Caution must be taken with drawing conclusions using these point mutations, as the full 
scope of potential N-terminal degron sequences is not covered by the in vitro validation using 
peptide pulldown assays and there could be some level of N-end Rule function within the 
mutant UBR2 proteins. However, the canonical phenylalanine Type II or arginine Type I 
degron binding ability is perturbed, and it appears that the majority of phenotypes identified 
using the Ubr2-/- mouse line do not act through these two N-end Rule pathways, and instead 
through a non-canonical function, whether involving ubiquitination or another function of 
the UBR2 protein altogether. 
Further work to generate more genetic models that can be used to separate out the functions 
of UBR2 will give an insight into the full scope of UBR2’s roles in the mouse, and potentially 


















The main aim of the work presented in this thesis was to study the role of E3 ubiquitin ligase 
UBR2 in the mouse, particularly in meiotic chromosome cohesion and in embryonic survival. 
UBR2 is essential in the oocyte for stability of the AcSMC3 cohesin subunit, and loss of the 
protein results in a loss of chromosome cohesion during meiosis. UBR2 is also required for 
placental support of embryonic growth, but the molecular basis of its role in placental 
development is not yet understood. 
Beyond the null phenotypes, I identified a gap in the scientific understanding of UBR2’s 
mechanism of action in the essential roles that have been identified. In order to study this 
using a genetic approach, I identified functional mutations within the substrate binding 
domains of UBR2 which perturb its role in the N-end Rule pathway of ubiquitination, and 
showed that the essential functions of the protein that have been identified in a null mouse 
are not perturbed in presence of the mutant alleles. This poses the question of non-N-end 
Rule activities of UBR2. It also potentially highlights the redundant nature of UBR proteins, 
as the currently identified N-end Rule substrates of UBR2 can also be regulated by other 
proteins such as UBR1, whereas UBR2-specific functions may exist outside of the roles 
encompassed by the UBR protein family. 
 
6.1 Separation of the TEX19.1 and UBR2 Functions 
UBR2 is a ubiquitous protein, being expressed across a wide variety of tissues in the mouse, 
and it is of particular interest that the major phenotypes identified in a Ubr2-/- mouse arise in 
those tissues expressing TEX19.1, which is able to form a 1:1 stoichiometric complex with the 
UBR2 protein (Yang et al. 2010; Maclennan et al. 2017). Indeed, although UBR2’s molecular 
N-end Rule substrates span a wide variety of tissues, from the innate immune system to 
myocardial tissue growth (H. Xu et al. 2019; M. J. Lee et al. 2005), very few Ubr2-/- mouse 
phenotypes are thus far identified outside of the Tex19.1 expression pattern, for example the 
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misregulation of the acetylated SMC3 cohesin subunit in the splenocyte (J Reichmann et al. 
2017). A mouse embryonic fibroblast (MEF) cell line, again a cellular context that does not 
express Tex19.1, exhibits UBR2 nuclear localisation and chromatin-associated ubiquitination. 
This is a result of DNA damage, indicating a regulatory role for UBR2 in the DNA damage 
response, potentially through regulatory monoubiquitination of histone H2A (Jee Young An 
et al. 2012). This role has also been identified in silencing of the XY sex body in spermatocyte 
prophase I (J Y An et al. 2010). It is potentially independent of TEX19.1 in this function, as a 
Tex19.1-/- spermatocyte arrests during a zygotene-like stage, as do a subset of Ubr2-/- 
spermatocytes, but does not appear to exhibit the later pachytene XY sex body silencing 
defects (Crichton et al. 2017; J Y An et al. 2010). Another possible explanation for increased 
DNA damage in somatic cells could be a misregulation of the cohesin complex. Some 
cohesinopathies, such as WABS, exhibit a DNA breakage phenotype resulting from 
misregulation of cohesins during S phase and replication fork instability (Cortone et al. 2018; 
Pisani et al. 2018). Therefore, large-scale chromatin capture assays or cohesin localisation 
could be assessed in these Ubr2-/- MEFs to ascertain the cause of genomic instability. 
The role of Ubr2 in cohesin regulation is multifaceted. Although downregulation of AcSMC3 
in the spleen is Tex19.1-independent, ESCs in culture express both Tex19.1 and Ubr2, and the 
Ubr2-/- ESC exhibits a similar chromatin-associated loss of cohesin. Tex19.1-/- ESCs have 
opposite changes in chromatin-associated AcSMC3 intensity and so we hypothesised that, in 
this cell type, TEX19.1 acts to regulate UBR2’s control of AcSMC3 levels. However, as 
discussed in Chapter 3, the Ubr2-/- oocyte has a loss of AcSMC3-containing cohesin complexes 
associated with the chromosome axis and a reduction in chromosome cohesion which, 
unexpectedly, at least partially phenocopies the Tex19.1-/- oocyte (J Reichmann et al. 2017). A 
Tex19.1-/- female has a pronounced increase in aneuploidy and chromosome missegregation that 
have not been observed in the Ubr2-/-, indicating that UBR2 and TEX19.1 may also have some 
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independent roles during female meiosis and that they are not directly working together in a 
1:1 sense in these cells. 
 
6.1.1 Spermatogenesis 
In the testis, UBR2 is required for TEX19.1 protein stability (Yang et al. 2010), presumably due 
to a requirement for a stable TEX19.1-UBR2 complex. As a result, the mammalian Ubr2-/- 
spermatocyte, not unexpectedly, has at least a partial phenocopy of the recombination deficits 
and asynapsis observed in the Tex19.1-/- spermatocyte. However, this is not fully penetrant and 
surviving Ubr2-/- male mouse also exhibits a later phenotype, progressing into pachytene and 
exhibiting defects in histone H2A regulatory monoubiquitination required for chromosome 
stability and transcriptional inhibition in the XY sex body (Jee Young An et al. 2012; J Y An et 
al. 2010). Defects in these processes have been associated with mosaic expression of X- and Y-
encoded genes, sperm heterogeneity and cell death (J. M. A. Turner 2007), and so it could be 
interesting to assay the chromatin structure of the XY sex body in a Ubr2-/- spermatocyte, 
using immunofluorescence against monoubiquitinated H2A. 
This potentially bimodal functionality of UBR2 in spermatogenesis could be further 
investigated using genetic systems such as the Ubr2T2/T2 mouse; one, but not both phenotypes 
may be regulated through the N-end Rule activity of this E3. Therefore, although there are no 
gross phenotypes in the Ubr2T2/T2 testis from these mice, subtle changes in histone regulation 
throughout prophase I, or potential low-level cell death, could be assayed in order to separate 




6.1.2 Placental development 
The most striking differences in phenotype between the Tex19.1-/- and Ubr2-/- mice can be 
observed in the placenta, outlined in Chapter 4. Both mice exhibit a partial embryonic 
lethality that presents at a perinatal stage, associated with an IUGR and changes in 
trophoblast-derived tissue development in the placenta (J Reichmann et al. 2013; Y T Kwon 
et al. 2003; Jee Young An et al. 2012). However, the Ubr2-/- exhibits no retrotransposition or 
upregulation of imprinted genes, which are characteristics of the Tex19.1-/- placental deficit 
(Woods, Perez-Garcia, and Hemberger 2018; Tunster, Jensen, and John 2013; Garcia-Perez, 
Widmann, and Adams 2016; Goodier 2016), posing questions about what role the UBR2 
protein plays in placental development and if this involves TEX19.1 protein at all. 
TEX19.1 is thought to act in a complex with KAP1 in the placenta, which is a transcriptional 
corepressor (Jang et al. 2018; Cheng, Kuo, and Ann 2014). This is involved in genome defence 
or regulation of transcriptional repression in a hypomethylated context (Cheng, Kuo and Ann, 
2014 and Playfoot et al. 2019, manuscript submitted, MRC HGU), and their interaction has 
been hypothesised to be involved in the recruitment of the histone methyltransferase SETDB1, 
laying down transcriptionally repressive H3K9me3 histone methylation marks . It is not 
understood whether UBR2 factors into this complex, or if the TEX19.1-UBR2 complex is 
distinct from TEX19.1-KAP1, or potentially not active in this tissue at all. 
The cohesin complex is tightly bound to a wide variety of cellular processes, and this includes 
genetic or chromosomal stability, mitotic chromosome segregation and regulation of cell cycle 
progression. All of these processes are vital to normal commencement of tissue growth, 
particularly in the placenta where the tissue is very fast-growing. For example, a null mutant 
of the known cohesin regulator ChlR1 helicase has severe cohesin defects in the placenta, 
leading to abnormal placental growth, perturbation of the cell cycle, aneuploid placental 
tissue and embryonic lethality at E10.5 (Inoue et al. 2007). Data in the Ubr2-/- splenocyte shows 
that UBR2 can regulate cohesin independently of TEX19.1, and this function does not depend 
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on the stability of the TEX19.1 protein, as has been observed in the testis (Yang et al. 2010). 
However, when TEX19.1 is present it acts to regulates UBR2’s activity towards cohesin. 
Therefore, the growth restrictions observed in the Ubr2-/- and the Tex19.1-/- placentas could be 
a result of cohesin misregulation, leading to aberrant somatic cell cycles and potentially 
aneuploidy, which could cause apoptosis. Cohesin misregulation could also halt or slow the 
cell cycle, reducing the rate of proliferation and resulting in a smaller tissue in that sense. 
TGCs (trophoblast giant cells) may be particularly vulnerable to this process, as discussed in 
Chapter 4. 
 
6.1.3 The interaction between TEX19.1 and UBR2 proteins 
As none of the phenotypes identified in the Ubr2 null mouse are grossly overt in a Ubr2T2/T2 
mouse, it appears that these phenotypes do not act through the Type II N-end Rule. Further 
work will be required to separate the functions of TEX19.1 and UBR2, and ascertain the 
importance of the TEX19.1-UBR2 interaction. This could include perturbation of the TEX19.1-
UBR2 interaction itself. 
The molecular interaction site between TEX19.1 and UBR2 has not been mapped; UBR2 is a 
very large 200kDa (1755 amino acid, aa) protein (T Tasaki et al. 2009) and there is a significant 
central region of the protein that does not have any known or predicted domain or structural 
data. It is generally understood that TEX19.1 is not a substrate of UBR2, instead acting as a 
cofactor or regulatory protein, as the protein is not degraded in presence of UBR2 (Maclennan 
et al. 2017) – indeed, UBR2 is required for TEX19.1 stability in the testis (Yang et al. 2010). 
Other interactors of UBR2 have also been identified in a stable complex with the E3 – for 
example RECQL4, which is a DNA helicase thought to be responsible for genetic stability 
through its interaction with the N-end Rule pathway (Yin et al. 2004). 
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Only a small proportion of the UBR2 protein has been mapped or studied in a structural assay, 
i.e. the UBR box, N-domain, RING domain and the UAIN domain. Bioinformatic analyses 
could be applied to identify conserved structural motifs within the large central region of the 
UBR2 protein, as compared to known mouse proteins, and structural folding could be 
predicted. This could lead to predictions of vital domains, which could carry out binding to 
either target proteins outside of the N-end Rule, to ubiquitin or ubiquitin-like structures, or 
to cofactor proteins such as TEX19.1 and RECQL4. 
Upon identification of candidate domains for TEX19.1 interaction, fragments of the UBR2 
protein could be isolated for in vitro binding assays, with a view to eventually generate point 
mutant or deletion mutant UBR2 proteins that are functional in N-end Rule or non N-end 
Rule abilities, but not able to detectably interact with TEX19.1. This is a similar approach as 
to that utilised in this thesis for perturbation of the N-end Rule binding abilities of UBR2, 
and as discussed in Chapter 5 could also be applied to the RING domain, for generation of a 
‘catalytic dead’ UBR2 that is unable to transfer ubiquitin to target proteins. Together, these 
would be useful tools to ascertain the importance of the TEX19.1-UBR2 complex and separate 
the functions of these proteins in vivo. While generating multiple mouse lines to incorporate 
separation-of-function mutants may be costly or time-consuming, the Ubr2D118A mESC line 
utilised in this thesis demonstrates that we are able to assay at least some of UBR2’s abilities 
using this approach, particularly cohesin regulation (Chapter 5) or retrotransposon 
derepression (Maclennan et al. 2017). Interesting candidate point mutations could then be 
extrapolated into a mouse model for study of essential UBR2 functions in either male or 




6.2 Redundancy in the UBR Protein Family 
As discussed in Chapter 1, there are seven UBR proteins encoded by the mammalian genome, 
which have arisen through duplication events during evolution (T Tasaki et al. 2005, 2009). 
The S. cerevisiae genome encodes only two proteins containing the UBR box domain: UBR1 and 
UBR2. UBR1 has documented activity in the N-end Rule, whereas UBR2 is active in non-N-
end Rule ubiquitination pathways (Akiyoshi et al. 2013). Mammalian UBR1 and UBR2 are 68% 
sequence conserved (T Tasaki et al. 2009), and probably arose as a duplication event quite 
recently during evolution. The only other mammalian UBR proteins that act in the N-end 
Rule are UBR4 and UBR5. UBR4 has no known E2 binding domain, and UBR5 carries out 
ubiquitination through a HECT domain (Edna Matta-Camacho et al. 2012). Finally, UBR3 is 
known to undergo non-N-end Rule ubiquitination activity (see Chapter 1) and is most closely 
sequence conserved to S. cerevisiae UBR2. 
The large number of E3 ubiquitin ligases encoded in the mammalian genome, the largest class 
of ubiquitination enzymes and encoded by over 600 genes (Wei Li et al. 2008), implies that 
there should be little functional redundancy between E3’s. Even within families sharing the 
same substrate binding domain, variation in the E2 binding mechanism leads to differences in 
the ubiquitination activity of each E3 (Deshaies and Joazeiro 2009; Metzger et al. 2014). UBR4 
and UBR5 are able to bind the same peptide sequences as UBR1 and UBR2 in vitro, but the 
variation in the rest of their protein structure indicates that substrates could vary between 
E3’s (T Tasaki et al. 2009, 2005), allowing the N-end Rule to cover a larger proportion of 
substrates in the mammalian system as compared to S. cerevisiae. 
UBR1 and UBR2, being so highly conserved, share a number of substrates. RGS4 and RGS5 
are N-terminally arginylated and levels are controlled by the Type I N-end Rule pathway. This 
is mediated by both UBR1 and UBR2, implying either a co-operative mechanism involving 
both E3 ligases, or a redundancy of RGS proteins as substrates for both, which are abundant 
in myocardial cells and so cannot be regulated by one alone (M. J. Lee et al. 2005). 
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Interestingly, another G-protein regulator RGS2 is regulated by the Ac/N-end Rule pathway, 
being N-terminally acetylated upon synthesis and then shielded in complex from E3 ubiquitin 
ligase Teb4 (Park et al. 2015), which demonstrates the level of diversity across N-end Rule 
regulatory pathways. Another shared in vivo substrate of UBR1 and UBR2 is SDE2, which is a 
DNA stress response regulator; upon cleavage, the neo-N-terminus of the C-fragment is a 
Type I N-terminal degron that requires both UBR1 and UBR2 for degradation (Rageul et al. 
2019). 
Finally, a Ubr1-/-Ubr2-/- double null mouse exhibits a fully penetrant embryonic lethality, 
associated with defects in both cardiovascular development and neurogenesis. Ubr1-/- mice 
alone survive to adulthood, exhibiting growth defects in the skeletal and adipose tissue (Y. T. 
Kwon et al. 2001), and Ubr2-/- mice have a partially penetrant embryonic lethality which 
exhibit no grossly abnormal embryonic features and is based on placental growth defects 
(Kwon et al., 2003 and Chapter 4). This indicates a shared substrate during these 
developmental events, either their already identified UBR1 or UBR2 substrates, or through an 
as-yet unidentified shared N-end Rule substrate. 
One of the major pathways of the UPS is the misfolded protein response, in which chaperones 
act to bind and guide unfolded or orphan proteins for degradation via the proteasome. The 
traditional Arg/N-end Rule relies on sequence-specific N-terminal interactions, which does 
not lend itself to the versatility of misfolded protein degradation. However, UBR proteins 
have been implicated in degradation of the non-acetylated Ac/N-end Rule substrates, which 
are known as Met-φ (J. M. Kim and Hwang 2014; Hwang, Shemorry, and Varshavsky 2010). 
This pathway is applicable to a wide variety of misfolded or orphan substrates. Moreover, 
there has been an N-end Rule like pathway identified in ER chaperone-mediated protein 
degradation (D. H. Kwon et al. 2018; Cha-Molstad et al. 2015). Through this pathway, the 
chaperone BiP itself is arginylated to become an N-end Rule like substrate, allowing for 
binding to a highly variable pool of substrates and degradation of both Arg-BiP and the 
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substrate together via the autophagy pathway. The presence of these peripheral N-end Rule 
pathways highlight the adaptability of the system beyond simple N-terminal degron binding 
and degradation in the UPS. 
The extent of the redundancy is difficult to study, as we cannot predict whether any other 
UBR protein or other E3’s may be involved in particular phenotypes or regulation of certain 
substrates. Redundancy could take multiple forms: all UBR’s present in specific cell types 
may be available to access substrates at all times, working together to control protein levels, 
or different UBR proteins could, either directly or indirectly, control levels of each other, so 
acting as a “backup plan” and being upregulated in response to loss of another UBR protein 
or E3 ubiquitin ligase. Therefore, mass spectrometry in order to study the proteome in 
presence or absence of a protein such as UBR2, or in cells in which UBR2 is inactivated or 
perturbed using the point mutations discussed in section 6.1.3, could give insights into the 
balance of E3 ubiquitin ligases in a proteome and whether any crosstalk or redundancy exists 
between related proteins. It could also give insights into the extent at which point mutation 








6.3 Further Applications for UBR2 N-end Rule Point Mutations 
Within this thesis, I was able to identify and validate two key point mutations in the Ubr2 
gene, and I have only scratched the surface of the potential investigation of UBR2 protein 
functionality utilising these mutations. Our group and others have been able to identify a 
novel role for UBR2 in the regulation of the cohesin complex across a variety of tissues, as well 
as in meiosis and placental growth (Kwon et al., 2003; Yang et al., 2010; Crichton et al., 2017; 
Reichmann et al., 2017, and Chapters 3 and 4). This work implies that UBR2 does not 
necessarily rely on the N-end Rule for all functionality, but there are limits to using this 
genetic approach and after a phenotype has been identified, it is difficult to link this to a 
molecular interaction or a particular ubiquitination substrate. Therefore, if these genetic 
models can be combined with a proteomic approach, this will greatly augment the power of 
our investigation into the effect of Ubr2-/-. 
 
6.3.1 Identification of UBR2 Substrates and Interactors 
Proteomic screening through mass spectrometry is a high-powered way of quickly identifying 
significant changes in the proteome as a result of genetic changes. By comparing the proteome 
of Ubr2-/- mouse tissues with either wild type or Ubr2T2/T2 tissues, we could elucidate the 
molecular changes as a result of loss of UBR2 protein and/or loss of the Type II UBR2 function. 
For example, we know that TEX19.1 protein is destabilised in absence of UBR2 in the mouse 
testis, but the UBR2-T2 protein is able to bind TEX19.1 protein, and TEX19.1 is stable in the 
Ubr2T2/T2 testis. These experiments would give insights into the changes in protein dynamics 
as a result of loss of UBR2 protein, and what is specifically affected by the Type II N-end Rule 
binding activity of the protein. This would show both direct and indirect effects of the loss of 
UBR2 protein, including the extent of UBR protein redundancy as a function of the protein 
degradation landscape with a lack of UBR2 protein, or a lack of its Type II functionality.  
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Mass spectrometry associated with co-immunoprecipation (coIP) with the UBR2 protein 
would potentially identify UBR2 interactions of three categories: novel E2 ubiquitin 
conjugating enzymes, other interacting cofactors such as TEX19.1 or RECQL4, or novel 
ubiquitination substrates. The TEX19.1-UBR2 interaction was identified in this way in a coIP 
mass spectrometry assay against TEX19.1 protein (Maclennan et al. 2017). However, transient 
interactions are common for an E3: both with E2’s, as they are continuously charging and 
transferring ubiquitin molecules, and with substrates that are short-lived and degraded via 
the proteasome (Iconomou and Saunders 2016). These can be difficult to detect via a standard 
co-immunoprecipitation assay, and as a result the majority of direct UBR2 substrates have 
been identified from the perspective of each individual substrate. In order to systematically 
and comprehensively compile a list of potential UBR2 substrates, so identifying candidates 
for the essential UBR2 functions identified in this thesis, I would propose the use of 
techniques such as BioID (biotinylated protein identification) or TurboID. Both these 
techniques utilise a proximity-based ligation mechanism, in which a fusion protein is 
constructed with the protein of interest and expressed in a cell line – for example in ESCs, 
which are known to require UBR2 for both cohesin and retrotransposon repression – 
alongside substrate treatment, allowing selective isolation and identification of transiently 
interacting proteins with affinity capture followed by mass spectrometry (Roux, Kim, and 
Burke 2013; Doerr 2018). BioID has been used to success, in combination with MG-132 
proteasomal inhibition, on a RING-type E3 complex: the (SCF)β-TrCP1/2 E3 ligases (Coyaud et 
al. 2015), in which over 50 candidate substrates were identified. Further to this, UBR2-T1 or 
UBR2-T2 proteins could be used as a BioID fusion protein in ESCs to assess Type I or Type II 
N-end Rule specific interactions, or the assay could be carried out using a wild type UBR2-
BioID fusion protein on a Tex19.1-/- background to assess if presence of TEX19.1 directly affects 




6.3.2 Further study of the UBR2 N-end Rule Functions 
Although the conclusions of this thesis largely focus on the importance of studying non-N-
end Rule activities of UBR2, it cannot be ignored that there are many canonical N-end Rule 
activities of the protein as well. UBR2, along with UBR1, is the canonical N-end Rule E3 
substrate interactor, containing both the UBR box and N-domain, and there are many known 
N-end Rule substrates of either protein, or both. Introduction of the D118A and D233A point 
mutations into either the UBR box or the N-domain gives a system in which these N-end Rule 
functions can be assessed in vivo. 
As an example, one such recently identified role of UBR2 within the N-end Rule is turnover 
of the NLRP1B inflammasome C-terminal fragment in macrophage cells. This is cleaved by 
anthrax lethal toxin (LT) under infection with B. anthracis bacteria, resulting in degradation 
of the C-terminal fragment, which contains a Type II neo-N-terminal degron, by UBR1 or 
UBR2. This allows the N-terminal fragment to initiate an innate immune response through 
caspase-1 activation (H. Xu et al. 2019). 
This role of UBR2 in the innate immune response was first identified in the mouse 
macrophage-like RAW 264.7 reporter cell line, but this has not been directly documented in 
the Ubr2-/- mouse. It would therefore be interesting to induce the B. anthracis immune response 
in these mice, and mice of the Ubr2T2/T2 genotype to observe the necessity of UBR2 in this 
pathway in vivo. 
Overall, we have only scratched the surface of the potential roles of the N-end Rule in protein 
degradation and regulation in the eukaryotic system. Tools such as the D118A and D233A 
point mutations will only further insights into the diversity of the UBR protein family, 
outlining the importance of protein control and regulation through ubiquitination, a vital and 








UBR2 is an E3 ubiquitin ligase that is primarily implicated in the N-end Rule pathway of the 
UPS, particularly through Type II N-terminal degron binding of substrate proteins (T Tasaki 
et al. 2005, 2009). Thus far, prior to this thesis, UBR2 was identified as an essential regulator 
of meiotic recombination in the male germline (Yang et al. 2010; Y T Kwon et al. 2003; J Y An 
et al. 2010). Aside from this function, which appears to depend on the presence of TEX19.1, 
this is the first study pertaining to UBR2’s role in female meiosis or embryonic survival as a 
consequence of placental development, the latter of which was identified in 2003 but has not 
been directly studied (Kwon et al.). At this current time, there is no published work directly 
addressing the in vivo roles of mouse UBR proteins within the Type I and Type II N-end Rule 
using a genetic approach. 
There is evidence for redundancy between these UBR proteins, particularly between UBR1 
and UBR2 (Jee Young An et al. 2006; T Tasaki et al. 2009), and so in depth understanding of 
the molecular activity of UBR2 in these tissues will lead to a further insight into the wider 
UBR family. It is already understood that at least three of the seven mammalian UBR proteins 
do not primarily use their UBR box as a substrate recognition domain for the ubiquitination 
pathway, whether they are active within it at all, and although UBR1, UBR2, UBR4 and UBR5 
all have in vitro activity in binding to either Type I or Type II substrates (T Tasaki et al. 2005), 
there is no guarantee that this is their sole mechanism of activity, either within our outside of 
ubiquitination. Indeed, it appears that the N-end Rule redundancy between these proteins 
allows a flexibility that can be accounted for in much of the identified N-end Rule UBR2 
protein functions and so there may be other, more vital, mechanisms of UBR2 action that have 
no such compensatory backstop. 
One of the more interesting aspects of the UBR2 protein’s activities is its interaction with the 
genome defence protein TEX19.1, encoded by the gene Tex19.1 and only expressed in the 
hypomethylated contexts of the placenta, the oocyte, the spermatocyte and, in culture, ESCs. 
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This interaction has been shown to regulate the Type II N-end Rule turnover of the UBR2 
ligase (J Reichmann et al. 2017), but this may not necessarily be the primary function of the 
TEX19.1-UBR2 complex within these tissues. TEX19.1 itself has been shown to be implicated 
in a range of UBR2-independent functions, and so future work will be key to ascertain the 
extent of the TEX19.1-UBR2 complex and what role this complex plays in regulation of either 
protein’s other functions. 
Although the N-end Rule has long been recognised as a primary substrate recognition 
pathway of the UPS and protein degradation, our current understanding of E3 ubiquitin 
ligases is shifting towards non-canonical roles, whether within regulatory functions of 
ubiquitination, or outside of the ubiquitin-proteasome system altogether. The major finding 
of this thesis is that UBR2 does not appear to act through its presumed activity in the Type II 
N-end Rule for a variety of essential functions, and so we must consider the possibilities of 
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